Regulation of type I interferons in health and autoimmune disease by Psarras, Antonios
   
 
 
 
 
Regulation of type I interferons in health and 
autoimmune disease 
 
Antonios Psarras 
 
 
 
 
 
Submitted in accordance with the requirements for the 
degree of Doctor of  Philosophy (PhD) 
 
 
University of  Leeds 
Leeds Institute of Rheumatic and Musculoskeletal Medicine 
 
September 2018 
  
  
i 
Intellectual property and publication statements 
The candidate confirms that the work submitted is his own, except where work which 
has formed part of jointly-authored publications has been included. The contribution 
of the candidate and the other authors to this work has been explicitly indicated 
below. The candidate confirms that appropriate credit has been given within the 
thesis where reference has been made to the work of others.  
 
Chapter 1 includes data from a jointly-authored publication: 
Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: 
pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford). 
2017;56(10):1662-75. 
Psarras A performed the review of literature, critically appraised scientific evidences 
of the relevant topics and led the writing of the manuscripts. Emery revised the 
manuscripts for important intellectual content and final approval of the manuscript. 
 
Chapter 3 includes data from two jointly-authored publications: 
El-Sherbiny YM*, Psarras A*, Yusof MYM, Hensor EMA, Tooze R, Doody G, et al. A 
novel two-score system for interferon status segregates autoimmune diseases and 
correlates with clinical features. Sci Rep. 2018;8(1):5793. 
*joint first author 
El-Sherbiny YM, Emery P, and Vital EM performed conception and design of research, 
data interpretation and writing the manuscript; El-Sherbiny YM, Md Yusof MY, 
Wittmann M, and Vital EM designed the research and recruited patients and clinical 
  
ii 
interpretation of the study; Tooze R and Doody G performed B cell design, analysis 
and interpretation, and writing the manuscript; El-Sherbiny YM, Md Yusof MY, 
Mohamed AAA, and Psarras A performed flow cytometry analysis and interpretation; 
El-Sherbiny YM and Psarras A performed gene expression analysis; Hensor EMA 
performed statistical and factor analysis method development and nanoparticle 
characterization; Psarras A, McGonagle D, and Vital EM performed data 
interpretation and writing the manuscript.  
 
Md Yusof MY*, Psarras A*, El-Sherbiny YM, Hensor EMA, Dutton K, Ul-Hassan S, et 
al. Prediction of autoimmune connective tissue disease in an at-risk cohort: 
prognostic value of a novel two-score system for interferon status. Ann Rheum Dis. 
2018;77(10):1432-9.  
*joint first author 
Md Yusof MY, Psarras A and Vital EM: substantial contributions to the conception or 
design of the work, or the acquisition, analysis or interpretation of data, drafting the 
work or revising it critically for important intellectual content, final approval of the 
version published and agreement to be accountable for all aspects of the work in 
ensuring that questions related to the accuracy or integrity of any part of the work 
are appropriately investigated and resolved. El-Sherbiny YM, Hensor EMA, Dutton K, 
Ul-Hassan S, Shalbaf M, Alase AA, Wittmann M and Emery P: substantial 
contributions to the conception or design of the work, or the acquisition, analysis or 
interpretation of data, drafting the work or revising it critically for important 
intellectual content and final approval of the version published. 
  
  
iii 
This copy has been supplied on the understanding that it is copyright material and 
that no quotation from the thesis may be published without proper 
acknowledgement. 
The right of Antonios Psarras to be identified as Author of this work has been 
asserted by him in accordance with the Copyright, Designs and Patents Act 1988. 
 
© 2018 The University of Leeds and Antonios Psarras 
  
  
iv 
Acknowledgements 
I would like to thank Dr Edward Vital, Prof Paul Emery and Dr Miriam Wittmann, my 
supervisors at Leeds Institute of Rheumatic and Musculoskeletal Medicine, for their 
guidance and endless support for my PhD thesis and my personal career 
development. I would also like to express my gratitude to Prof George Tsokos at Beth 
Israel Deaconess Medical Center, who kindly supervised the work I carried out in his 
lab at Harvard Medical School in 2017 for my PhD thesis. 
I am especially indebted to the consultants Prof Paul Emery, Dr Edward Vital, Prof 
Maya Buch, Dr Shouvik Dass, Prof Mark Goodfield, Dr Emma Dunn, Dr John Bamford, 
specialist registrars Dr Md Yuzaiful Md Yusof, Dr Andrew Barr, Dr Lesley-Anne Bissell, 
clinical trial coordinator Huma Cassamoali and clinical trial assistant Sabina Khan as 
well as nurses and healthcare assistants for their services at the Leeds Connective 
Tissue Disease and Vasculitis Clinic. Registering patients to research cohorts and 
collecting biological samples on weekly basis would have not been made possible 
without their endless assistance and valuable contribution. I would also like to thank 
Diane Corscadden and Katie Mbara at Chapel Allerton Hospital for collecting and 
sending any patient samples to St. James’s University Hospital. 
I am grateful to Dr Elizabeth Hensor, who helped with statistical analysis performing 
the factor analysis, Dr Mohammad Shalbaf, who performed the tissue sectioning of 
skin biopsies and Dr Adewonuola Alase, who helped with in situ hybridization of the 
skin and in vitro culturing of human skin cells. I would also like to mention Dr Yasser 
El-Sherbiny, post-doctoral fellow, and Zoe Wigston, research technician, for their 
valuable help in the lab. Special thanks to Adam Davison and Liz Straszynski from 
  
v 
Flow Cytometry and Imaging Facility in Wellcome Trust Brenner Building for 
providing induction courses in flow cytometry and confocal microscopy as well as 
facility’s precious service in cell sorting. I am also indebted to Next Generation 
Sequencing Facility for performing and analysing the RNA-sequencing data from the 
samples given, especially Dr Ian Carr, lecturer in medical bioinformatics, Dr Agne 
Antanaviciute, bioinformatician, and Ummey Hany, technical specialist, for their 
major contribution to the project. 
In addition to all contributors above, I would like to express my special thanks and 
respect to all researchers at University of Leeds and Harvard Medical School I have 
shared my data and scientific thoughts with, but more importantly, to all the patients 
that without their actual contribution I would not have been able to perform my 
experiments and investigate basic mechanisms of human autoimmunity. 
I would like to express my gratitude to the University of Leeds for enabling me to 
undertake the current PhD by supporting me with University of Leeds 110 
Anniversary Research Scholarship in the research theme “Immunology, Inflammation 
& Infection”. Moreover, I would like to special mention the Erdheim Travel 
Scholarship awarded by the School of Medicine at Leeds and the Summer Placement 
Award Scheme awarded by the British Society for Immunology, which provided 
financial support during my research visit at Harvard Medical School in Boston, USA. 
Last but not least, I would like to thank my beloved family and friends for their 
endless support, love and patience throughout all these years of hard work and 
scientific challenges that enabled me to submit this PhD thesis. 
  
  
vi 
List of publications and presentations arising from this thesis 
Original articles: 
El-Sherbiny YM*, Psarras A*, et al. A novel two-score system for interferon status 
segregates autoimmune diseases and correlates with clinical features. Sci Rep. 
2018;8(1):5793. 
*joint first author 
Md Yusof MY*, Psarras A*, et al. Prediction of autoimmune connective tissue disease 
in an at-risk cohort: prognostic value of a novel two-score system for interferon 
status. Ann Rheum Dis. 2018;77(10):1432-9.  
*joint first author 
 
Review articles: 
Psarras A, et al. Type I interferon-mediated autoimmune diseases: pathogenesis, 
diagnosis and targeted therapy. Rheumatology (Oxford). 2017;56(10):1662-75. 
 
Oral presentations: 
Psarras A, et al. The role of skin tissue in initiation of Systemic Lupus Erythematosus. 
Annual Northern and Yorkshire Rheumatology Meeting, York (UK), September 2018. 
Psarras A, et al. Type I interferon is produced by non-haematopoietic tissue cells but 
not pDCs in preclinical autoimmunity and SLE. Annual European League Against 
Rheumatism (EULAR) Congress, Madrid (Spain), June 2018. 
  
vii 
Psarras A, et al. Prediction of connective tissue disease in at-risk cohort using a novel 
interferon-stimulated gene expression score. Annual Congress of Japanese College 
of Rheumatology (JCR), Tokyo (Japan), April 2018. 
Psarras A, et al. Type I interferon regulation in preclinical and established 
autoimmunity. Annual Northern and Yorkshire Rheumatology Meeting, York (UK), 
September 2017. 
Psarras A, et al. Towards prevention of Systemic Lupus Erythematosus: predicting 
disease and identification of therapeutic targets. 7th NIHR Infrastructure Doctoral 
Research Training Camp, Ashridge Business School (UK), July 2016. 
Psarras A, et al. Distinct subsets of interferon-stimulated genes are associated with 
incomplete and established systemic lupus erythematosus. 36th European Workshop 
for Rheumatology Research, York (UK), February 2016. 
 
Poster presentations: 
Psarras A, et al. TNF-α regulates plasmacytoid dendritic cells by suppressing IFN-α 
production and enhancing Th1 and Th17 cell differentiation. Annual European 
League Against Rheumatism (EULAR) Congress, Madrid (Spain), June 2018. 
Psarras A, et al. TNF-α is a major regulator of human plasmacytoid dendritic cells by 
promoting a functional drift to antigen presentation. Annual Congress of British 
Society for Immunology, Brighton (UK), December 2017. 
  
  
viii 
Abstract 
Type I interferons (IFN) have a crucial role in the pathogenesis of a range of 
autoimmune diseases including systemic lupus erythematosus (SLE). Increased IFN 
activity is observed at preclinical stages and associated with disease progression, but 
the cause of this dysregulation remains unclear. Plasmacytoid dendritic cells (pDCs) 
produce large amounts of IFNs in viral infection, however their precise role in 
autoimmunity is still elusive.  
Peripheral blood and skin biopsies from different patient groups were used for gene 
expression assays, immunophenotyping, in vitro functional assays, transcriptomics 
and other assays to investigate the dysregulated IFN axis and the role of pDCs in 
preclinical autoimmunity and SLE.  
In preclinical autoimmunity and SLE, pDCs were found to exhibit an exhausted 
phenotype with: (i) loss of TLR-mediated IFN-α production; (ii) failure to induce T cell 
activation; (iii) transcriptional profile of cellular senescence; (iv) increased telomere 
erosion. In contrast, diffuse expression of type I IFNs was observed in the epidermis 
but not in leucocyte-infiltrating areas of patients with SLE as well as in non-lesional 
skin of individuals with preclinical autoimmunity. Additionally, keratinocytes isolated 
from non-lesional skin of patients with SLE and individuals with preclinical 
autoimmunity showed a significantly enhanced type I IFN expression in response to 
UV light and nucleic acids. Lastly, TNF-α regulates the function of pDCs by 
suppressing IFN-α production but enhancing a functional drift to antigen 
presentation and T cell activation.  
  
ix 
These findings revise our understanding of immune regulation in human 
autoimmunity. Non-haematopoietic tissue cells can perpetuate IFN responses; 
meanwhile the professional IFN-producing pDCs have lost their immunogenic 
properties. In patients with SLE, these insights may indicate potential therapeutic 
targets outside the conventional immune system, while knowledge of how IFN 
dysregulation initiates could allow disease prevention. 
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 1 
CHAPTER 1.  
REVIEW OF THE LITERATURE 
1.1 Systemic Lupus Erythematosus (SLE) 
Systemic Lupus Erythematosus (SLE) is a multisystemic autoimmune disorder 
characterised by a general breakdown of immune tolerance. The pathogenesis of SLE 
is quite complex and the immune mechanisms contributing to disease development 
still remain unclear. SLE is a heterogeneous disease and it often comes along with a 
wide spectrum of clinical manifestations affecting virtually any organ or tissue and 
typically running a relapsing and remitting course. The severity of symptoms can 
range from mild to severe and may vary significantly between patients. 
1.2 Epidemiology of SLE 
SLE can affect all individuals of every gender, race or age. However, it predominantly 
affects women between 15 and 45 years old, approximately 9 times more frequently 
than men (1). While the prevalence of SLE is notably higher among women of 
childbearing age, men tend to develop more severe disease with multiple organ 
complications often requiring more intensive treatment. On the other hand, 
postmenopausal women generally present milder disease in comparison with 
younger premenopausal women. The majority of patients (65%) have a disease onset 
between 15 and 55 years old, while only 20% of patients present clinical 
manifestations before the age 16. Interestingly, children and adolescents with SLE 
present more severe disease and higher morbidity, especially in lupus nephritis (2). 
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The incidence of SLE has nearly tripled in the last 40 years mainly due to improved 
recognition of symptoms and diagnosis of mild disease (3). Incidence rates of SLE in 
North America, South America and Europe are estimated between 1 to 23 per 100 
000 per year (4). The prevalence of SLE in the USA population is estimated to be 51 
cases per 100,000 people, while certain ethnic groups like women of Afro-Caribbean 
origin tend to present lupus more frequently (up to 9 times) and with greater severity 
than populations of Caucasian origin (5). In the UK, the age-standardised incidence is 
8.3 per 100 000 per year for females and 1.4 per 100 000 per year for males, of which 
the highest incidence rates are seen in those of African-Caribbean descent; 31.4 per 
100 000 per year compared with 6.7 per 100 000 per year for those of white 
European descent (6).  
1.3 Classification criteria for SLE 
Classification criteria for SLE were initially developed by the American College of 
Rheumatology (ACR) in 1971 (7), and subsequently revised in 1982 (8) and 1997 (9).  
Based on 1997 criteria, the classification of SLE was typically based on the presence 
of at least 4 out of 11 criteria (Table 1.1). These criteria presented high sensitivity 
(>85%) and specificity (>95%) and included both clinical and serological parameters; 
all features contributed equally to the diagnosis without any weight on any particular 
feature. However, these criteria were developed and validated in patients with 
longstanding disease and might have excluded those with early or limited disease. 
Apart from that, some systems were over-represented (for instance, mucocutaneous 
manifestations), whilst there was a significant problem to classify patients with 
organ-threatening manifestation such as lupus nephritis. Lastly, there were 
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individuals presenting only immunological abnormalities or individuals fulfilling four 
clinical criteria but they were negative for ANA. 
Criteria Definition 
Malar Rash Fixed erythema, flat or raised, over the malar eminences, tending to 
spare the nasolabial folds 
Discoid Rash Erythematous raised patches with adherent keratotic scaling and 
follicular plugging; atrophic scarring occurs in older lesions 
Photosensitivity Skin rash as a result of unusual reaction to sunlight, by patient history 
or physician observation 
Oral Ulcers Oral or nasopharyngeal ulceration, usually painless, observed by a 
physician 
Arthritis Non-erosive arthritis involving two or more peripheral joints, 
characterised by tenderness, swelling or effusion 
Serositis a. Pleuritis: convincing history of pleuritic pain or rub heard by a 
physician or evidence of pleural effusion or 
b. Pericarditis: documented by ECG or rub or evidence of pericardial 
effusion 
Renal Disorder a. Persistent proteinuria >0.5 g per day or >3+ if quantitation is not 
performed or 
b. Cellular casts: may be red cell, haemoglobin, granular tubular, or 
mixed 
Neurological Disorder a. Seizures: in the absence of off ending drugs or known metabolic 
derangements (eg, uraemia, acidosis, or electrolyte imbalance) or 
b. Psychosis: in the absence of off ending drugs or known metabolic 
derangements (eg, uraemia, acidosis, or electrolyte imbalance) 
Haematological 
Disorder 
a. Haemolytic anaemia with reticulocytosis, or 
b. Leucopenia: <4000/mm3, or 
c. Lymphopenia: <1500/mm3, or 
d. Thrombocytopenia: <100 000/mm3 in the absence of off ending 
drugs 
Immunological 
Disorder 
a. Anti-DNA: antibody to native DNA in abnormal titer, or 
b. Anti-Sm: presence of antibody to Sm nuclear antigen, or 
c. Positive finding of antiphospholipid antibodies based on: (1) an 
abnormal serum concentration of IgG or IgM anticardiolipin 
antibodies, (2) a positive test result for lupus anticoagulant using a 
standard method, or (3) a false positive serologic test for syphilis 
known to be positive for at least 6 months and confirmed by 
Treponema pallidum immobilisation or fluorescent treponemal 
antibody absorption test 
Antinuclear Antibody An abnormal titre of antinuclear antibody by immunofluorescence or 
an equivalent assay at any point in time and in the absence of drugs 
known to be associated with ‘drug-induced lupus’ syndrome 
Table 1.1 The American College of Rheumatology revised classification criteria for SLE. 
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To solve the problem of individuals fulfilling clinical but not immunological criteria, a 
revision of the criteria was suggested in 2012 by the Systemic Lupus International 
Collaborating Clinics (SLICC), so each patient has to have at least one clinical and one 
laboratory criteria in the total 4 for the diagnosis of SLE. This demonstrated the 
significance of both clinical and immunological features for diagnosis and disease 
evaluation (10). However, the SLICC 2012 criteria were validated again for SLE 
patients with longstanding disease history, therefore patients at early stages of 
disease might be excluded. The advantages of the 2012 SLICC classification criteria 
over the ACR criteria included a greater sensitivity but similar specificity for 
classifying patients with SLE as well as a reduction in overlapping clinical features, for 
instance malar rash and photosensitivity. In addition, lupus nephritis in the presence 
of at least one of the immunologic variables was classified as a “stand alone” criterion 
(10). The 2012 SLICC classification criteria for SLE can be seen in Table 1.2. At the 
time of this review, the 2018 revised ACR/European League Against Rheumatism 
(EULAR) Classification criteria for SLE is undergoing validation process and drafting. 
This proposed new criteria add weighting to the immunological and clinical items 
that are attributed to SLE with a classification threshold of 10 (11).  
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Criterion Definition 
Mucocutaneous 1. Acute cutaneous lupus (ACLE) [lupus malar rash, bullous lupus, 
toxic epidermal necrolysis variant of SLE, maculopapular lupus rash 
and photosensitive lupus rash] OR subacute cutaneous lupus (SCLE) 
[non-indurated psoriasiform and/or annular polycyclic lesions that 
resolve without scarring] 
2. Chronic cutaneous lupus (CCLE) [classic discoid rash: localised or 
generalised, hypertrophic verrucous lupus, lupus panniculitis 
(profundus), mucosal lupus, lupus erythematosus tumidus, chilblains 
lupus, discoid lupus/lichen planus overlap] 
3. Non-scarring alopecia 
4. Oral or nasal ulcers 
Arthritis 5. Inflammatory synovitis in ≥2 joints: 
a. Characterised by swelling or effusion, or 
b. Tenderness and ≥30 minutes of morning stiffness 
6. Any of 
a. Typical pleurisy lasting >1 day, or pleural effusions or 
pleural rub 
b. Typical pericardial pain (pain with recumbency, improved 
by sitting forward) for >1 day, or pericardial effusion, or 
pericardial rub or pericarditis by electrocardiography 
Renal 7. Any of: 
a. Urine protein/creatinine (or 24 h urine protein) 
representing ≥500 mg of protein/24 hour, or 
b. Red blood cell casts 
Neurological 8. Any of: 
a. Seizures 
b. Psychosis 
c. Mononeuritis multiplex 
d. Myelitis 
e. Peripheral or cranial neuropathy 
f. Cerebritis (acute confusional state) 
Haematological 9. Haemolytic anaemia 
10. Leukopenia (<4000/mm3), or lymphopenia (<1000/mm3) of at 
least once 
11. Thrombocytopaenia (<100 000/mm3) of at least once 
Immunological 12. Anti-dsDNA above laboratory reference range (except enzyme-
linked immunosorbent assay (ELISA): twice above reference range) 
13. Anti-Sm 
14. Anti-phospholipid antibody, SLE anti-coagulant, false-positive 
test for syphilis 
15. Anti-cardiolipin (at least twice normal or medium–high titre), or 
anti-β2 glycoprotein 1 
16. Low complement: low C3, or low C4, or low CH50 
17. Direct Coombs test in the absence of haemolytic anaemia 
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Criterion Definition 
Anti-nuclear antibody 
(ANA) 
18. ANA above laboratory reference range 
Rules for 
Classification 
Either biopsy-proven lupus nephritis in the presence of ANA OR anti-
dsDNA as a ‘stand-alone’ criterion,  
OR 
four criteria with at least one of the clinical and one of the 
immunological/ANA criteria 
Table 1.2 The 2012 SLICC classification criteria for SLE. 
 
1.4 Clinical manifestations of SLE 
As presented in the clinical criteria above, SLE is characterised by significant 
heterogeneity in clinical manifestations and patients usually come along with several 
clinical symptoms varying in severity (12, 13). Most of the patients complain about 
general symptoms, such as fatigue, arthralgia, myalgia, fever and lymphadenopathy. 
Mucocutaneous manifestations are among the most frequent clinical findings and 
lupus-specific skin lesions can be classified as acute, subacute and chronic as 
described in the 2012 SLICC criteria. The “butterfly rash” is typical of acute cutaneous 
SLE, although it can be found only in 30% of patients, and it usually appears as an 
acute, painful and erythematous region with malar distribution. The malar rash is 
strongly related to exposure to sunlight. Other mucocutaneous manifestations 
include non-scarring alopecia and oral and/or nasal ulcers (14). Moreover, serositis –
inflammation of pleural and pericardial cavities– can be persistent in patients with 
SLE and it can require high doses of corticosteroids to be treated (15). 
Musculoskeletal manifestations are considered to be universal, as more than 90% of 
lupus patients will present a form of arthritis. In comparison with rheumatoid 
arthritis, lupus arthritis is less severe and not erosive. However, a deforming non-
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erosive joint disorder known as Jaccoud's arthropathy can be seen in up to 5% of SLE 
patients (16-18).  
Haematological manifestations such lymphopenia, neutropenia, thrombocytopenia, 
autoimmune haemolytic anaemia, thrombotic thrombocytopenic purpura and 
myelofibrosis are also known features of SLE (19). Coagulopathies are strongly 
correlated with the coexistence of antiphospholipid antibodies, which can promote 
activation of endothelial cells, platelets, and other cells of the immune system 
leading to venous, arterial, small-vessel thrombosis, and pregnancy loss (20). Apart 
from the thromboembolic events closely related to secondary antiphospholipid 
syndrome, the chronic inflammatory state of patients with SLE is linked to 
acceleration of the atherosclerotic process and in turn to an increased incidence of 
cardiovascular disease (myocardial infarction, stroke) (21). Premature coronary heart 
disease has emerged as a major cause of morbidity and mortality in SLE (22).  
SLE can affect both the central and the peripheral nervous system, which is referred 
as neuropsychiatric SLE (NPSLE). NPSLE can often be severe with multiple symptoms 
imitating other neurological or psychiatric diseases (23). Although the underlying 
mechanisms are still unclear, several pathogenic pathways are related to antibody-
mediated neurotoxicity, vasculopathy due to anti-phospholipid antibodies and 
cytokine-induced neurotoxicity (24).  
Despite the wide spectrum of clinical features, renal involvement (“lupus nephritis”) 
still remains one of the most severe complications and important cause of morbidity 
and mortality amongst patients with SLE (25). Kidney disease in lupus is related to 
glomerular inflammation and the clinical symptoms of glomerulonephritis often 
include edema and weight gain, high blood pressure, nephritic or nephrotic 
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syndrome. Lupus nephritis usually requires close monitoring of 24-hour urine for 
total protein and intensive treatment with immunosuppressant drugs (26). Lupus 
nephritis can be characterised by low levels of serum albumin, whilst urinalysis 
demonstrates increased cellular casts, dysmorphic red blood cells, and the presence 
of haematuria or proteinuria (27). Although clinical features and laboratory 
investigations are important for the diagnosis of renal involvement, renal biopsy is 
the gold standard for the diagnosis and staging of lupus nephritis, since 
histopathological classification is essential for the management and treatment of 
patients (28). The initial classification of lupus nephritis was suggested in 1974 and it 
was lastly modified in 2003 by the International Society of Nephrology/Renal 
Pathology Society (ISN/RPS) (29, 30). The new classification of glomerulonephritis in 
SLE can be seen in Table 1.3. 
 
Stage I Minimal mesangial lupus nephritis 
Stage II Mesangial proliferative lupus nephritis 
Stage III Focal lupus nephritisa 
Stage IV Diffuse segmental (IV-S) or global (IV-G) lupus nephritisb 
Stage V Membranous lupus nephritisc 
Stage VI Advanced sclerosing lupus nephritis 
a Indicate the proportion of glomeruli with active and with sclerotic lesions (<50%). 
b Indicate the proportion of glomeruli with fibrinoid necrosis and cellular crescents (>50%). 
c Class V may occur in combination with class III or IV in which case both will be diagnosed. 
Indicate and grade (mild, moderate, severe) tubular atrophy, interstitial inflammation and 
fibrosis, severity of arteriosclerosis or other vascular lesions. 
Table 1.3 Abbreviated International Society of Nephrology/Renal Pathology Society 
(ISN/RPS) classification of glomerulonephritis in SLE. 
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1.5 Management and treatment of SLE 
Despite the fact that 5-year survival for patients with SLE has improved from 50% in 
the 1950s to more than 90% nowadays, lupus patients still have worse health-related 
quality of life in comparison with the general population or even patients with other 
chronic diseases (31). The major factors for this notorious decrease in mortality seen 
in patients with SLE are undoubtedly the introduction of steroids and other 
immunosuppressants. For patients with general symptoms and mild-to-moderate 
SLE, current guidelines recommend the use of antimalarial drugs (for instance, 
hydroxychloroquine), glucocorticosteroids, non-steroidal anti-inflammatory drugs 
and additional immunosuppressive therapy in case of persistently high disease 
activity (32). The management of severe SLE requires intensified immunosuppressive 
therapy and higher doses of glucocorticosteroids. Particularly, patients with class III 
and IV lupus nephritis require induction therapy with combined glucocorticosteroids, 
and other immunosuppressants such as azathioprine, cyclophosphamide, 
mycophenolic acid/sodium and mycophenolate mofetil (MMF), whilst for 
maintenance therapy, glucocorticosteroids, azathioprine and MMF are 
recommended (33). 
Novel agents targeting specific immune cells and pathways are under clinical trials 
evaluating safety and effectiveness in treating patients with SLE (34). B cell clonal 
expansion is crucial in SLE pathogenesis and begins at preclinical stages (35). 
Rituximab is a chimeric anti-CD20 monoclonal antibody depleting naïve B cells and is 
currently used for treatment of patients with lupus nephritis who are not responsive 
to first-line therapy (36, 37). B-cell activating factor (BAFF) alongside a proliferation-
inducing ligand (APRIL) has a crucial role in regulation of B cells promoting plasma 
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cell survival and naïve B-lymphocyte repertoire selection. Belimumab is a human 
monoclonal antibody targeting BAFF and is approved to treat adult patients with 
autoantibody-positive SLE with active disease despite receiving standard therapy 
(38). Apart from autoreactive B cells, T cells are also important in the development 
and progression of SLE. Abatacept is a CTLA-4-IgG1 fusion protein that inhibits T-cell 
activation. Although it failed to demonstrate any difference in complete response in 
patients with lupus compared to placebo, treatment with abatacept was associated 
with greater improvements from baseline in anti-double-stranded DNA antibody, C3, 
and C4 levels (39). Novel drugs focusing on type I IFN pathway will be analysed in 
detail in the relevant section below. 
Assessment and monitoring of disease activity in patients with SLE is complicated, 
thus relevant indices have been developed and validated for use in clinical practice 
as well as clinical trials. For the purpose of this thesis, the revised British Isles Lupus 
Assessment Group Index (BILAG-2004) was used, which measures disease activity in 
different target organs/systems (domains) affected by SLE based on clinical 
assessments and laboratory results (40, 41). The BILAG-2004 index covers 97 items 
over nine domains (constitutional, mucocutaneous, neuropsychiatric, 
musculoskeletal, cardiorespiratory, gastrointestinal, ophthalmic, renal and 
haematological) recording disease activity that has occurred during the past 4 weeks. 
Disease activity in each domain is then categorised into five grades: A (severe 
disease), B (moderate active disease), C (mild stable disease), D (inactive disease) and 
E (never affected). The global BILAG-2004 score can be calculated by adding the total 
points from the nine BILAG grades (42). The grading system for BILAG-2004 Index can 
be seen in Table 1.4. 
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Grade Definition 
A Severely active disease (sufficient to require disease-modifying treatment, i.e. 
>20mg/day prednisolone, immunosuppressant and cytotoxic drugs) 
B Moderately active disease (requires only symptomatic therapy, i.e. 
prednisolone ≤20mg/day prednisolone, or anti-malarials) 
C Mild stable disease (no indication for changes in treatment) 
D Inactive now but previously active 
E Never affected 
Table 1.4 Grade and definition of BILAG-2004 Index for disease activity in SLE. 
1.6 Pathogenesis of SLE 
Individuals with specific genetic polymorphisms are at greater risk for developing SLE 
compared to the general population, whilst environmental triggers contribute to the 
initiation and perpetuation of the disease. Activation of the innate immune system 
leads to enhanced antigen presentation to T cells and aberrant production of 
proinflammatory cytokines and type I IFNs, which in turn results in activation of the 
adaptive immune system and the production of autoantibodies by autoreactive 
plasma cells. The onset of clinical manifestations is associated with systemic 
inflammation and tissue injury, which in turn amplifies the autoimmune responses 
and irreversible end-organ damage.  
1.6.1 Genetics  
The importance of genetics in the pathogenesis of SLE is supported by the high 
concordance rate (up to 57%) of SLE in monozygotic twins (43, 44). In addition, 
siblings of patients with SLE are 29 times more likely to develop SLE than the general 
population, whilst first-degree relatives of patients with SLE have a 17-fold increased 
risk to develop the disease compared with the general population (45, 46). The 
commonest genetic predisposition is found at the major histocompatibility locus 
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which contains genes for antigen-presenting molecules such class I HLA molecules 
(HLA-A, -B and -C) and class II HLA molecules (HLA-DR, -DQ and -DP) (47, 48). In more 
detail, HLA-DRB1*0301 and HLA-DRB1*1501 loci predispose to development of SLE, 
but HLADRB1*1401 reduces the risk of disease development (49). Genetic factors 
associated with deficiencies in the complement components (C1q, C2, C4A and C4B) 
and the presence of TREX1 mutations consist of the highest risk for developing lupus-
like disease (50-52).  
Genome-wide association studies (GWAS) have identified over 50 gene loci with 
polymorphisms predisposing to SLE (53-55). Most of the SLE susceptibility genes are 
associated with pathways related to regulation apoptosis and clearance of apoptotic 
material, autophagy, the NF-κB pathway, other immune cell signalling pathways and 
cell migration as well as pathways related to activation type I IFN axis (56-58). Several 
single-nucleotide polymorphisms (SNPs) are associated with specific organ 
manifestations such as lupus nephritis (59). However, lupus is beyond genetics, as 
this accounts for only 20% of susceptibility to SLE suggesting a large component of 
epigenetic and environmental triggers (60). 
1.6.2 Epigenetic and environmental factors 
Epigenetic effects such as DNA methylation, post-translational histone modifications 
and micro ribonucleic acids (miRNAs) greatly influence the risk of SLE (61). The role 
of epigenetics in the pathogenesis of SLE is supported by the studies carried out in 
identical twins who are discordant for SLE (62). Abnormal methylation has been 
associated with development of SLE, whilst aberrantly expressed miRNAs in different 
cell types and tissues are thought to play an important role in the progression of SLE 
(63, 64).  
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Amongst the most important environmental triggers for lupus pathology is exposure 
to ultraviolet (UV) light culminating in aberrant apoptosis of keratinocytes (65). 
Accumulation of apoptotic cells due to defective phagocytosis leads to secondary 
necrosis and subsequently production of pro-inflammatory cytokines including IL-1, 
IL-3, IL-6, granulocyte macrophage colony-stimulating factor (GM-CSF), type I and II 
IFNs, which in turn activate B cells to differentiate into plasma cells secreting 
antibodies (66). Furthermore, a number of exogenous viruses, particularly Epstein-
Barr virus (EBV), have been linked to the pathogenesis of SLE. High antibody titres to 
EBV alongside increased circulating EBV viral loads amongst patients with SLE have 
been suspected for the development of systemic autoimmunity via molecular 
mimicry of viral protein regions that are homologous to nuclear antigens (67). Apart 
from EBV, human endogenous retroviruses including HRES-1, HERV-3, HERV-E4-1, 
HERV-K10 and HERV-K18 have been linked to the development of SLE (68). Finally, 
drug-induced lupus is defined as a syndrome with clinical and serological features 
similar to SLE that is temporally related to continuous drug exposure and which 
resolves after discontinuation of this drug (69). More than 100 drugs have been 
associated with this entity in genetically predisposed individuals (70). Unlike SLE, 
clinical manifestations of drug-induced lupus subside when the drug is withdrawn.  
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1.6.3 Apoptosis and autoantibodies 
A defect in both regulation of apoptosis and clearance of apoptotic material is a 
hallmark of the pathogenesis of SLE. As mentioned above, inherited complement 
deficiency of the classical pathway is one of the strongest associations with systemic 
autoimmunity. C1q knock-out murine models and humans with C1q deficiency, a rare 
monogenic disorder, develop autoantibodies and lupus-like disease due to impaired 
apoptotic cell debris clearance (71). Experimental lupus models presented an 
increased generation of apoptotic material and a decreased phagocytic function, so 
that usual clearance mechanisms are overwhelmed (72). The apoptotic cells can 
release nucleosomes, the main component of which is chromatin, into the cytoplasm 
and subsequently attach them to the plasma membrane (73, 74). Moreover, blebs of 
apoptotic keratinocytes in SLE contain autoantigens that can be found clustered on 
the cell surface (66). Additionally, lupus nephritis is correlated with nucleosome 
release within the glomeruli due to increased cell apoptosis locally in the kidney (75). 
On the other hand, anti-dsDNA antibodies can be found in approximately 70% of 
patients with SLE and this percentage is higher in patients with renal disease (76). 
Autoantibodies can bind to exposed nuclear antigens and form in situ immune 
complexes that can potentially cause tissue damage via binding to Fc receptors and 
subsequent activation of cellular immunity and/or via the activation of complement 
cascade. In murine models, certain monoclonal anti-dsDNA antibodies were able to 
bind to the glomeruli leading to proteinuria and histopathological lesions (77). A 
study using immune electron microscopy demonstrated that nephritogenic anti-
dsDNA antibodies were able to target intraglomerular membrane-associated 
nucleosomes in lupus nephritis (78).  
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1.6.4 Cellular components 
Innate and adaptive immune cell present a series of abnormalities contributing to 
autoreactivity and lupus pathology. Altered functional properties of neutrophils such 
as diminished phagocytic and lysosomal activity, upregulation of adhesion molecules 
and intravascular activation in vivo are prominent in SLE (79). Neutrophils undergo a 
particular cell death realising neutrophil extracellular traps (NETs) and this NET 
formation is linked to the exposure of nuclear autoantigen in SLE (80). Interestingly, 
mitochondrial reactive oxygen species (ROS) production can enhance NET formation 
in low-density granulocytes from patients with SLE without activation of functional 
NADPH, which is normally required in NET formation (81).  
Professional antigen presenting cells (for instance, cDCs, macrophages, B cells) 
express MHC class II molecules along with co-stimulatory molecules and pattern 
recognition receptors, being very potent T cell stimulators. cDCs have been proposed 
to perform prolonged self-antigen presentation and produce pro-inflammatory 
cytokines production in autoimmune diseases, while they exhibit a defective 
tolerogenic function failing to contribute to self-tolerance (82). In addition, a 
reduction in numbers of macrophages alongside with their impaired function in 
uptake of apoptotic bodies leads to the accumulation of apoptotic cells near germinal 
centres (83). 
CD4+ T cells in SLE display an altered signalling phenotype exhibiting a rewiring of 
their T cell receptor (TCR); expression of the CD3ζ chain is decreased and replaced by 
the homologous Fcγ receptor chain, which recruits the downstream signalling Syk 
kinase instead of the normal CD3ζ partner Zap70 (84). This autoreactive profile is 
linked to defective gene transcription and altered cytokine production; a defect in IL-
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2 production and an increased production of interleukin 17 (IL-17) having their 
effector and regulatory capacities significantly compromised (85). Although 
CD4+CD25hiFoxP3+ regulatory T cell (Treg) numbers appear to be reduced in patients 
with active SLE, it is not clear whereas they actively contribute to SLE pathogenesis 
(86, 87). CD4+CXCR5+PD1+OX40+ICOS+ follicular T helper (Tfh) cells is a dynamic subset 
of CD4+ T cells secreting IL-21 essential for B cell immunoglobulin production, isotype 
switching, and somatic hypermutation (88). In addition, extrafollicular helper T cells 
(eTfh) represent a CD4+ T cell subpopulation analogous to Tfh that can promote 
immunoglobulin production by B cells in extrafollicular compartments (89). 
Remarkably, eTfh produce more IL-21 in SLE patients and eTfh numbers are increased 
in the peripheral blood correlating with disease activity and other immunological 
features such as plasmablast numbers as well as with anti-dsDNA titres (90, 91).  
Apart from T cell abnormalities, B cell phenotype seems to be notably affected in SLE. 
Reduced numbers of naïve B cells (CD19+CD27−) and IL-10-secreting Breg 
(CD19+CD24hiCD38hi) subsets as well as increased numbers of transitional B cells 
(CD19+CD24hiCD38hi), switched memory B cells (CD19+CD27+IgD−), double-negative B 
cells (CD19+CD27−IgD−) and plasmablasts (CD27hiCD38+CD19dimsIglowCD20−CD138+) 
correlate with disease activity characterising active SLE (92-94). 
Apart from differences in enumeration of B cell subsets, SLE patients also exhibit 
increased numbers of self-reactive B cells in emigrating and mature naïve B cell 
subsets (35). The 9G4+ antibody correlates with disease activity in SLE, whilst it 
represents a significant component of the anti-apoptotic cell repertoire in SLE 
comprising an important step in development of SLE (95). Furthermore, DNA-reactive 
B cells carry risk alleles such as BANK1, BLK, CSK, FCGR2B linked to increased 
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susceptibility to SLE and can promote hyper-responsiveness to B-cell receptor (BCR) 
engagement and enhanced B cell activation as well as PTPN22 risk allele resulting in 
diminished tolerance in immature B cells. DNA-reactive B cells are more likely to 
mature, participate in germinal centre reactions, and eventually undergo plasma cell 
differentiation in lupus patients (96).  
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Figure 1.1 Overview of the pathogenesis and the main organs affected in SLE. Genetic, 
environmental, hormonal, epigenetic, and immunoregulatory factors act either sequentially 
or simultaneously on the immune system resulting in the generation of autoantibodies, 
immune complexes, autoreactive or inflammatory T cells, and inflammatory cytokines that 
may initiate and amplify inflammation and damage to various organs. (97). 
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1.7 Preclinical autoimmunity and progression to SLE 
Up to 25% of the general population present positive ANA, usually at low titre (1:40), 
but only a small percentage will progress to a clinically overt systemic autoimmune 
disease (98, 99). ANA positivity correlates with female gender and age, a feature that 
might be associated with higher prevalence of SLE among women. African Americans 
also present a greater titre of ANA in comparison with other populations in the 
United States (100).  
The high prevalence of autoreactivity in the general population suggests that 
autoantibodies may be a major part of a healthy immune response critical to immune 
regulation. Healthy individuals usually have IgM autoantibodies, also known as 
natural autoantibodies. In mice, natural IgM antibodies can recognise apoptotic cells 
enhancing the phagocytic clearance of dead and dying cells and suppressing innate 
immune signaling pathways (101). In patients with SLE, natural IgM autoantibodies 
can bind to neo-epitopes on apoptotic cells and are present at higher levels in 
patients with lower disease activity and less severe organ damage (102). Natural IgM 
autoantibodies are predominantly produced by CD5+ B cells, which consist of around 
20% of peripheral blood B lymphocytes in adults, and are polyreactive presenting low 
affinity for a variety of autoantigens (103).  
Many individuals who might have features suggestive of an autoimmune disease do 
not necessarily complete the criteria for SLE diagnosis. This condition has been 
described as incomplete lupus erythematosus (104, 105). A period of ANA positivity 
and other immune dysregulation can precede clinically overt disease (106). 
Approximately 15-20% of these individuals eventually progress to full SLE within 5-
10 years (107). In some individuals, presumably with additional pre-existing genetic 
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and/or epigenetic susceptibility factors, these autoantibodies might promote 
activation of immune responses that culminate in progression from benign 
autoimmunity to clinical disease. The severity of disease might also increase as 
autoimmune responses escalate and tissue damage accumulates (108). 
Nevertheless, the factors determining the transition from this benign preclinical 
stage are still unclear, since the majority of people presenting ANA positivity will not 
develop any further clinical manifestations. A better understanding of early stages of 
SLE pathogenesis can improve on time diagnosis, early intervention and potentially 
more effective treatment options. A schematic presentation of the gradual 
progression from the stage of ANA positivity to clinical symptoms and established 
SLE can be seen in Figure 1.2. 
 
Figure 1.2 Schematic presentation of the gradual progression from the stage of ANA 
positivity to SLE. Immunological abnormalities and clinical symptoms accumulate before the 
diagnosis of SLE, while organ damage is escalated due to disease activity and drug toxicity. 
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1.8 Type I interferons (IFNs) 
Autoimmune rheumatic diseases are characterised by a breakdown of immune 
tolerance leading to inflammation and irreversible end-organ tissue damage. Diverse 
cellular components and molecules contribute to the development of autoimmunity, 
and their roles vary between individuals as well as diseases. However, common 
features may be used to classify, diagnose and target therapy to groups or subsets of 
patients. The use of anti-TNF and B cell-depleting therapies has led to a rethinking of 
diagnosis and investigation in terms of ultimate therapy. Dysregulation of type I 
interferons (IFNs) is a common factor in multiple autoimmune rheumatic diseases 
and is of increased interest recently due to appreciation that it may define clinical 
phenotypes and therapy responses, as well as the potential to treat with direct type 
I IFN blockade (109, 110). 
IFNs are generally classified into 3 families –IFN-I, IFN-II and IFN-III– which differ in 
their immunomodulatory properties, their structural homology and the group of cells 
they are secreted from (111, 112). Type I IFNs (IFN-α, -β, -ω, -ε, -κ) consist of the 
largest family and alongside IFN-III (IFN-λ) activate intracellular signalling pathways 
which mediate immune responses against viruses and tumours (111, 113, 114). 
Although most cells are capable of producing type I IFNs, in most situations the 
majority comes from dedicated danger-sensing cells called plasmacytoid dendritic 
cells (pDCs). Type I IFNs act on all nucleated cells during viral invasion to inhibit viral 
replication (112). They also have potent immunostimulatory properties, including 
inducing the maturation and activation of myeloid dendritic cells (DCs), favouring Th1 
phenotype and promote B cell activation, antibody production and Ig class switching 
(115-117). These immunostimulatory properties underlie their roles in 
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autoimmunity. In contrast, although there is overlap in the gene sets whose 
expression they induce, IFN-II (IFN-γ) is functionally distinct. It is produced mainly by 
NK cells and certain T cell subsets, and regulates aspects of immune responses like 
phagocytosis and antigen presentation (118).  
1.9 Plasmacytoid dendritic cells (pDCs) 
1.9.1 Development of pDCs 
Plasmacytoid dendritic cells (pDCs) have a distinct phenotype compared to 
conventional dendritic cells (cDCs) and play a crucial role mediating type I IFN 
production predominantly during acute viral infections (119). Both pDCs and cDCs 
derive from a common DC progenitor, which is characterised by lack of lineage 
markers and expression of Fms-like tyrosine kinase 3 (FLT3; CD135), macrophage 
colony-stimulating factor receptor (M-CSFR; CD115) and the receptor tyrosine kinase 
KIT (CD117) (120-122). Another progenitor characterised as LIN−KITint/loFLT3+IL-
7Rα−M-CSFR- expresses high levels of E2-2, the main transcription factor defining pDC 
lineage, and it can be generated by the common DC progenitor under conditions that 
favour E2-2 upregulation such as exposure to thrombopoietin or M-CSF (123, 124). 
E2-2 can bind to a large fraction of pDC-enriched genes and its continuous expression 
is required to maintain cell fate (125). E2-2 targets transcriptional factors that encode 
proteins involved in the development, homeostasis and function of pDCs, for 
instance SPIB, BCL11A, IRF8, RUNX2 and CIITA, the pDC-related surface markers 
BDCA-2, ILT7, SIGLEC-H and the intracellular nucleic acid sensors TLR7, TLR9 and 
PACSIN1 (124, 125). Deletion of E2-2 in mature pDCs causes the loss of pDC-related 
markers and differentiation into cDC-like cells by upregulating MHC-II molecules and 
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therefore enhancing the ability to prime T cells (125). On the other hand, ID2 is the 
repressor of E2-2 and its expression is absent in pDCs but prominent in cDCs (126).  
FLT3 and its ligand (FLT3L) are of paramount importance in pDC development 
inducing activation of signal transducer and activator of transcription 3 (STAT3)- and 
phosphoinositide 3-kinase (PI3K)-dependent activation of mammalian target of 
rapamycin (mTOR) (127-129). Intriguingly, pDCs can also derive from a lymphoid-
primed multipotent progenitor characterised by lack of lineage markers and as 
KIT+SCA1+CD34+FLT3+, in which type I IFNs and FLT3L act synergistically to promote 
pDC development by inducing FTL3 expression (123, 130).  
1.9.2 pDCs as IFN-α-producing cells 
pDCs appear distinct from the cDCs, since instead of antigen presentation pDCs’ 
primary role is the production of type I IFNs in response to danger signals (131, 132). 
Their main function is to produce type I IFNs, predominantly IFN-α, after sensing 
nucleic acids mainly via toll-like receptors (TLRs) -TLR7 and TLR9- located in 
endosomal compartments. TLR7 can sense RNA viruses, endogenous RNA and 
synthetic oligoribonucleotides, whereas TLR9 can detect DNA viruses containing 
unmethylated CpG-rich DNA sequences, synthetic CpG oligodeoxyribonucleotides, 
and endogenous DNA (133). Upon binding of TLRs to viral or self-nucleic acids, the 
myeloid differentiation primary response protein 88 (MyD88)-IRF7 and the MyD88-
nuclear factor-κB (NF-κB) pathways are activated inducing the secretion of type I IFNs 
and other pro-inflammatory cytokines (134, 135).  
The type of compartment in which TLR7 and TLR9 encounter their ligands is crucial 
for the production of type I IFNs and/or pro-inflammatory cytokines (136). 
Multimeric CpG-A oligonucleotides aggregate in early endosomes where they 
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activate the MyD88-IRF7 pathway that induces type I IFNs. On the other hand, 
monomeric CpG-B is transferred to an endo-lysosomal compartment, in which it 
induces the MyD88-NF-κB pathway upregulating costimulatory molecules and 
triggering the secretion of pro-inflammatory cytokines (137). Notably, IkappaB 
kinase-alpha (IKKα), osteopontin, and mTOR are key elements of the MyD88-IRF7 
signalling pathway, while IRF5 is necessary for MyD88-NF-κB signalling pathway (136-
141). Trafficking of TLR9 to the appropriate compartment for type I IFN production is 
dependent on adapter protein 3 (AP3) (142, 143). The peptide/histidine transporter 
1 (PHT1), BLOC1 and BLOC2 Hermansky-Pudlak syndrome proteins are encoded by 
Slc15a4 and are thought to be key mediators of TLR9 signalling in pDCs (143). 
Nonetheless, TLR9-mediated sensing of large DNA-containing immune complexes is 
independent of AP3 requiring phagocytic and autophagic pathways instead. TLR7-
mediated sensing of single stranded RNA (ssRNA) also occurs in a distinct subcellular 
compartment requiring transport of viral nucleic acids from cytosol into the lysosome 
by autophagy (144). 
TLR7 and TLR9 consist of the main receptor sensing nucleic acids leading to activation 
of pDCs and the production of type I IFNs and pro-inflammatory cytokines. However, 
TLR-independent pathways of sensing nucleic acids mediated via other transcription 
factors play important role as well (145). CpG-A oligonucleotides can bind to the 
DExD/H-box helicase 36 (DHX36) resulting in the translocation of IRF7 to the nucleus 
and type I IFN production (146). In contrast, CpG-B oligonucleotides can bind to DHX9 
resulting in nuclear translocation of NF-κB and eventually the secretion of pro-
inflammatory cytokines. Viral nucleic acids can be detected in a RIG-I-like helicase-
dependent manner, while other major cytosolic sensors include cGAS and STING 
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(147, 148). The main intracellular pathways of TLR-mediated type I IFN and pro-
inflammatory cytokine production can be seen in Figure 2.3. 
 
 
Figure 1.3 TLR7 and TLR9 intracellular signalling pathways in pDCs leading to type I IFN and 
pro-inflammatory cytokine production. 
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1.9.3 pDCs as antigen-presenting cells 
Although not as efficient as cDCs, pDCs express MHC class II molecules and they are 
able to capture, process and present antigens to CD4+ T cells inducing their activation 
(149, 150). TLR-activated pDCs have enhanced antigen-presenting function and can 
promote Th1 and Th17 differentiation (151-153). Combination of TLR stimulation and 
antigen delivery via BST2 (CD317, tetherin) can induce robust cellular and humoral 
immune responses against viral infection or tumour growth (154). Despite their 
weaker antigen-presenting properties, pDCs can also cross-present exogenous 
antigens to CD8+ T cells and therefore induce antiviral and antitumor responses (155-
157). Recycling endosomes are also important features of pDCs which allow peptides 
to be continuously loaded on to MHC-I molecules. This process facilitates the 
presentation of viral antigens to CD8+ T cells contributing to antiviral immunity. 
However, unstimulated or alternatively stimulated (e.g. HIV) pDCs are predominantly 
known to be involved in the induction of tolerogenic immune responses by 
expressing indoleamine-2,3-dioxygenase (IDO), ICOSL, OX40L, PD-L1 and by 
promoting CD4+ T cell anergy and Treg differentiation (158-162). pDCs that capture 
antigens in peripheral tissues use CCR9 to migrate to the thymus, where they can 
promote deletion of antigen-specific thymocytes, actively inducing immune 
tolerance (163). Interestingly, conjugation of antigens with BDCA-2 on pDC cell 
surface can promote immune tolerance by inhibiting antigen-specific CD4+ T cell as 
well as antibody responses upon secondary exposure to antigen in the presence of 
adjuvant. This process involves increase in Treg cells and decrease in effector CD4+ T 
cells (164). Therefore, pDCs have strong tolerogenic properties apart from their main 
role to mediate type I IFN immune responses. 
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A schematic summary of the pleiotropic functions of pDCs on the immune system 
can be seen in Figure 1.4. 
 
Figure 1.4 Pleiotropic functions of pDCs on the immune system. 
 
1.10 Regulation of type I IFN production 
The balance of immune responses induced by type I IFNs is regulated at multiple 
stages to limit the toxicity to the host by preventing tissue damage and autoimmunity 
(165). These include regulation of IFN production and response to target cells. 
The interferon regulatory factor (IRF) family of transcription factors is crucial for the 
propagation of IFN production (166). IRFs have heterogeneous functions in the 
regulation of both innate and adaptive immunity and are associated with the 
recognition of PAMPs from TLRs (167). PDCs constitutively express IRF7, which –
alongside IRF5– induces the transcription of IFN-α related genes (23, 24). A wide 
range of regulatory receptors including BDCA-2, ILT7, NCR2, CD32 (FcγRII), are 
expressed on the cell surface of human pDCs, which modulate the intracellular 
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signalling pathways in response to TLR ligands (119, 168, 169). In particular, the 
interaction between BST2 (CD317; tetherin) and ILT7 was proposed as a regulatory 
mechanism to control the continuous activation of TLR signalling in pDCs (170). 
Although cross-linking of ILT7 was confirmed to truly inhibit type I IFN production, 
another study showed that BST2-mediated ILT7 cross-linking failed to act a negative 
feedback for IFN production in TLR-activated pDCs (171). 
Although pDCs are the main source of type I IFNs, other cells such as epithelial cells 
or fibroblasts can secrete these cytokines (172). IFN production by neutrophils may 
be important in autoimmunity (173). NK cells can induce secretion of IFN-α by pDCs 
stimulated by RNA-containing immune complexes, while monocytes play an 
inhibitory role (174). Furthermore, microRNAs such as miR-155 and miR-146a seem 
to have an immunomodulatory effect on activation signalling pathways (175, 176). 
Oestrogen might favour type I IFN production through activation of TLR7 signalling 
pathway, consistent with female predominance of these diseases (177). 
1.11 Effects of type I IFNs on target cells 
Outcomes of type I IFN signalling may be as diverse as promotion of cell survival and 
promotion or prevention of apoptosis (178-180). Interestingly, although all type I IFN 
ligands signal through the same receptor (IFNAR), they result in different biological 
outcomes (181). This is important for therapy as either ligands or receptors may be 
targeted. The IFNAR2 subunit of the receptor has a surface-bound (IFNAR2b) and a 
soluble form, both with regulatory activity (182). In contrast, type II IFN (IFN-γ) signals 
via the IFNGR receptor. Type III IFN signals via a receptor that combines a unique 
subunit (IFNLR1) with one also used by IL-10 family cytokines and its expression is 
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much more restricted to cells of epithelial origin and dendritic cells (183). 
Interestingly, our group found that type III IFN signalling could also vary between 
cells: skin fibroblasts respond to type III IFNs (not only keratinocytes as previously 
thought) but they do so via MAPK instead of STAT1 (184). Each receptor type is 
associated with different pathways of STAT signalling and gene promoters. However, 
there is considerable overlap between the genes whose expression is induced by 
these pathways. This makes measurement of activity using gene expression, as in an 
interferon signature, complex. Effect of type II and III IFNs, variations in circulating 
immune cells, for example lymphopenia seen in lupus patients, and changes in other 
immune functions could all influence results. 
Early evidence about the link of type I IFNs to autoimmunity was given in patients 
receiving immunotherapy with IFNs for chronic viral infections or malignant carcinoid 
tumours (185, 186). Interestingly, the presence of autoantibodies prior to IFN 
therapy considerably increased the risk for autoimmune phenomena that often 
characterise SLE, RA, polymyositis, suggesting that type IFNs might contribute to the 
development of clinical manifestations from a preclinical stage. Nevertheless, 
autoimmunity may remit after cessation of treatment, implying that regulatory 
factors control autoimmune responses and the transition to clinically overt disease 
is much more complicated (187). 
Whilst the mechanisms behind the dysregulation of the IFN system are complex and 
remain unclear, advances have been made in understanding their role in systemic 
autoimmune diseases. 
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1.12 Systemic Lupus Erythematosus and type I IFNs 
SLE is a prototypic type I interferon-mediated autoimmune disease whose clinical 
manifestations are diverse in organs affected, severity, and response to targeted and 
non-targeted therapies (1). Its pathogenesis is similarly complex, but a defining 
feature is an immune response against endogenous nuclear antigens, with anti-
nuclear antibodies (ANA) being central to diagnosis, activity and tissue inflammation 
(188). ANA positivity may precede clinical symptoms by years, and only a proportion 
of such individuals develop organ inflammation, suggesting that autoantibodies are 
an incomplete explanation for pathology (108). ANA production by B cells may arise 
secondary to innate immune abnormalities in the sensing of nuclear antigens; type I 
IFNs are crucial mediator by which innate immune cells stimulate B cells. 
Increased levels of serum IFN-α were described in patients with SLE over 30 years 
ago and were associated with disease activity and specific clinical manifestations 
such as fever, arthralgia, rash, and leukopenia (189, 190). High dose IFN-α treatment 
can induce a variety of neuropsychiatric adverse effects, while similar symptoms in 
neuropsychiatric SLE are linked to IFN-α production. Higher levels of IFN-α were 
detected in cerebrospinal fluid but decrease, when the manifestations of lupus 
psychosis subsided (191, 192). Type I IFNs also contribute to lupus nephritis (193). In 
murine lupus models, it exacerbated glomerulonephritis by increasing immune 
complex deposition in the kidneys (194). Patients with SLE have reduced numbers of 
pDCs in blood, but increased numbers of BDCA-2+ cells intraglomerularly (195). In 
cutaneous lupus erythematosus, there is a unique IFN environment in the skin. 
Keratinocytes produce type III IFNs. Both type I and III IFNs mediate immune 
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responses, and the latter stimulates further type I IFN production (196). Patients with 
active CLE also have detectable serum levels of IFN-λ1 (197). 
Genes in the IFN-pathway and regulation of innate immune responses are prominent 
in SLE susceptibility. These include variants in HLA and Fcγ receptor genes, IRF5, 
STAT4, PTPN22, TNFAIP3, BLK, BANK1, TNFSF4 and ITGAM (198). Intriguingly, high 
type I IFN activity seems to be a heritable risk factor being clustered in specific 
families in both SLE patients and their healthy first-degree relatives (199). The risk 
haplotypes in the interferon regulatory factors IRF5 and IRF7 are associated with 
increased type I IFN activity and risk is dependent on particular autoantibodies (58, 
200-204). The risk haplotype of IRF5 is also associated with risk of progression to 
clinical disease in ANA positive individuals (205). Gene variants in IFIH1 (a cytoplasmic 
dsRNA sensor that activates IFN-α signalling) correlate to anti-dsDNA antibodies and 
increased sensitivity to IFN-α (206). In addition, IRF8 is strongly related to increased 
cardiovascular risk in mouse models as well as SLE patients (207, 208). 
What is the environmental trigger for induction of type I IFN production? It has been 
proposed that nucleic acids from common viruses like Epstein-Barr virus (EBV) could 
initiate the IFN-α production via activation of intracellular TLR7 and TLR9 leading to 
disease in genetically predisposed individuals (209). An alternative theory suggests 
that self-derived nucleic acids comprise the major inducer of IFN-α secretion in SLE 
via the intracellular receptors responsible for antiviral immunity (210). Apoptosis and 
clearance of apoptotic material are defective in SLE allowing the maintenance of DNA 
(or RNA)-containing immune complexes (211). These nucleic acid-autoantibody 
complexes can be internalised by Fc receptors and recognised by endosomal TLR7 
and TLR9 inducing aberrant IFN-α production by pDCs (168, 212). Degradation of 
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nucleic acids or inhibition of FcγRIIa can negate IFN-α production (172). 
Autoantibodies against RNA-associated proteins such as snRNP, Ro (SSA), La (SSB) 
can also augment immune responses (213, 214). The RNA binding protein Ro60 has 
been recently shown to regulate IFN-stimulated gene expression (215). 
Expansion of plasmablasts/plasma cells is a hallmark of SLE positively correlated to 
disease activity and type I IFN enhances the differentiation of B cells to plasmablasts 
(216, 217). Hence, there may be positive feedback between B cells and pDCs via 
autoantibodies and IFN-α respectively. Type I IFNs can promote differentiation of 
plasma cells in vitro and can also confer a unique phenotype; type I IFNs can stimulate 
plasma cells, including those derived from SLE patients, secrete ISG15, via which they 
have pro-inflammatory effects independently of antibody secretion (218). 
In mice TLR9-MyD88 signalling is crucial for switching of autoreactive of IgM anti-self 
B cells to the pathogenic IgG2a and 2b subclasses (219). T cells are directly affected 
by IFN-α promoting the generation of effector and memory CD8+ T cells (220). 
Therefore, innate immunity may moderate adaptive immune responses against self-
antigens. 
Although self-nucleic acid containing immune complexes have been proposed as 
trigger of pDCs to produce IFN-α, other cells could an equally important role. For 
instance, there is increasing interest in the role of neutrophils in autoimmunity. The 
presence of neutrophils in inflamed kidney tissue was reported long ago in both 
experimental models and patients with autoimmune conditions affecting the kidneys 
(221, 222). Neutrophils seem to be key players in inducing type I IFN production by 
pDCs in a DNA- and TLR9-dependent manner (223). As mentioned above, neutrophils 
undergo special type of cellular death (NETosis), in which they release web-like 
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structures known as neutrophil extracellular traps (NETs) composed of chromatin 
and granule proteins that can bind and kill microorganisms (224). NETs also contain 
nuclear material, DNA and histones, and antimicrobial agents (LL37, HMGB1) that 
prevent nucleic acids from degradation. Thus, they can potentially facilitate the 
internalisation of endogenous DNA and immune complexes by pDCs and 
subsequently IFN-α production (223, 225). Many cytokines, including IFN-α, can 
actually act as priming factors on mature neutrophils, allowing the formation of NETs 
upon subsequent stimulation with complement factor 5a (226). As a consequence, 
neutrophils could be in the centre of another positive feedback loop between 
induction and maintenance of type I IFNs perpetuating immune responses. 
1.13 Sjögren’s Syndrome 
Although dysregulation of type I IFN system has been mostly studied in SLE, there is 
evidence of increased type I IFN activity in many other rheumatic and inflammatory 
disorders, potentially sharing common molecular pathways (227, 228). Primary 
Sjögren’s Syndrome (pSS) is an autoimmune disorder primarily affecting the salivary 
and lacrimal glands. It is characterised by autoantibodies against ribonucleoproteins, 
Ro (SSA) and La (SSB) (229). ISG expression is upregulated in both humans and mouse 
models, especially in those with detectable autoantibodies, and many studies tried 
to correlate these findings with disease pathogenesis (230). As in SLE, autoantigens 
of apoptotic origin provide the immunogenic stimulus for the initiation of pathogenic 
responses (231). RNA-containing immune complexes can activate pDCs in salivary 
glands and enhance the production of IFN-a, while IFN-a itself can upregulate the 
expression of ISGs in the target organs (232, 233). Immune responses being 
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developed in affected tissues appear mainly TLR-dependent (234, 235). Early studies 
clearly identified an IFN signature in salivary glands from patients with pSS; IRF7, 
IRF8, and IRF9 were significantly upregulated (236, 237). PBMCs also expressed an 
IFN signature and closely correlated with anti-Ro(SSA) and anti-La(SSB) titres (238, 
239). A subgroup of pSS patients with monocyte IFN signature also presented higher 
disease activity alongside higher BAFF mRNA expression (240). 
1.14 Inflammatory Myositis 
In myositis, pDCs infiltrate tissues and secrete aberrant amounts of type I IFNs and 
ISGs are significantly upregulated in both inflamed muscles and PBMCs (241-243). 
Serum IFN-a is correlated to serum muscle enzyme levels in untreated disease 
among patients with juvenile dermatomyositis and inversely correlated to the 
duration of untreated disease (244). Additionally, anti-Jo1 and anti-Ro(SSA) 
autoantibodies were associated with higher expression of ISGs in PBMCs and higher 
disease activity in patients with dermatomyositis (245).  
1.15 Other Systemic Autoimmune Diseases 
Other connective tissue diseases associated with anti-nuclear antibodies also have 
some evidence for involvement of type I IFNs, at least in subsets of patients. An 
interferon signature similar to SLE and myositis was identified in patients with 
scleroderma (243). Antiphospholipid syndrome was reported as a side effect in 
patients receiving interferon-alpha therapy for unrelated diseases (246, 247). 
Patients with early incomplete forms of connective tissue diseases, of whom a 
proportion progressed to SLE or other diseases, had increased interferon activity 
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(248). Furthermore, a subgroup of patients with established undifferentiated 
connective tissue diseases of more than 12 months duration also had increased 
interferon activity (249). 
1.16 Rheumatoid Arthritis 
IFN signature was studied in RA as a biomarker for disease activity and response to 
therapy. In preclinical RA individuals with arthralgia and elevated type I IFN signature 
were at greater risk to develop arthritis (250). Type I IFN also predicted therapy 
response, and interestingly had opposite predictive value for two targeted therapies. 
Patients with high type I IFN signature had a poor response to rituximab (251, 252). 
Although RA patients with high IFN signature presented higher disease activity, in a 
recent study higher IFN score in neutrophils correlated with a good response to anti-
TNF treatment (253, 254). Type I IFN status may predict complications of RA. 
Increased IFN-regulated transcripts, including IFIT, IFIT2, and IRF7, in a subset of RA 
patients were associated with upregulated pathways related to coagulation, 
complement activation and fatty acid metabolism (255).  
1.17 Outside systemic autoimmunity: roles for type I IFNs in other diseases 
Type I IFN axis influences host immune response to cancer as well as response to 
radiotherapy (256). Intratumorally, type I IFNs can enhance antitumor immunity as 
well as having beneficial anti-angiogenic effects (257). Type I IFNs have complex roles 
in chronic infection. They are mediators of antiviral defence and evasion of type I IFN 
effects significantly influences the pathogenicity of HIV and CMV infection, although 
unhelpful immunosuppressive effects of type I IFNs have also been described (258-
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261). Type I IFNs may mediate atherosclerosis, which is of particular interest given 
the prevalence of this complication in autoimmune rheumatic diseases (262). 
1.18 Interferonopathies 
“Interferonopathies” are a heterogeneous group of disorders mainly presenting an 
autosomal recessive inheritance pattern, which are characterised by constitutive 
upregulation of type I IFNs. Aicardi-Goutieres syndrome (AGS), the most well studied 
interferonopathy, usually presents an early onset during childhood with lupus-like 
symptoms (263). IFN signature in peripheral blood has been reported to be universal 
in AGS patients with mutations in TREX1, IFIH1, RNASEH2A, RNASEH2C, ADAR1, while 
each mutation in these genes has been correlated with different clinical 
manifestations (264-266). These monogenic diseases culminating in the 
dysregulation of IFN-related responses strongly support the linkage between type I 
IFNs and autoimmunity. 
1.19 Therapeutic targeting of type I IFN pathway 
Given its pleotropic roles diverse diseases, blockade of type I IFN axis has potential 
to become a versatile treatment throughout in rheumatology and beyond. The most 
direct approach, with greatest use in human clinical trials, is the monoclonal antibody 
blockers of IFN-alpha or its receptor. However, the traditional lupus therapy 
hydroxychloroquine has relatively selective effects on type I IFNs. It blocks TLR7 and 
TLR9 activation by engaging TLR-binding epitopes and can efficiently impair the 
ability of pDCs to produce IFN-a upon stimulation, also suggesting that TLR-7 and 
TLR-9 antagonists might be potential treatment options in the future for many 
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autoimmune diseases (267-269). A number of small molecules or oligonucleotide 
inhibitors of TLRs for potential use in SLE or other autoimmune diseases are in 
preclinical or Phase I development (270). IFN signalling may also affect the efficacy 
of glucocorticoids. Glucocorticoids present decreased activity to inhibit the IFN 
pathway in pDCs activated via TLR-dependent pathways in SLE patients and lupus-
mouse models (271, 272). 
New therapeutic approaches targeting directly IFN-a by neutralizing monoclonal 
antibodies (sifalimumab, rontalizumab, AGS-009) have shown encouraging results. 
Phase I clinical trials confirmed their safety, tolerability and their ability to partially 
inhibit the overexpression of ISGs (273-275). The inhibition of IFN-a/b-inducible 
genes in whole blood was dose-dependent and the expression of genes for BAFF, IL-
10, IL-1b, GM-CSF were also suppressed (276). In a phase IIb, randomised, double-
blind, placebo-controlled study, sifalimumab achieved its primary endpoint by 
reducing disease activity in patients with SLE with acceptable safety profile in both 
IFN signature positive and negative subjects. However, immunological parameters 
such as complement levels and anti-dsDNA antibodies remained unchanged (277). In 
a recent phase II study, rontalizumab proved superiority in comparison with the 
control only in the group of patients with low IFN signature, who presented higher 
SLE response index and had lower use of steroids (278). Given the multiple forms of 
type I IFNs, targeting the shared IFNAR1 receptor may more effectively block type I 
IFN signalling (279, 280). Anifrolumab, an anti-IFNAR1 monoclonal antibody, met its 
primary endpoints of reduction in global disease activity score in patients with SLE 
and the level suppression of IFN signature was clearly associated with increased 
anifrolumab concentrations (281). Inhibition of IFNAR1 reduced ISG expression more 
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than sifalimumab with better efficacy in the IFN signature high subset and is now in 
phase III clinical trials. 
Other strategies have directly targeted pDCs. Early, transient depletion of pDCs in 
BXSB lupus-prone mice before disease initiation led to reduced expansion of T and B 
cells, reduced production of autoantibodies an amelioration of glomerulonephritis 
(282). In NZB/NZW lupus-prone mice, inhibition of Bcl-2, a necessary molecule for 
pDC survival, resulted in selectively depletion of pDCs and reduction of IFN-a 
production (283). Furthermore, proteasome inhibitors (carfilzomib, bortezomib) 
managed to suppress the IFN-a production by TLR-activated pDCs by inhibiting pDC 
survival and function in lupus mice models (284). More recently, the pDC inhibitory 
receptor BDCA-2 (CD303) has been used to block type I IFN production in preclinical 
studies (285).   
Finally, the immunization of SLE patients presenting mild to moderate disease with 
IFN-a-kinoid (IFN-K), a drug composed of inactivated IFN-a coupled to a carrier 
protein, induced anti-IFN-a antibodies and significantly improved disease 
biomarkers in all patients (286). Interestingly, a higher titre of anti-IFN-a antibodies 
were found in IFN signature positive patients, which were also linked to the reduction 
of IFN score. A summary of the main pharmaceutical agents targeting the type I IFN 
pathway can be seen in Table 1.5. 
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Pharmaceutical agent Manufacturer Definition Therapeutic target 
Sifalimumab MedImmune, Inc. Fully human mAb IFN-α 
Rontalizumab Genetech Recombinant 
humanized mAb 
IFN-α 
AGS-009 Argos Therapeutics Humanized IgG4 mAb IFN-α 
Anifrolumab MedImmune, Inc. Fully human mAb IFN-α/β receptor 
IFN-α-kinoid Neovacs Vaccine IFN-α 
IMO-3100 Idera 
Pharmaceuticals 
Oligonucleotide 
antagonist 
TLR7/9 inhibition 
DV1179 Dyvanax Oligonucleotide 
antagonist 
TLR7/9 inhibition 
Table 1.5 Main pharmaceutical agents targeting type I IFN pathway. 
 
1.20 Measuring Interferon Activity in Patients 
While type I IFNs are known to mediate clinical manifestations of SLE, assays for IFN 
activity have not yet become routinely used in the care of SLE patients in the same 
way as B cell biomarkers such as autoantibody titres and complement levels. Type I 
IFN activity is commonly measured in patients using presence or absence of 
expression of interferon stimulated genes (ISGs), referred to as an interferon 
signature, or level of expression, referred to as an interferon score. 
In research cohorts, 60-80% of lupus patients exhibit an increased expression of ISGs 
in PBMCs, known as interferon signature. In childhood-onset SLE the IFN signature is 
almost universally observed (287). Interferon scores are similar but are generally 
used to refer to a continuous parameter derived from qPCR rather than absence or 
presence of increased expression. Interferon signatures and scores consistently have 
increased B cell biomarkers of activity such as titres of anti-dsDNA, anti-Ro, anti-
U1RNP, anti-Sm autoantibodies and lower complement (C3) levels (288). Type I IFN 
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assays showed association with disease activity in cross-sectional studies (287, 289, 
290). However, these were inconsistent with other studies failing to demonstrate any 
association (291, 292). Longitudinal analyses of ISG expression in SLE patients have 
also given more complex results. Although patients with higher IFN scores had 
greater disease activity, scores of individual patients could not predict flares (293). 
This discrepancy might be due to the choice of ISGs or methods used to derive 
unidimensional interferon scores from genome-wide micro-array data (294). Some 
studies have suggested that higher ISG expression is associated with particular organ 
involvement in SLE. For instance, five type I IFN-inducible genes (LY6E, OAS1, OASL, 
MX1, ISG15) were highly expressed in patients with active renal or neurological 
disease but not in other manifestations (291). However, this is complex to analyse; 
variations in methodology for measurement of type I IFN activity comparing activity 
between different organ domains is complex. That study used a categorical 
measurement for each organ. 
Given the pleotropic effects of type I IFNs on all cells, the varying transcriptional 
response of individual circulating populations may also be important. Although high-
density oligonucleotide microarray has proven to be valuable to investigate the 
genetic mechanism of pathogenesis of SLE, most of these studies used unseparated 
leukocytes or whole blood (295). A recent study investigated the ISG expression in 
multiple sorted cell types, including monocytes, dendritic cells, NK cells, B and T 
lymphocytes, from SLE patients and showed distinct profiles in different cell types 
(296). A distinct gene expression profile has been recently identified even in classical 
and non-classical monocytes from SLE patients (297). Genome-wide DNA 
methylation analyses of CD4+ T cells from SLE patients revealed a persistent 
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hypomethylation of certain ISGs, for example IFIT1, IFIT3, MX1, STAT1, IFI44L, USP18, 
TRIM22, BST2, suggesting that epigenetic modifications could influence the 
responsiveness of autoreactive T cells (248, 294, 298-300).  
IFN signature might contribute to the early stages of the disease development, as the 
expression of certain genes has been linked to certain autoantibody profiles in 
patients with incomplete lupus erythematosus, suggesting that IFN signature might 
be used as a biomarker for individuals with higher risk for disease progression (301). 
The results confirmed a different IFN signature in peripheral B cells, T cells and 
myeloid cells leading to the upregulation of distinct transcriptional factors, which 
favour a pro-inflammatory phenotype. Interestingly, cytosolic nucleic acid sensing 
pathways were mostly upregulated in myeloid cells. 
1.21 Hypothesis 
Type I interferon axis is critically implicated in the pathogenesis of the SLE. However, 
the source of this dysregulation still remains unclear. As pDCs are the main type I IFN 
producing cells during viral infection, I have hypothesised: (1) pDCs are overactive in 
SLE producing aberrant amounts of type I IFNs and potentially contributing to disease 
progression from preclinical benign autoimmunity to clinically overt disease; (2) pDCs 
are compromised for their function to produce type I IFNs by immune regulatory 
mechanisms and the source of type I IFN dysregulation is located outside of the 
immune system, for example in non-haematopoietic tissues.  
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1.22 Aims 
To address the above hypothesis, the current PhD thesis aims: 
• To investigate whether pDCs from patients with SLE as well as individuals with 
preclinical autoimmunity present distinct immunological abnormalities 
compared to pDCs of healthy individuals. 
• To investigate whether certain defects in immune function of pDCs are 
associated with clinical and immunological features in patients with SLE and 
individuals with preclinical autoimmunity. 
• To investigate whether non-haematopoietic tissue resident cells contribute 
to type I IFN dysregulation observed in patients with SLE and individuals with 
preclinical autoimmunity 
• To investigate immune mechanisms regulating the function of human pDCs, 
particularly the effect of TNF-α on IFN- α production. 
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CHAPTER 2.  
MATERIALS AND METHODS 
2.1 Patients and controls 
Peripheral blood and skin biopsies were obtained from healthy individuals and 
patients from different disease groups: 
1. Systemic Lupus Erythematosus (SLE) 
2. Primary Sjögren’s Syndrome (pSS) 
3. At-Risk individuals (At-Risk) 
Patients were recruited based on 2012 SLICC classification criteria for SLE, 2016 
ACR/EULAR classification criteria for pSS, while At-Risk individuals were classified as 
ANA positive, £1 SLE clinical criterion, symptom duration <12 months and being 
treatment-naïve. Table 2.1 summarises the characteristics and treatment of SLE 
patients.  
2.2 Ethical approval 
All individuals provided informed written consent and this research was undertaken 
in compliance with the Declaration of Helsinki. The patients’ blood samples used for 
this study were collected under ethical approval, REC 10/H1306/88, National 
Research Ethics Committee Yorkshire and Humber–Leeds East, while blood samples 
from healthy individuals were collected under the study number 04/Q1206/107. All 
experiments were performed in accordance with the relevant guidelines and 
regulations. The University of Leeds was contracted with administrative sponsorship. 
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Table 2.1 Clinical characteristics and treatment of SLE patients recruited in this study. 
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2.3 Clinical immunology assessment 
ANA was tested using indirect immunofluorescence. A panel of nuclear 
autoantibodies including anti-dsDNA, extractable nuclear antigens (ENA, including 
Ro52, Ro60, La, Sm, Chromatin, RNP, Sm/RNP and Ribosomal P) and anti-
phospholipid antibodies (Cardiolipin and β2-Glycoprotein IgGs) was assessed using 
Bioplex 2200 Immunoassay. Lupus anti-coagulant tests including activated prolonged 
thromboplastin time (APTT), APTT- synthetic peptide (APTT-SP) (with correction) and 
dilute Russell’s viper venom test (dRVVT) (with correction) were deemed positive if 
persistent when repeated at 12 weeks. Full blood count was processed at a single 
accredited diagnostic laboratory. Complement levels (C3 and C4) were measured by 
nephelometry. 
2.4 Isolation of human peripheral blood mononuclear cells 
Human peripheral blood mononuclear cells (PBMCs) were separated from the whole 
blood by a density gradient centrifugation method using 50 mL LeucoSep tubes 
(Greiner Bio-One; Cat. No.: 227290P). Fresh human venous blood was collected in 
EDTA-containing vials. After collection, the tubes were mixed well by gently inverting 
several times. The blood was gently layered on the top of the porous barrier using an 
auto-pipette. Then the tubes were centrifuged (without any delay) for 20 min at 800 
x g at 20°C in a swing-out bucket. The whitish buffy coat (about 1 ml) of PBMCs 
formed in the interphase between porous barrier and medium was aspirated and 
washed with 50 mL of sterile PBS followed by centrifugation in 500 x g for 10 min at 
20°C. After centrifugation, the supernatant was decanted carefully and the pellet of 
PBMCs was washed with 50 mL of sterile filtrated RBC lysis buffer (8.99 g NH4Cl, 1 g 
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KHCO3, 2 mL EDTA, 1,000 mL ddH2O) to lyse any remaining RBCs followed by 
centrifugation in 500 x g for 10 min at 20°C. Finally, PBMCs were washed with 50 mL 
of sterile PBS and centrifuged in 500 x g for 10 min at 20 °C. 
2.5 Evaluating IFN activity in peripheral blood 
2.5.1 RNA isolation from PBMCs 
RNA was extracted from freshly isolated PBMCs by using an Animal Tissue RNA 
Purification Kit (Norgen Biotec; Cat. No.: 25700) according to the manufacturer’s 
instructions. RNA was eluted into 50 μL of the provided buffer; the final 
concentration of purified RNA was then quantified by using NanoDrop Lite (Labtech 
International). The purified RNA samples were stored at -80oC. 
2.5.2 Gene probe selection 
To evaluate IFN activity, interferon-stimulated genes (ISGs) from each one of IFN-
annotated modules (M1.2, M3.4, M5.12) of a previous microarray study reported by 
Chiche et al. (294) were selected; additional common ISGs, for instance IFI27 and IFI6, 
were also included. Therefore, a total of 31 ISGs were evaluated.  
2.5.3 Gene quantification 
Purified RNA from each sample was reverse-transcribed to cDNA using the Fluidigm 
Reverse Transcription Master Mix buffer including a mixture of random primers and 
oligo dT for priming. TaqMan assays (Applied Biosystems, Invitrogen) were used to 
perform the quantitative real-time reverse transcriptase-polymerase chain reaction 
(qRT-PCR) for the selected 31 ISGs. These assays were performed using the 
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BioMarkTM HD System with appropriate cycling protocols for the 96.96 chip. Data 
were normalised using PP1A as the reference gene to calculate ΔCt. 
2.5.4 Factor analysis 
Factor analysis is a statistical method that was used to describe the variability among 
observed, correlated variables in terms of a potentially smaller number of 
unobserved (latent) continues variables. In this case, the observed variables were the 
gene expression values (∆Ct) of multiple interferon-stimulated genes (ISGs), which 
were clustered into only two variables (called factors) explaining the majority of the 
variability in the data. The factor analysis for all samples collected was kindly 
performed by Dr Elizabeth Hensor, biostatistician at Leeds Institute of Rheumatic and 
Musculoskeletal Medicine and it is described in detail in my relevant published work 
(302). The two factors derived by the factor analysis explained 84% of the variance 
in the data with limited cross-loading among the ISGs. Table 2.2 shows the ISGs that 
contributed to each factor; these factors were named IFN Score A, which comprised 
12 co-clustered genes (ISG15, IFI44, IFI27, CXCL10, RSAD2, IFIT1, IFI44L, CCL8, XAF1, 
GBP1, IRF7, CEACAM1), and IFN Score B, which comprised 14 co-clustered genes 
(LAMP3, IFIH1, PHF11, SERPING1, IFI16, BST2, SP100, NT5C3B, SOCS1, TRIM38, 
UNC93B1, UBE2L6, STAT1, TAP1). 
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Genes 
Modules from 
previous study using 
microarray 
Rotated Factor Loading 
IFN Score A IFN Score B 
ISG15 1.2 0.96*  
IFI44 1.2 0.80*  
IFI27 n/a 0.77*  
CXCL10 1.2 0.71*  
RSAD2 1.2 0.70*  
IFIT1 1.2 0.67*  
IFI44L 1.2 0.66*  
CCL8 3.4 0.58*  
XAF1 1.2 0.54*  
IFI6 n/a 0.51 0.45 
GBP1 3.4 0.46*  
IRF7 3.4 0.46*  
CEACAM1 3.4 0.45*  
HERC5 1.2 0.43 0.59 
EIF2AK2 3.4 0.42 0.64 
MX1 1.2 0.40 0.56 
LAMP3 1.2  0.40* 
IFIH1 3.4  0.45* 
PHF11 5.12  0.58* 
SERPING1 1.2  0.60* 
IFI16 5.12  0.64* 
BST2 5.12  0.74* 
SP100 5.12  0.74* 
NT5C3B 5.12  0.80* 
SOCS1 3.4  0.84* 
TRIM38 5.12  0.87* 
UNC93B1 5.12  0.88* 
UBE2L6 3.4  0.89* 
STAT1 3.4  0.94* 
TAP1 5.12  0.98* 
CASP1 5.12 <0.40 <0.40 
Table 2.2 Interferon-stimulated genes used for developing IFN scores to measure IFN 
activity. Gene expression was measured in PBMCs by TaqMan assays and analysed by factor 
analysis to reduce the variability in the data acquired. Two factors explained 84% of the 
variance of the data with limited cross-loading among the ISGs. These factors were named 
IFN Score A and IFN Score B. 
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2.6 Evaluating IFN activity in skin biopsies 
Skin biopsies (4 mm) were obtained from non-lesional, non-sun-exposed areas 
(upper back or upper arms) of At-Risk individuals (n=10) and healthy individuals (n=6) 
as well as from active lesions of SLE patients (n=10). Biopsies were snap frozen in 
optimum cutting temperature compound and sectioned at a thickness of 5 μm 
ensuring no remaining material contaminating subsequent RNA extraction/RT 
procedures. Total RNA was extracted using RNeasy mini kit (Qiagen) according to 
manufacturer’s instructions. The RNA quantity was measured and assessed for 
quality using NanoDrop spectrophotometer (ND-1000). Gene expression analysis by 
TaqMan assays and calculation of IFN scores by factor analysis were performed as 
described above for evaluating IFN activity in peripheral blood. 
2.7 Isolation of human plasmacytoid dendritic cells 
pDCs were purified from freshly isolated PBMCs by negative selection using the 
Diamond Plasmacytoid Dendritic Cell Isolation Kit II (Miltenyi Biotec). Briefly, after 
determining the PBMC number, the cell suspension was centrifuged at 300 x g for 10 
minutes before the supernatant was aspirated completely and the cell pellet was 
resuspended in 400 μL of MACS buffer [PBS, pH 7.2, 0.5% bovine serum albumin 
(BSA), and 2 mM EDTA] and 100 μL of Non-PDC Biotin-Antibody Cocktail II per 108 
total cells. The suspension was mixed well and incubated at 4oC for 10 minutes. After 
incubation, the cells were washed by adding 10 ml of MACS buffer and centrifuged 
at 300 x g for 10 minutes. The supernatant was then aspirated completely and the 
cell pellet was resuspended in 400 μL of MACS buffer and 100 μL of Non-PDC 
Microbead Cocktail II per 108 total cells. The suspension was mixed well and 
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incubated at 4oC for 15 minutes. After incubation, the cells were washed by adding 
10 ml of MACS buffer, centrifuged at 300 x g for 10 minutes and resuspended in a 
final volume of 500 μL of MACS buffer per 108 total cells. For depletion of non-PDCs 
by magnetic separation, LD columns (Cat. No. 130-042-901, Miltenyi Biotec) were 
placed in the magnetic field of a suitable MACS Separator. The columns were 
prepared by rinsing 2 mL of MACS buffer and the cell suspension was applied onto 
the column. The unlabelled cells passing through were collected and the columns 
were washed with 2 x 1 mL of MACS buffer. Finally, the number of pre-enriched pDCs 
was counted using an automated cell counter (Beckmann Coulter).  
2.8 Isolation of human naïve CD4+ T cells 
Naïve CD4+ T cells were purified by negative selection using the Naïve CD4+ T Cell 
Isolation Kit II (Miltenyi Biotec). Briefly, Briefly, after determining the PBMC number, 
the cell suspension was centrifuged at 300 x g for 10 minutes before the supernatant 
was aspirated completely and the cell pellet was resuspended in 40 μL of MACS 
buffer and 10 μL of Naïve CD4+ T Cell Biotin-Antibody Cocktail II per 107 total cells. 
The suspension was mixed well and incubated at 4oC for 5 minutes before 30 μL of 
MACS buffer and 20 μL of Naïve CD4+ T Cell MicroBead Cocktail II were added per 107 
total cells. For magnetic cell separation, LS columns (Cat. No. 130-042-401, Miltenyi 
Biotec) were placed in the magnetic field of a suitable MACS Separator. The columns 
were prepared by rinsing 3 mL of MACS buffer and the cell suspension was applied 
onto the column. The unlabelled cells passing through were collected and the 
columns were washed with 3 x 1 mL of MACS buffer. Finally, the number of enriched 
naïve CD4+ T cells was counted using an automated cell counter (Beckmann Coulter). 
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2.9 Sorting of plasmacytoid dendritic cells 
Pre-enriched pDCs were initially purified by negative selection as described above 
and were finally sorted using an antibody to BDCA-4 (Miltenyi Biotec). Cell sorting 
was carried out at the SCIF Flow Cytometry and Imaging Facility of the Wellcome 
Trust Brenner Building, University of Leeds, with a BD Influx 6 Way Cell Sorter (BD 
Biosciences). Representative sorting images of unstained cells and BDCA-4+ pDCs can 
be seen in Figure 2.1 and Figure 2.2 respectively. 
 
 
Figure 2.1 Sorting of BDCA-4+ cells from pre-enriched pDCs previously purified by negative 
selection. Representative picture of unstained cells used as a gating control. 
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Figure 2.2 Sorting of BDCA-4+ cells from pre-enriched pDCs previously purified by negative 
selection. Representative picture of a sample. 
 
2.10 Culture and stimulation of plasmacytoid dendritic cells in vitro 
After isolation of PBMCs, cells were resuspended in RPMI medium 1640 with 
GlutaMAX supplement (ThermoFisher Scientific) containing 10% (vol/vol) FBS and 
100 U/ml penicillin/streptomycin. The cells were then seeded into 96-well 
polystyrene round bottom plates (2 x 106 cells per well, 100 μL per well). TLR9 
(ODN2216; Miltenyi Biotec) or TLR7 (ORN R-2336; Miltenyi Biotec) agonists were 
used at concentration of 2 μM to stimulate pDCs within the context of PBMCs. The 
stimulated cells were incubated for 2 hours at 37oC with 5% CO2 before GolgiPlug (BD 
Biosciences) at concentration of 10 μg/mL was added to inhibit cytokine secretion. 
The cells were incubated for additional 4 hours at 37oC with 5% CO2.  
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2.11 Co-culture of pDCs and T cells in vitro 
For pDC/T-cell co-culture, pDCs (1 x 104) purified by negative selection were cultured 
for 5 days with autologous or allogeneic naïve CD4+ T cells (5 x 104) purified by 
negative selection in the absence or presence of anti-CD3/CD28 beads (T cell 
activation/expansion kit; Miltenyi Biotec). Briefly, Anti-Biotin MACSiBead Particles 
were resuspended thoroughly by vortexing to obtain a homogenous suspension. 
Then 500 μL of Anti-Biotin MACSiBead Particles (1 x 108) were mixed with 100 μL of 
CD3-Biotin and 100 μL of CD28-Biotin and 300 μL of buffer [PBS pH 7.2, 
supplemented with 0.5% human serum albumin (HSA) and 2 mM EDTA] to adjust to 
a total volume of 1 mL. The mixture was incubated for 2 hours at 4oC under constant, 
gentle rotation at approximately 4 rpm. The desired amount of Anti-Biotin 
MACSiBead Particles was added to the cell culture to achieve a bead-to-cell ratio of 
1:2.  
On the last day of culture, cells were re-stimulated with PMA (500 ng/mL) and 
Ionomycin (1 μl/mL) for 6 hours in the presence of GolgiPlug (BD Biosciences) in the 
last 4 hours at concentration of 10 μg/mL to prevent cytokine secretion. Cytokine 
production was measured by intracellular staining following the protocol described 
in the flow cytometry analysis. 
2.12 T cell proliferation 
Cell proliferation was measured using the CellTrace Violet Cell Proliferation kit 
(ThermoFisher Scientific) according to the manufacturer’s instructions. Briefly, 
CellTrace Violet stock solution was prepared immediately prior to use by adding 20 
μL of DMSO to one vial of CellTrace Violet reagent and mixing well. Then 1 μL of 
  
54 
CellTrace Violet stock solution in DMSO was added to 1 mL of cell suspension in PBS 
for a final working solution, which was incubated for 20 minutes at 37oC protected 
from light. After incubation, 5 mL of RPMI medium 1640 with GlutaMAX supplement 
(ThermoFisher Scientific) containing 10% (vol/vol) FBS and 100 U/ml 
penicillin/streptomycin was added to the cells and incubated for further 5 minutes 
to remove any free dye remaining in the solution. The suspension was then 
centrifuged at 300 x g for 10 minutes, the supernatant was decanted carefully and 
the cell pellet was resuspended in fresh pre-warmed culture medium. The cells were 
incubated for 5 days before they were analysed for their proliferation using flow 
cytometry. 
2.13 Human TNF-α neutralisation 
Pre-enriched pDCs were stimulated with ODN 2216 (1 ng/mL) or ORN R-2336 (1 
ng/mL) in the presence or absence of human TNF-α antibody (R&D Systems). After 
24 hours, the plates were centrifuged to collect the supernatants and the cells were 
washed twice before they were stimulated again with ODN 2216 (1 ng/mL) or ORN 
R-2336 (1 ng/mL) for additional 24 hours. Supernatants collected at 24 and 48 hours 
were analysed by Human IFN-alpha Platinum ELISA Kit (eBioscience) according to the 
manufacturer’s protocol. 
2.14 Flow cytometry analysis 
2.14.1 Surface staining 
Following 6 hours of incubation, the cells were washed with sterile PBS and 
centrifuged at 500 x g at 20°C for 5 minutes. The supernatant was then decanted, the 
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pellet was resuspended in 50 μL of blocking buffer (20% mouse serum) and incubated 
for 15 minutes at 4oC. After incubation with blocking buffer, 5 μL of each monoclonal 
antibody for surface proteins were added in a total volume of 100 μL per well. The 
cells were incubated for 30 minutes at 4oC and were then washed with 200 μL of PBS 
and centrifuged at 500 x g at 20°C for 5 minutes. The washing step was repeated 
twice. Finally, the cells were resuspended in 300 μL of FACS buffer (x1 PBS, 1% BSA, 
1% Sodium Azide Solution) and analysed by flow cytometry. 
2.14.2 Intracellular staining 
After following the protocol for surface staining, an Intracellular Fixation & 
Permeabilization Buffer Set (Affymetrix eBioscience; Cat. No.: 88-8824-00) was used. 
The kit included both fixation and permeabilization solution (containing 
formaldehyde) and 10x permeabilization/wash buffer (containing saponin). Each well 
containing 2 x 106 cells was resuspended in 200 μL of fixation and permeabilization 
solution according to manufacturer’s instructions and incubated for 30 minutes at 
4oC. The cells were then washed with permeabilization/wash buffer, centrifuged (300 
x g at 4°C) for 10 minutes, and resuspended in a total volume of 100 μL containing 
permeabilization/wash buffer and antibodies for detection of intracellular proteins 
as well as appropriate isotype controls. The cells were incubated for 30 minutes at 
4oC before they were washed with 200 μL of permeabilization/wash buffer twice 
(centrifugation at 300 x g for 10 minutes at 4°C). Finally, the cells were resuspended 
in 300 μL of FACS buffer (x1 PBS, 1% BSA, 1% Sodium Azide Solution) and analysed 
by flow cytometry. 
For FoxP3 intracellular staining, cells were first stained for surface markers and then 
fixed and permeabilised using the FoxP3 Staining Buffer Set (Miltenyi Biotec) 
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according to manufacturer’s instructions. Briefly, after surface staining up to 106 cells 
were resuspended in 1 mL of cold, freshly prepared Fixation/Permeabilization 
solution and mixed well. After incubation of 30 minutes in the dark at 4oC, the cells 
were washed with the appropriate buffer and centrifuged at 300 x g for 5 minutes at 
4oC. The supernatant was aspirated completely and the cells were washed by adding 
1 mL of cold 1x Permeabilization Buffer and centrifuged again at 300 x g for 5 minutes 
at 4oC. The supernatant was aspirated completely and the cells were resuspended in 
80 μL of cold 1x Permeabilization Buffer and 20 μL of FcR Blocking Reagent; after 
incubation of 5 minutes, 10 μL of Anti-FoxP3 antibody were added and the cells were 
further incubated for 30 minutes in the dark at 4oC. The cells were then washed by 
adding 1 mL of cold 1x Permeabilization Buffer and centrifuged at 300 x g for 5 
minutes at 4oC. After aspirating the supernatant completely, the cell pellet was 
resuspended in 300 μL of FACS buffer and analysed by flow cytometry. 
2.14.3 Data acquisition and analysis 
Flow cytometry data acquisition was performed on LSRII (BD Biosciences) or Cytoflex 
S (Beckman Coulter) and the data were further analysed using FACS DiVA (BD 
Biosciences) or CytExpert (Beckman Coulter) software. 
2.15 RNA-sequencing data generation 
RNA from sorted pDCs was extracted using PicoPure RNA Isolation Kit (ThermoFisher 
Scientific) according to manufacturer’s instructions and quantified using Qubit RNA 
HS Assay Kit (Thermo Fisher Scientific). RNA libraries were made by using SMART-Seq 
V4 ultra low Input RNA Kit (Takara Bio USA) and Nextera XT DNA Library Preparation 
Kit (Illumina) for NGS sequencing. Indexed sequencing libraries were pooled and 
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sequenced on a single lane on HiSeq 3000 instrument as 151bp paired-end reads. 
Pooled sequence data was then demultiplexed using Illumina bcl2fastq software 
allowing no mismatches in the read index sequences. 
2.16 RNA-sequencing data processing and analysis 
Raw paired-end sequence data in Fastq format was initially analysed using FastQC 
software in order to identify potential issues with data quality. Cutadapt software 
was then used to remove poor quality bases (Phred quality score <20) and 
contaminating technical sequences from raw sequenced reads. Contaminating 
technical sequences identified at the initial QC stage were as follows: 
CTGTCTCTTATA – Next Era Transposase Sequence 
GTATCAACGCAGAGTACT– SmartSeq Oligonucleotide Sequence 
dT30 – SmartSeq 3’ CDS Primer II sequence 
Reads trimmed to fewer than 30 nucleotides and orphaned mate-pair reads were 
discarded to minimise alignment errors downstream.  
Reads were aligned to human hg38 analysis set reference sequences, obtained from 
UCSC database (303) using splicing-aware STAR aligner (304) for RNA-Sequencing 
data. STAR aligner was run in 2-pass mode, with known splice junctions supplied in 
GTF file format, obtained from hg38 RefSeq gene annotation table from UCSC 
database using Table Browser tool (305). The resulting alignments in BAM file format 
were checked for quality using QualiMap software (306) and Picard tools (307). 
Picard tools were used to mark PCR/Optical duplicate alignments. Custom code was 
used to filter out contaminating ribosomal RNA alignments, using ribosomal RNA 
coordinates for hg38 analysis set reference obtained using UCSC Table Browser tool. 
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The final alignment files were sorted and indexed using Samtools software (308) and 
visualised using IGV browser (309).  
Bioconductor R package RSubread (310) was used to extract raw sequenced 
fragment counts per transcript using RefSeq hg38 transcript annotation set, as 
before. Paired-end reads were counted as a single fragment and multi-mapping read 
pairs were counted as a fraction of all equivalent alignments. Raw count data was 
normalised for library size differences using median ratio method (311), as 
implemented in DESeq2 R Bioconductor package (312). DESeq2 was also used to 
perform additional data QC steps and differential expression analyses. Differentially 
expressed gene expression was visualised as clustered heatmaps using Pheatmap R 
package (313) using log-transformed normalised gene expression values as input. 
Gene functional and pathway enrichment analyses were performed using R 
Bioconductor packages clusterProfiler (314) and ReactomePA (315). Additionally, 
KEGG (316) pathways were visualised using Pathview package (317). 
2.17 Measurement of relative telomere length 
Purification of human pDCs from freshly isolated PBMCs was carried out following 
the protocol for negative selection (Miltenyi Biotec) described in detail above. To 
achieve maximum purity (> 95%) for pDCs, an additional step of positive selection 
was added to the protocol. Briefly, the cell suspension of pre-enriched fraction of 
pDCs collected by negative selection was centrifuged at 300 x g for 10 minutes at 4oC 
before the supernatant was aspirated completely and the cell pellet was 
resuspended directly in 100 μL of CD304 (BDCA-4/Neuropilin-1) Diamond 
MicroBeads. The suspension was mixed well and incubated for 15 minutes in the dark 
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at 4oC. After incubation, the cells were washed by adding 1 mL of cold MACS buffer 
and centrifuged at 300 x g for 10 minutes at 4oC. The supernatant was aspirated 
completely and the cell pellet was resuspended in 500 μL of MACS buffer. In the 
meantime, MS columns (Miltenyi Biotec) were placed in the magnetic field of a 
suitable MACS Separator. The columns were prepared by rinsing 2 mL of MACS buffer 
and the cell suspension was applied onto the column. The flow-through containing 
the unlabelled cells was collected and the columns were washed with 2 x 1 mL of 
MACS buffer. Then the column was removed from the separator and it was placed 
immediately on a suitable collection tube. The column reservoir was added with 1 
mL of MACS buffer and the magnetically labelled cells were flushed out by firmly 
pushing the plunger into the column. Finally, the number of BDCA-4+ pDCs was 
counted using an automated cell counter (Beckmann Coulter). 
Relative telomere length was measured using Telomere PNA Kit/FITC for Flow 
Cytometry (Agilent) according to manufacturer’s protocol. Briefly, on a single cell 
suspension consisting of purified pDCs and control cells (1301 cell line; Sigma-
Aldrich), the sample DNA was denatured for 10 minutes at 82οC either in the 
presence of hybridization solution without probe or in hybridization solution 
containing fluorescein-conjugated PNA telomere probe. Then hybridization took 
place in the dark at room temperature overnight. The sample was then resuspended 
in appropriate buffer for further flow cytometric analysis. The data obtained were 
used for determination of the relative telomere length (RTL) as the ratio between the 
telomere signal of each sample (pDCs) and the control cell (1301 cell line) with 
correction for the DNA index (which is to be 1 for known diploid cells such as human 
pDCs and 2 for the tetraploid cell line used as a control) of G0/1 cells: 
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RTL
= (mean	FL1	sample	cells	with	probe −mean	FL1	sample	cells	withour	probe)x	DNA	index	of	control	cells	x100(mean	FL1	control	cells	with	probe− mean	FL1	control	cells	withour	probe)x	DNA	index	of	sample	cells  
2.18 Oxidative stress assay 
Freshly isolated PBMCs from healthy donors were exposed to H2O2 (0 – 500 μM) for 
15 minutes. After exposure, cells were washed thoroughly and resuspended at 1 x 
106 in culture medium at 37oC before they were stimulated with 2μM ODN 2216 
(Miltenyi Biotech) for 6 hours. GolgiPlug (BD Biosciences) at concentration of 10 
μg/mL was added in the last 4 hours of culture to inhibit cytokine secretion. The 
production of IFN-α in viable pDCs was measured by intracellular staining as 
described above in flow cytometry analysis. The viability of the cells was assessed 
using 7-AAD (7-amino-actinomycin D; Miltenyi Biotec), which is excluded from viable 
cells, but can penetrate cell membranes of dead or dying cells 
2.19 UV provocation 
UV provocation was performed based on a published protocol designed for use in 
clinical trials (318, 319). Briefly, a solar simulator was used in routine clinical practice, 
which replicated the protocol of UV-A and UV-B provocation in a single exposure. On 
day 1, four 1.5 cm2 areas of skin were exposed to solar simulated radiation depending 
on skin type; 4, 8, 12, 16 J/cm2 for skin types I and II, and 6, 12, 18, 24 J/cm2 for skin 
types III-VI. On day 2, the minimal erythema dose was then determined. A 10 cm2 
non-sun exposed area of skin was exposed to minimal erythema dose x 1.5 on three 
consecutive days. A biopsy of the pre-exposed and exposed area of skin was obtained 
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when a reaction was seen clinically (mean time to a positive reaction to provocation 
was 7 (±6) days, and rarely more than 14 days). 
2.20 Tissue section 
Skin biopsies were obtained from healthy individuals and patients, then snap frozen 
in liquid nitrogen within 5 minutes, embedded in OCT and stored in -80oC freezer. 
Fresh frozen skin biopsies were cryosectioned to 10-20 μM, placed on superfrost plus 
slides (Thermo Scientific) and used for in situ hybridization. 
2.21 In situ hybridization and fluorescence microscopy 
In situ hybridization of type I IFNs transcripts in skin samples was performed using 
RNAscope Multiplex Fluorescent Reagent Kit v2 (Advanced Cell Diagnostics) 
according to manufacturer’s instructions. Before hybridization of the tissue, 
cryosections were fixed and dehydrated before they were exposed to hydrogen 
peroxide and protease treatment. Negative and positive controls for hybridization 
were provided by the manufacturer. A schematic procedure of the RNAscope assay 
can be seen in Figure 2.3. 
In brief, materials were prepared by warming 50X Wash Buffer for 10–20 minutes to 
remove any precipitation and preparing 3 L of 1X Wash Buffer by adding 2.94 L 
distilled water and 1 bottle (60 mL) of 50X Wash Buffer to a large carboy. Probes were 
warmed up for 10 minutes at 40°C, then cooled down to room temperature, before 
they were mixed and added to the tissue section. To hybridize the probes, excess 
liquid was initially removed from the tissue slides, which were placed in the HybEZ 
Slide Rack, and then 4–6 drops of the probe mix were added to entirely cover each 
  
62 
slide. The rack containing the slides was inserted into the HybEZ Oven for 2 hours at 
40°C and then the slides were washed twice with 1X Wash Buffer for 2 minutes at 
room temperature. The slides were then stored overnight at room temperature in 
saline-sodium citrate buffer (5x; 0.75M NaCl, 0.075M sodium citrate).  
After the overnight incubation, hybridize amplification 1 was applied by adding 4-6 
of Amp 1 and by further incubating in the HybEZ Oven for 30 minutes at 40°C before 
the slides were washed twice in 1X Wash Buffer for 2 MIN at room temperature. The 
same amplification step was applied for hybridize amplification 2. The reconstitution 
of TSA® Plus fluorescein and TSA® Plus Cyanine 3 stocks following Perkin Elmer’s TSA® 
Plus System instructions; the TSA® Plus fluorophore stocks were diluted in the TSA 
buffer provided in the RNAscope® Multiplex Fluorescent Kit V2 (1:1,500).  
The next step was the development of HRP-C1 and HRP-C2 signal. The excess liquid 
was removed from slides, which were placed in the HybEZ Slide Rack and 4–6 drops 
of RNAscope® Multiplex FL V2 HRP-C1 were added to entirely cover each slide. The 
slides were incubated in the HybEZ Oven for 15 minutes at 40°C before they were 
washed twice in 1X Wash Buffer for 2 minutes at room temperature. The excess 
liquid was removed from slides again, they were placed in the HybEZ Slide Rackand 
4-6 drops of RNAscope® Multiplex FL V2 HRP blocker were added to entirely cover 
each slide. Then the slides into the HybEZ Oven for 15 minutes at 40°C and washed 
twice in 1X Wash Buffer for 2 minutes at room temperature. The exactly same step 
was applied for RNAscope® Multiplex FL V2 HRP-C2.  
Finally, the excess liquid was removed from slides and ~4 drops of DAPI were added 
to each slide before they were incubated for 1-2 minutes at room temperature. The 
DAPI was removed and 1–2 drops of Prolong Gold antifade mounting medium was 
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immediately added on the slide. A 24 mm x 50 mm glass coverslip was carefully 
placed over each tissue section avoiding trapping air bubbles. Then the slides were 
dried overnight in the dark before they were stored in the dark at 2–8°C. 
Images were acquired on a Nikon A1R confocal laser scanning microscope system at 
20-40x magnification. Images were analysed in Nikon NIS Elements software. 
Representative images of negative and positive controls can be seen in Figure 2.4 
 
 
Figure 2.3 Schematic procedure of the RNAscope assay. In step 1, tissues are fixed and 
permeabilised to allow for target probe access. In step 2, target RNA-specific oligonucleotide 
probes (Z) are hybridized in pairs (ZZ) to multiple RNA targets. In step 3, multiple signal 
amplification molecules are hybridized, each recognising a specific target probe, and each 
unique label probe is conjugated to a different fluorophore or enzyme. In step 4, signals are 
detected using a fluorescent microscope. Picture and text adapted from (320). 
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Figure 2.4 Representative pictures of in situ hybridization using RNAscope Multiplex 
Fluorescent Reagent Kit v2: (A) negative control; (B) positive control (unknown transcript; 
provided by the manufacturer). 
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2.22 Culture of human keratinocytes and dermal fibroblasts 
Human keratinocytes and dermal fibroblasts were isolated from 3 mm punch skin 
biopsies. For keratinocytes, the epidermal component of the biopsy was placed in a 
T75 flask and cultured at 37oC in low glucose DMEM (Fischer Scientific) containing 
10% (vol/vol) FBS (Fischer Scientific) and 1% penicillin/streptomycin. Keratinocytes 
were passaged and sub-cultured into keratinocyte growth medium (PromoCell) for 
continuous culture. For dermal fibroblasts, the dermal compartment of the biopsy 
was placed in a T25 flask and cultured at 37oC in low glucose DMEM. Dermal 
fibroblasts were then passaged and sub-cultured. Both keratinocytes and dermal 
fibroblasts were passaged and plated in 24-well plates for subsequent stimulation. 
At 90% confluence, cells were either untreated or treated with 1 μg/ml Poly I:C 
(InvivoGen) or 100 ng/ml Poly dA:dT (InvivoGen) for 6 or 24 hours.  
2.23 Quantitative RT-PCR for keratinocytes and dermal fibroblasts 
RNA was extracted from keratinocytes and dermal fibroblasts using Quick-RNA 
MiniPrep kit (Zymo Research) according to manufacturer’s instructions. Extracted 
RNA was reverse transcribed using First Strand cDNA Synthesis kit (ThermoFisher). 
The cDNA was then used in qRT-PCR assay using QuantiFast SYBR Green PCR kit 
(Qiagen). For the assay, the following quantitech primers were used: IFNK 
(QT00197512; Qiagen), IFNB1 (QT00203763; Qiagen), IFNL1 (QT00222495; Qiagen), 
IFNA2 (QT00212527; Qiagen), U6snRNA (forward—5ʹ-CTCGCTTCGGCAGCACA-3ʹ; 
reverse—5ʹ-AACGCTTCACGAATTTGC-3ʹ; Sigma-Aldrich). For gene expression 
analysis, ddCt method was used and all samples were normalised to the 
housekeeping gene (U6snRNA). 
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2.24 Statistical analysis 
Statistical analyses were carried out with Prism software (GraphPad). Continuous 
variables were compared using either Student’s T test or ANOVA followed by 
pairwise Tukey tests. Pearson’s correlation was used for associations. A p value of ≤ 
0.05 was considered significant (ns, not significant; *P < 0.05; **P < 0.01; ***P < 
0.001; ****P < 0.0001). In all figures, error bars indicate SEM. 
2.25 Key resources table 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Anti-human CD3 clone BW264/56, VioBlue Miltenyi Biotec Cat# 130-094-363 
Anti-human CD3 clone BW264/56, VioGreen Miltenyi Biotec Cat# 130-096-910 
Anti-human CD4 clone M-T466, APC-Vio770 Miltenyi Biotec Cat# 130-100-457 
Anti-human CD19 clone LT19, VioBlue Miltenyi Biotec Cat# 130-098-598 
Anti-human CD14 clone TÜK4, VioBlue Miltenyi Biotec Cat# 130-094-364 
Anti-human CD56 clone B159, BV450 BD Biosciences Cat# 560360 
Anti-human CD11c clone MJ4-27G12, VioBlue Miltenyi Biotec Cat# 130-097-328 
Anti-human HLA-DR clone AC122, APC-Vio770 Miltenyi Biotec Cat# 130-104-200 
Anti-human CD123 clone AC145, PerCP-Vio700 Miltenyi Biotec Cat# 130-103-802 
Anti-human CD303 (BDCA-2) clone AC144, FITC Miltenyi Biotec Cat# 130-090-510 
Anti-human CD304 (BDCA-4) clone AD5-17F6, 
VioBright FITC 
Miltenyi Biotec Cat# 130-104-272 
Anti-human CD85g clone REA100, PE-Vio770 Miltenyi Biotec Cat# 130-099-009 
Anti-human CD85j clone GHI/75, PE-Vio770 Miltenyi Biotec Cat# 130-101-552 
Anti-human CD69 clone FN50, FITC Miltenyi Biotec Cat# 130-092-166 
Anti-human CD25 clone 4E3, PE Miltenyi Biotec Cat# 130-091-024 
Anti-human CD317 clone RS38E, PE BioLegend Cat# 348406 
Anti-human IFN-α clone LT27:295, APC Miltenyi Biotec Cat# 130-092-602 
Anti-human TNF-α cA2, PE-Vio770 Miltenyi Biotec Cat# 130-096-755 
Anti-human IL-6 clone MQ2-13A5, PE Miltenyi Biotec Cat# 130-096-086 
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Anti-human IFN-γ clone 45-15, APC Miltenyi Biotec Cat# 130-091-640 
Anti-human IL-10 clone JES3-9D7, PE Miltenyi Biotec Cat# 130-096-043 
Anti-human TNF-α clone Mab11, APC/Cy7 BioLegend Cat# 502944 
Anti-human IFN-γ clone 4S.B3, PE/Cy7 BioLegend Cat# 502528 
Anti-human IL-17A clone BL168, APC BioLegend Cat# 512334 
Anti-human TLR9 clone eB72-1665, APC BD Biosciences Cat# 560428 
Anti-human TLR7 clone 533707, PE R&D Cat# IC5875P 
Anti-human FoxP3 clone 3G3, APC Miltenyi Biotec Cat# 130-093-013 
Human TNF alpha antibody clone 1825 R&D Systems Cat# MAB210-SP 
Chemicals, Peptides, and Recombinant Proteins 
ODN 2216 Miltenyi Biotec Cat# 130-100-243 
ORN R-2336 Miltenyi Biotec Cat# 130-104-431 
Human IL-3, premium grade  Miltenyi Biotec Cat# 130-095-071 
Human TNF-α, premium grade Miltenyi Biotec Cat# 130-094-014 
Hydrogen peroxide solution [30% (w/w) in H2O2] Sigma-Aldrich Cat# H1009 
Prolong Gold Antifade Mountant ThermoFischer 
Scientific 
Cat# P36930 
Poly(I:C) LMW InvivoGen Cat# 31852-29-6 
Poly(dA:dT) InvivoGen Cat# 86828-69-5 
TaqMan Universal PCR master Mix ThermoFischer 
Scientific 
Cat# 4304437 
SYBR Green PCR Master Mix ThermoFischer 
Scientific 
Cat# 4309155 
T cell activation/expansion kit Miltenyi Biotec Cat# 130-091-441 
7-AAD Staining Solution Miltenyi Biotec Cat# 130-111-568 
Critical Commercial Assays 
Diamond Plasmacytoid Dendritic Cell Isolation Kit II Miltenyi Biotec Cat# 130-097-240 
Naive CD4+ T Cell Isolation Kit II Miltenyi Biotec Cat# 130-094-131 
Intracellular Fixation & Permeabilization Buffer Set eBioscience Cat# 88-8824-00 
FoxP3 Staining Buffer Set Miltenyi Biotec Cat# 130-093-142 
CellTrace Violet Cell Proliferation Kit ThermoFischer 
Scientific 
Cat# C34571 
Total RNA Purification Kit Norgen Biotek Cat# 17200 
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PicoPure RNA Isolation Kit ThermoFischer 
Scientific 
Cat# KIT0204 
Qubit RNA HS Assay Kit ThermoFisher 
Scientific 
Cat# Q32852 
SMART-Seq V4 ultra low Input RNA Kit Takara Bio Cat# 634888 
Nextera XT DNA Library Preparation Kit Illumina Cat# FC-131-1024 
Telomere PNA Kit/FITC for Flow Cytometry Agilent Cat# K532711-8 
Superfrost plus slides ThermoFisher 
Scientific 
Cat# J1800AMNT 
RNAscope Multiplex Fluorescent Reagent Kit v2 Advanced Cell 
Diagnostics 
Cat# 323100 
TSA Cy 3, Cy 5, TMR, Fluorescein Evaluation Kit Perkin Elmer Cat# NEL760001KT 
RevertAid First Strand cDNA Synthesis Kit ThermoFisher 
Scientific 
Cat# K1622 
QuantiFast SYBR Green PCR Kit Qiagen Cat# 204054 
Quick-RNA MiniPrep Kit Zymo Research Cat# R1055A 
Human IFN alpha Platinum ELISA Invitrogen Cat# BMS216 
Experimental Models: Cell Lines 
Human: 1301 cell line Sigma-Aldrich Cat# 0105161 
Oligonucleotides 
U6snRNA Primer: Forward 5ʹ-
CTCGCTTCGGCAGCACA-3ʹReverse 5ʹ-
AACGCTTCACGAATTTGC-3ʹ 
Sigma-Aldrich N/A 
IFNK Primer  Qiagen Cat# QT00197512 
IFNA Primer Qiagen Cat# QT00212527 
IFNB1 Primer Qiagen Cat# QT00203763 
IFNL1 Primer Qiagen Cat# QT00222495 
Software and Algorithms 
Prism 7 Graphpad Software, Inc. https://www.graphpad.com/ 
FACS DiVA BD Biosciences http://www.bdbiosciences.com/ 
CytExpert 2.0 Beckman Coulter https://www.beckman.com/ 
Fluidigm Real Time PCR 
Analysis 
Fluidigm https://www.fluidigm.com/software 
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FastQC BaseSpace Labs https://www.illumina.com/ 
Cutadapt Cutadapt http://cutadapt.readthedocs.io/en/stab
le/index.html/ 
Table Browser UCSC Genome Browser https://genome.ucsc.edu/ 
QualiMap 2.0 QualiMap http://qualimap.bioinfo.cipf.es/ 
Picard tools Broad Institute https://broadinstitute.github.io/picard/ 
ReactomePA Bioconductor https://www.bioconductor.org/ 
KEGG Kyoto University https://www.genome.jp/kegg/ 
Nikon NIS Elements Nikon Instruments https://www.nikoninstruments.com/ 
Other 
50mL Leucosep Tubes Greiner Bio-One Cat# 89048-938 
Table 2.3 Key reagents and resources used for experiments and data analysis. 
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CHAPTER 3.  
TYPE I INTERFERON REGULATION IN PRECLINICAL 
AUTOIMMUNITY AND SYSTEMIC LUPUS 
ERYTHEMATOSUS 
3.1 Introduction 
Systemic lupus erythematosus (SLE) and related conditions represent a group of 
autoimmune connective tissue diseases (CTDs) characterised by the breakdown of 
immune tolerance and systemic inflammation (97). Clinical symptoms and severity 
may significantly vary among patients with SLE, but an immune response against 
endogenous nuclear antigens as well as other immune dysregulation are central in 
disease pathogenesis (188). Although the presence of anti-nuclear antibodies (ANA) 
may precede clinical symptoms by years, only a minority of individuals at this stage 
of preclinical benign autoimmunity will eventually progress to clinically overt disease 
and develop irreversible end-organ tissue damage (108).  
Alongside ANA positivity, the dysregulation of type I IFN axis has been recognised as 
a common feature in multiple autoimmune rheumatic diseases, predominantly SLE 
(172, 321). A lot of lupus susceptibility genes are related to IFN pathway, while the 
risk haplotypes in IRF5 and IRF7 are associated with increased IFN activity and specific 
autoantibodies (198, 200, 203, 204). Increased levels of serum IFN-α were described 
in patients with SLE more than 30 years ago, while 60 – 80% of SLE patients can 
exhibit increased expression of interferon-stimulated genes (ISGs) in their peripheral 
blood, as described by IFN signatures or scores (189, 287, 290, 322). Overall, a higher 
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IFN signature or score was often associated with higher disease activity, whilst some 
studies suggested an association with particular organ involvement in SLE (288, 291, 
294, 322). Notably, increased type I IFN activity was observed in individuals with 
preclinical autoimmunity, particularly in those who progressed to clinical disease, 
suggesting that early activation of IFN pathways could be of pivotal importance in 
disease initiation (301, 323). 
Despite the increased interest in the role of type I IFNs in the pathogenesis of SLE, 
the source of this dysregulation still remains elusive. The majority of both 
haematopoietic and non-haematopoietic cells are capable of producing type I IFNs 
(IFN-α, -β, -κ, -ω, -ε) as first line of defence against viral infections. Plasmacytoid 
dendritic cells (pDCs) are thought to be the professional IFN-α-producing cells upon 
recognition of nucleic acids via intracellular toll-like receptors, particularly TLR7 and 
TLR9 (119, 132). Engagement of TLRs within endosomal compartments with 
appropriate ligands can lead to activation of IRF7 and NFκB pathways and eventually 
production of IFN-α and pro-inflammatory cytokines (TNF-α, IL-6) (135). Apart from 
the secretory function, pDCs exhibit antigen-presentation properties potentially 
leading to T cell activation (149). TLR-activated pDCs can promote Th1 and Th17 
differentiation (151, 153). On the other hand, unstimulated or HIV-stimulated pDCs 
can induce tolerogenic immune responses promoting Treg differentiation (159, 161, 
162). In the context of autoimmunity, nucleic acids from common viruses or 
alternatively self-DNA or self-RNA forming immune complexes with autoantibodies 
were proposed as possible stimuli for pDC activation (134, 168, 174, 324). However, 
more recent data suggested that pDCs might not contribute to type I IFN activity seen 
in SLE as previously thought (325). Experimental work on interferon-mediated 
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autoimmune disorders (interferonopathies) suggested that type I IFN responses 
could initially emerge in epithelial tissues, which in turn could promote the 
development of autoreactive T cell and B cell clones and systemic inflammation 
(326).  
3.2 Results 
3.2.1 High IFN activity in peripheral blood characterises preclinical autoimmunity 
and SLE  
The type I IFN activity was evaluated based on expression of multiple ISGs measured 
by TaqMan assays and further analysed by factor analysis as described in detail in 
Materials and Methods. Factor analysis indicated two distinct sets of genes (IFN 
Score A and IFN Score B), which explained > 80% of the variability in the data and 
associated with different features in patient groups. At baseline, IFN Score A differed 
among healthy controls, At-Risk individuals and SLE patients (P < 0.001). IFN Score A 
was found to be significantly higher in both At-Risk individuals [n = 105; FD (95% CI) 
2.21 (1.22, 4.00), P = 0.005] and SLE patients [n = 114; 7.81 (4.33, 14.04), P < 0.001] 
compared to healthy controls (n=49); it was also increased in SLE patients relative to 
At- Risk individuals [3.54 (2.22, 5.63), P < 0.001]. Regarding IFN Score B, although it 
differed among groups overall (F = 63.35; P < 0.001), it did not show any difference 
in expression level between At-Risk individuals and healthy controls [0.98 (0.66, 
1.46), P = 0.993]. However, IFN Score B was increased in SLE patients compared to 
both healthy controls [3.85 (2.60, 5.72), P < 0.001] and At-Risk individuals [3.93 (2.87, 
5.37), P < 0.001]. The summary of the results can be seen in Figure 3.1. 
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Figure 3.1 Expression of IFN scores at baseline in At-Risk individuals and patients with 
established SLE. (A) Baseline expression of IFN Score A was higher in patients with SLE and 
At-Risk individuals compared with healthy controls. (B) For IFN Score B, only patients with 
SLE had an increased expression; At-Risk individuals showed no statistically significant 
difference compared to healthy controls. **P < 0.01; ***P < 0.001.  
 
After 12 months of follow up, At-Risk individuals were divided into two groups 
according to their status of progression to an autoimmune connective tissue disease. 
Both IFN Score A and B differed among the groups overall (P < 0.001) with both scores 
to be significantly higher in At-Risk individuals who eventually progressed 
(progressors; n = 19) versus in those who did not progress (non-progressors; n = 86). 
Nevertheless, IFN Score B was found to be increased at a greater extent [FD 3.22 
(1.74, 5. 95), P < 0.001] in comparison with IFN Score A [2.94 (1.14, 7.54), P = 0.018]. 
The level of expression of both scores did not show any statistical difference between 
non-progressors and healthy controls (IFN Score A, p=0.096; IFN Score B, P = 0.520). 
Interestingly, neither IFN Score A nor IFN Score B differed between At-Risk 
progressors and SLE patients (P > 0.1). The summary of the results can be seen in 
Figure 3.2. 
  
74 
 
Figure 3.2 Baseline expression IFN scores in peripheral bloods as prognostic marker for 
disease progression. (A–B) Baseline expression of both IFN Score A and IFN Score B were 
higher in At-Risk individuals who progressed to an autoimmune connective tissue disease 
compared with the non-progressors, but to a greater fold difference in IFN Score B.  
 
3.2.2 Phenotyping pDCs in peripheral blood 
Peripheral blood pDCs were enumerated and immunophenotyped from freshly 
isolated PBMCs using flow cytometry in At-Risk individuals (n = 64), patients with SLE 
(n = 81) and pSS (n = 21) as well as age- and sex-matched healthy controls (n = 37). 
pDCs are characterised by the lack of lineage markers CD3 (T cells), CD19 (B cells), 
CD56 (NK cells), CD14 (monocytes) and CD11c (conventional DCs), intermediate to 
high expression of HLA-DR (MHC-II), high expression of CD123 (IL-3R) and other 
markers such as CD303 (BDCA-2) and CD304 (BDCA-4). pDCs were gated as lineage-
HLA-DR+CD123+CD303+ cells (Figure 3.3).  
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Figure 3.3 Gating strategy to identify the pDC population within PBMCs. pDCs are 
characterised by the lack of expression of lineage markers (CD3, CD19, CD56, CD14, CD11c), 
intermediate to high expression of HLA-DR, high expression of CD123 (IL-3R) and CD303 
(BDCA-2). 
 
The cells were studied for the surface expression of multiple molecules known to be 
important in regulating immune functions of pDCs. In more detail, pDCs in SLE 
patients showed no statistically significant difference in the expression of HLA-DR or 
BDCA-2 (CD303), which are known to be involved in antigen presentation and 
negative regulation of IFN-α production respectively. On the other hand, CD123 (IL-
3R) and ILT2 (CD85j), molecules involved in regulation of immune responses, were 
found to be upregulated on pDCs of SLE patients compared to healthy controls (P < 
0.001). Interestingly, CD317 (BST2; tetherin), a molecule known to be induced by 
type I IFNs, also presented higher expression on pDCs of SLE patients (P < 0.05); 
however, its ligand ILT7 (CD85g) appeared to be downregulated on pDCs of SLE 
patients (P < 0.05). The expression levels of pDC surface molecules in healthy 
controls, At-Risk individuals and SLE patients are summarised in Figure 3.4. 
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Figure 3.4 Phenotyping of peripheral blood pDCs in At-Risk individuals and SLE patients. 
Surface expression of: (A) HLA-DR (MHC-II), (B) BDCA-2 (CD303), (C) CD123 (IL-3R), (D) ILT2 
(CD85j), (E) BST2 (CD317), (F) ILT7 (CD85g). *P < 0.05; **P < 0.01, ***P < 0.001, ****P < 
0.0001. 
 
3.2.3 Circulating pDCs are decreased in preclinical autoimmunity and SLE 
The literature has contradictory data about the number of circulating pDCs in 
patients with SLE, whilst the data about patients with pSS and are more limited. Here, 
I investigated whether or not there were any discrepancies in the number of pDCs in 
peripheral blood not only in patients with established autoimmune diseases such as 
SLE and pSS, but also in individuals with preclinical autoimmunity (At-Risk). The 
average percentage of pDCs in PBMCs was found significantly decreased in patients 
with SLE (n = 81; P < 0.0001) and pSS (n = 21; P < 0.0001) compared to healthy controls 
(n = 37). Intriguingly, this reduction in circulating pDCs was also observed in 
treatment-naïve At-Risk individuals (n = 64; P < 0.0001), the majority of whom (83%) 
remained at the stage of preclinical benign autoimmunity after 12 months of follow 
up (Figure 3.5). 
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Figure 3.5 Enumeration of pDCs in peripheral blood. Average percentage of pDCs in PBMCs 
of At-Risk individuals (At-Risk; n = 64), patients with systemic lupus erythematosus (SLE; n = 
81) and primary Sjögren’s Syndrome (pSS; n = 21) in comparison with age- and sex-matched 
healthy controls (HC; n = 37). ****P < 0.0001. 
 
Next, to determine whether this reduction in numbers of circulating pDCs was 
associated with other immunological biomarkers such as type I IFN activity and 
autoantibody profile, I evaluated the expression of IFN Score A in PBMCs from the 
patients (SLE and pSS), At-Risk individuals and healthy controls using TaqMan assays 
as described in Materials and Methods. Overall, IFN Score A was notably higher in 
patients with both SLE and pSS as well as At-Risk individuals. Nevertheless, no 
association was found between the level of expression of IFN Score A and the 
percentage of circulating pDCs (Figure 3.6A-D). Although IFN Score A was associated 
with increased number of autoantibodies (ENA count), no association was found 
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between serology and the percentage of pDCs in any of the sample groups (Figure 
3.6E-F).  
 
 
Figure 3.6 pDC numbers are decreased in SLE independently of IFN activity. No association 
was found between the percentage of pDCs in PBMCs and type I IFN activity measured by 
IFN Score A in: (A) healthy controls (HC; n = 37), (B) At-Risk individuals (At-Risk; n = 64), (C) 
patients with systemic lupus erythematosus (SLE; n = 81), and (D) primary Sjögren’s 
Syndrome (pSS; n = 21). (E) Higher expression of IFN Score A was associated with higher 
number of autoantibodies (ENA count) in patients with SLE and pSS as well as At-Risk 
individuals. (F) No association was found between ENA count and the percentage of 
peripheral blood pDCs in patients with SLE and pSS as well as At-Risk individuals. 
 
Particularly in SLE patients, the reduction of circulating pDCs was found to be 
independent of disease activity (Figure 3.7A). In addition, treatment with 
hydroxychloroquine (Figure 3.7B), other immunosuppressants (Figure 3.7C) or 
prednisolone dose (Figure 3.7D) did not correlate with the reduction of circulating 
pDCs either.  
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Figure 3.7 pDC numbers are decreased in SLE independently of disease activity and 
treatment. (A) Percentage of pDCs in PBMCs in SLE patients with inactive and active disease. 
(B) Percentage of pDCs in PBMCs in SLE patients treated with or without hydroxychloroquine 
(HCQ). (C) Percentage of pDCs in PBMCs in SLE patients treated with other 
immunosuppressants (MTX, methotrexate; AZA, azathioprine; MMF, mycophenolate 
mofetil; None, no immunosuppression). (D) Association of pDCs in PBMCs and prednisolone 
dose in patients with SLE. ns = not significant. 
 
Finally, the reduction of circulating pDCs in At-Risk individuals, SLE and pSS patients 
was not associated with the general lymphocyte count and especially, the 
lymphopenia particularly seen in SLE patients suggesting the decreased pDCs in 
peripheral blood is an independent feature of autoimmunity (Figure 3.8).  
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Figure 3.8 pDC numbers are decreased in SLE independently of the lymphocyte count. No 
association was found between the percentage of pDCs in PBMCs and the lymphocyte count 
in: (A) At-Risk individuals, (B) patients with SLE, and (C) patients with pSS. 
 
3.2.4 TLR-stimulated pDCs present decreased cytokine production in preclinical 
autoimmunity and SLE 
The production of IFN-α and other pro-inflammatory cytokines, for example TNF-α, 
in response to TLR-mediated stimulation is the hallmark of pDC function. To evaluate 
the capacity of cytokine production by pDCs, I stimulated freshly isolated PBMCs 
from At-Risk individuals (n = 26), patients with established SLE (n = 40) and pSS (n = 
7) alongside healthy controls (n = 14) for 6 hours with TLR9 (ODN 2216) or TLR7 (ORN 
R-2336) agonists. I measured both IFN-α and TNF-α produced by lineage-HLA-
DR+CD123+CD303+ pDCs using intracellular staining according to the protocol 
described in Materials and Methods.  
Whereas pDCs from healthy controls produced large amounts of IFN-α in response 
to TLR9 or TLR7 agonists, pDCs from SLE patients showed little or no cytokine 
production (Figure 3.9A). In more detail, TLR9- and TLR7-mediated IFN-α production 
was diminished in pDCs from patients with pSS similarly to SLE (Figure 3.9C-D). 
Although TLR9-mediated IFN-α production showed similar results in At-Risk 
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individuals, their pDCs seemed to partially maintain some TLR7-mediated IFN-α 
production (Figure 3.9A-C).  
 
Figure 3.9 pDCs from At-Risk individuals, SLE and pSS patients produce less IFN-α after 
stimulation with synthetic TLR agonists. (A) Freshly isolated PBMCs were cultured in the 
absence or presence of TLR9 (ODN 2216) or TLR7 (ORN R-2336) agonists for 6 hours, then 
IFN-α production by pDCs was measured using intracellular staining. Results shown are 
representative of a healthy control (HC) and a patient with SLE. Average percentage of IFN-
α produced by TLR9-stimulated (B) and TLR7-stimulated (C) pDCs in HC (n = 14), At-Risk (n = 
26), SLE (n = 40) and pSS (n = 7) patients. *P < 0.05; **P < 0.01, ***P < 0.001, ****P < 0.0001. 
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TLR9- and TLR7-mediated TNF-α production was also significantly decreased in pDCs 
from patients with SLE compared to healthy controls (Figure 3.10A). pDCs from pSS 
patients showed a significant decrease in TNF-α production similar to that of SLE 
patients, whilst pDCs from At-Risk individuals showed the same trend as IFN-α 
production, partially maintaining some TLR7-mediated TNF-α production (Figure 
3.10B-C). No IFN-α and/or TNF-α production by pDCs was detected in any of the 
samples without external stimulation.  
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Figure 3.10 pDCs from At-Risk individuals, SLE and pSS patients produce less TNF-α after 
stimulation with synthetic TLR agonists. (A) Freshly isolated PBMCs were cultured in the 
absence or presence of TLR9 (ODN 2216) or TLR7 (ORN R-2336) agonists for 6 hours, then 
TNF-α production by pDCs was measured using intracellular staining. Results shown are 
representative of a healthy control (HC) and a patient with SLE. Average percentage of TNF-
α produced by TLR9-stimulated (B) and TLR7-stimulated (C) pDCs in HC (n = 14), At-Risk (n = 
26), SLE (n = 40) and pSS (n = 7) patients. *P < 0.05; **P < 0.01, ***P < 0.001, ****P < 0.0001. 
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I also evaluated whether there was any association between type I IFN activity and 
IFN-α production by pDCs. No association was found between the levels of TLR-
mediated IFN-α production and the level of IFN Score A in patients with SLE as well 
as At-Risk individuals (Figure 3.11).  
 
 
Figure 3.11 No association between TLR9- and TLR7-mediated IFN-α production and IFN 
Score A in SLE patients and At-Risk individuals. 
 
To further investigate the decreased production of cytokines by TLR-stimulated pDCs 
in SLE, I measured the intracellular expression levels of both TLR9 and TLR7 using 
flow cytometry. pDCs (lineage-HLA-DR+CD123+CD303+) from At-Risk individuals and 
SLE patients showed similar expression levels of both receptors compared to those 
of healthy controls (Figure 3.12). 
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Figure 3.12 No difference in the expression of TLR7 and TLR9 in pDCs of At-Risk and SLE 
patients compared to healthy controls. Intracellular expression of TLR9 and TLR7 in pDCs 
was measured using flow cytometry in healthy controls (HC; n = 7), At-Risk (n = 8) and SLE (n 
= 19) patients. 
 
Interestingly, while culturing PBMCs, a population within monocytes was aroused 
which was characterised by no expression of HLA-DR but positive expression of 
CD303 (BDCA-2), which was previously thought to be a pDC-specific marker. These 
cells showed no response to TLR stimulation, as neither IFN-α nor TNF-α production 
was detected (Figure 3.13). 
 
Figure 3.13 CD303+ cells arise from the monocytic population after culture. (A) Gating of 
HLA-DR-CD303+ cells from cultured PBMCs. (B) No production of IFN-α or TNF-α was detected 
by HLA-DR-CD303+ cells after TLR-mediated stimulation (ODN 2216). 
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3.2.5 IL-3 triggers TLR-independent production of IL-6 by pDCs 
IL-3 is known to maintain pDC survival in vitro and to enhance IFN-α production upon 
TLR-mediated stimulation (327, 328). I confirmed that pre-treatment for 24 hours 
with IL-3 amplified IFN-α production by both TLR9- and TLR7-stimulated pDCs from 
healthy controls (n = 6). However, a statistically significant increase in IFN-α 
production was not seen in pDCs of At-Risk individuals (n = 4) and SLE patients (n = 
7) (Figure 3.14A-B). Furthermore, I discovered a new effect of IL-3 on pDCs’ function; 
IL-3 triggered the spontaneous production of IL-6 by pDCs without any exogenous 
TLR-mediated stimulation. In contrast to the defective IFN-α and TNF-α production 
in pDCs from SLE patients described above, this TLR-independent IL-6 production by 
IL-3 stimulation was not impaired in the patient samples (Figure 3.14C-D). 
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Figure 3.14 IL-3 triggers TLR-independent production of IL-6 by pDCs. PBMCs from healthy 
controls (HC; n = 6), At-Risk individuals (At-Risk; n = 4) and SLE patients (n = 7) were cultured 
for 18 hours in the absence or presence of IL-3 (10 ng/mL). The cells were then stimulated 
by TLR9 (ODN 2216) or TLR7 (ORN R-2336) agonists for 6 additional hours. The production of 
cytokines was measured by intracellular staining. (A) IL-3 significantly enhanced TLR9-
mediated IFN-α production by pDCs of healthy controls (P < 0.001); this effect was not seen 
in pDCs of At-Risk (P = 0.3) and SLE (P = 0.4) patients. (B) IL-3 significantly enhanced TLR7-
mediated IFN-α production by pDCs of healthy controls (P < 0.0001); this effect was not that 
prominent in pDCs of At-Risk (P = 0.09) and SLE (P = 0.6) patients. (C and D) Treatment with 
IL-3 (10 ng/mL) induced the production of IL- 6 by pDCs of both healthy controls and SLE 
patients without exogenous TLR stimulation. The production of IL-6 was detected by 
intracellular staining. Data are represented as mean ±SEM. ***P < 0.001; ***P < 0.0001; ns 
= not significant. 
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3.2.6 pDCs from SLE patients have decreased capacity of inducing T cell 
proliferation and activation 
Although pDCs possess antigen-presentation properties and can trigger T cell 
responses, little is known about the capacity of pDCs in SLE to induce T cell 
proliferation and activation. Firstly, I co-cultured freshly isolated pDCs from SLE 
patients with active disease and healthy controls with allogeneic CellTrace Violet-
labelled naïve CD4+ T cells in the presence of anti-CD3/CD28 beads (cell-to-bead ratio 
2:1). After 5 days, the proliferation of T cells was measured based on CellTrace Violet 
dilution (Figure 3.15A). Even though pDCs from both groups induced T cell 
proliferation, pDCs from SLE patients were substantially less efficient, based on the 
lower percentage of co-cultured T cells that proliferated (Figure 3.15B).  
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Figure 3.15 pDCs from SLE patients display decreased ability to induce T cell proliferation. 
(A) Allogeneic naïve CD4+ T cells were labelled with CellTrace Violet and cultured alone or 
with pDCs purified from healthy controls (HC) or patients with active SLE for 5 days in the 
presence of anti-CD3/CD38 beads at ratio 2:1 to avoid excessive T cell activation and 
expansion. T cell proliferation was analysed by flow cytometry based on CellTrace Violet 
dilution. One representative experiment is shown out of four independent experiments. (B) 
Average percentage of proliferated CD4+ T cells co-cultured with pDCs from healthy controls 
(n = 8) and SLE patients (n = 7). ***P < 0.001. 
Secondly, as pDCs are also known to trigger the induction FoxP3+ T cells, I co-cultured 
pDCs from SLE patients with active disease and healthy controls with allogeneic naïve 
CD4+ T cells in the presence of anti-CD3/CD28 beads (cell-to-bead ratio 2:1). In 
accordance to the findings above, less CD25highFoxP3+ cells were generated from 
naïve CD4+ T cells after 5 days of co-culturing with pDCs from SLE patients in 
comparison with pDCs from healthy controls (Figure 3.16A-B). 
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Figure 3.16 pDCs from SLE patients display decreased ability to induce FoxP3+ T cells. (A) 
Induction of CD4+CD25highFoxP3+ T cells from naïve CD4+ T cells co-cultured for 5 days with 
pDCs from healthy controls or SLE patients in the presence of anti-CD3/CD38 beads at ratio 
2:1. One representative experiment is shown out of three independent experiments. (B) 
Percentage of CD4+CD25highFoxP3+ T cells derived from the co-culture with pDCs from healthy 
controls (n = 5) and SLE patients (n = 5). ***P < 0.001. 
 
Lastly, to investigate the ability of pDCs to trigger cytokine production in T cells, I co-
cultured pDCs from patients with active SLE and healthy controls with allogeneic 
naïve CD4+ T cells in the presence of anti-CD3/CD28 beads (cell-to-bead ratio 2:1) for 
5 days. On the fifth day, cells were stimulated with PMA/Ionomycin for 5 hours and 
the production of TNF-α, IFN-γ and IL-10 was measured by intracellular staining 
following the protocol described in detail in Materials and Methods. In comparison 
with T cells alone, pDCs from healthy controls enhanced the production of TNF-α 
(34.07% vs. 48.18%), IFN-γ (5.05% vs. 6.01%) and IL-10 (1.75% vs. 3.42%) from the 
co-cultured T cells. However, pDCs from SLE patients suppressed the production of 
all cytokines measured; TNF-α (34.07% vs. 27.95%), IFN-γ (5.05% vs. 3.65%) and IL-
10 (1.75% vs. 0.83%). The summary of results can be seen in Figure 3.17. 
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Altogether, pDCs from SLE patients exhibit decreased capacity of triggering T cell 
proliferation and activation, whilst they might actually contribute to regulation of T 
cell responses. 
 
Figure 3.17 pDCs from SLE patients display decreased ability to induce T cell activation. (A-
C) Allogeneic naïve CD4+ T cells were cultured alone or with pDCs from healthy controls or 
SLE patients for 5 days in the presence of anti-CD3/CD38 beads at ratio 2:1. On the fifth day, 
the cells were stimulated with PMA/Ionomycin and the production of TNF-α, IFN-γ and IL-10 
by CD4+ T cells was measured by intracellular staining. One representative experiment is 
shown out of three independent experiments. ***P < 0.001. 
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3.2.7 pDCs from IFNlow and IFNhigh SLE patients present distinct transcriptional 
profiles 
To investigate disease-associated transcriptional changes in pDCs of autoimmune 
disorders, I purified pDCs from healthy controls (n = 8), At-Risk individuals (n = 4) and 
SLE patients (n = 13) by negative selection; I then sorted the cells to achieve purity > 
99% based on CD304 (BDCA-4) expression, which is known not to have significant 
effect on type I IFN production. RNA was purified by sorted pDCs using PicoPure RNA 
Isolation kit and the extracted RNA was then sequenced using Smart-seq2 for 
sensitive full-length transcriptomic profiling.  
Due to the high variability among the samples, each sample was first scored based 
on the expression profile of a core set of interferon-stimulated genes (IFN Score) 
similar to the previously described IFN Score A; then each sample was assigned to 
IFNlow or IFNhigh subgroups (Figure 3.18A). pDCs from SLE patients were characterised 
by a range of IFN Score, but overall exhibiting a higher IFN Score than pDCs from 
healthy controls and At-Risk individuals (Figure 3.18B). pDCs from most At-Risk 
individuals (3/4) presented a higher IFN Score compared to pDCs from healthy 
controls and they were assigned to the IFNhigh subgroup. Common interferon-
stimulated genes (MX1, STAT1, XAF1, IFI44, RSAD2) were found upregulated in the 
majority of pDCs in IFNhigh SLE patients and At-Risk individuals, whilst pDCs in IFNlow 
SLE patients showed similar expression levels to those of healthy controls (Figure 
3.18C). 
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Figure 3.18 pDCs from IFNlow and IFNhigh SLE patients display distinct transcriptomic profiles. 
(A) Sorted pDCs from HC (n = 7), At-Risk (n = 4) and SLE (n = 13) were classified according to 
the expression level of the IFN Score described. (B) Average expression level of IFN Score 
measured in samples described in (A). (C) Expression level of representative ISGs in sorted 
pDCs from sample groups described in (A). 
 
I next sought to investigate changes in gene expression profiles of pDCs associated 
with each IFNlow or IFNhigh subgroup compared to those of healthy controls. The 
analysis of IFNlow patients revealed 543 dysregulated transcripts (Figure 3.19A), 
which were particularly enriched for MAPK family signalling cascades, IL-4 and IL-13 
signalling, IL-10 signalling, cell migration and pathogen interaction pathways, 
amongst others (Figure 3.19B-C). Amongst the upregulated genes were chemokines, 
for instance CXCL3, CXCL2 and CXCL16 (Figure 3.12A). A detailed table of the top 
genes differentially expressed in pDCs of IFNlow SLE patients can be found in Table 
3.1.  
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Figure 3.19 Transcriptional profile of pDCs from IFNlow SLE patients compared to pDCs of 
healthy controls (HC). (A) Differentially expressed transcripts (n = 543) in IFNlow SLE pDCs 
compared to HC pDCs. (B) Reactome Pathway Enrichment in differentially expressed genes 
of IFNlow SLE pDCs. (C) Gene Ontology Biological Process Term Enrichment in differentially 
expressed genes in pDCs of IFNlow SLE patients. 
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In IFNhigh SLE patients, 674 transcripts were found to be significantly (FDR < 5%) 
differentially expressed (Figure 3.20A). Unsurprisingly, these genes were found to be 
heavily enriched for interferon response related pathways such as ISG15 antiviral 
mechanisms, but also pathways related to cellular stress, DNA repair and MAPK 
pathway signalling (Figure 3.20B-C). Several phosphatases known to 
dephosphorylate MAP kinases (DUSP1, DUSP2, DUSP5 and DUSP8), transcriptional 
repressors associated with cell differentiation (HESX1, ETV3) and NF-κB inhibitors 
(NFKBIA, NFKBID) were found to be upregulated in IFNhigh SLE patients (Figure 3.21B-
D). A detailed table of the top genes differentially expressed in pDCs of IFNlow SLE 
patients can be found in Table 3.2. 
Detailed tables of the genes commonly differentially expressed in pDCs of both IFNlow 
and IFNhigh SLE patients compared to pDCs from healthy controls can be found in 
Table 3.3. Transcripts for any IFN subtype were confirmed not to be expressed in any 
of the samples.  
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Figure 3.20 Transcriptional profile of pDCs from IFNhigh SLE patients compared to pDCs of 
healthy controls (HC). (A) Differentially expressed transcripts (n = 674) in IFNhigh SLE pDCs 
compared to HC pDCs. (B) Reactome Pathway Enrichment in differentially expressed genes 
of IFNhigh SLE pDCs. (C) Gene Ontology Biological Process Term Enrichment in differentially 
expressed genes in pDCs of IFNhigh SLE patients. 
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Table 3.1 Top 50 genes that are differentially expressed in pDCs of IFNlow SLE patients in 
comparison with pDCs from healthy controls (HC). 
IFNlow SLE pDCs vs. HC pDCs
Gene Fold Change (log2) P value FDR
ULBP2 19.757 < 0.001 < 0.001
C10orf35 18.302 < 0.001 < 0.001
TPSB2 18.228 < 0.001 < 0.001
TMEM216 -4.981 < 0.001 < 0.001
CXCL2 6.379 < 0.001 < 0.001
PLA2G7 9.712 < 0.001 < 0.001
DNAJB4 1.965 < 0.001 0.001
ZBP1 -7.254 < 0.001 0.001
LUCAT1 6.207 < 0.001 0.006
LOC100861532 2.839 < 0.001 0.007
LGALSL 6.161 < 0.001 0.007
SNORD95 4.390 < 0.001 0.007
LOC100008587 3.428 < 0.001 0.007
BBC3 2.962 < 0.001 0.011
SPR 6.792 < 0.001 0.015
FN1 4.352 < 0.001 0.015
PHF3 1.125 < 0.001 0.015
HSPB1 1.527 < 0.001 0.015
CLEC5A 8.287 < 0.001 0.015
CKAP4 -6.563 < 0.001 0.015
IRAIN 5.493 < 0.001 0.015
FAM157C 3.945 < 0.001 0.015
DNAJB1 2.108 < 0.001 0.015
ETV3 3.037 < 0.001 0.017
TPSAB1 9.650 < 0.001 0.020
SLC6A6 3.758 < 0.001 0.020
NPAS1 5.880 < 0.001 0.020
GADD45B 2.245 < 0.001 0.021
IFITM1 -3.619 < 0.001 0.022
COCH -7.844 < 0.001 0.022
ANO8 3.516 < 0.001 0.022
LINC00623 3.718 < 0.001 0.022
HSPA4 -2.406 < 0.001 0.023
AOAH -6.704 < 0.001 0.023
HOXB3 4.793 < 0.001 0.023
SLC8A2 5.243 < 0.001 0.023
NPL 4.663 < 0.001 0.025
ZNF678 4.063 < 0.001 0.025
CNST 2.130 < 0.001 0.025
RNY5 3.224 < 0.001 0.025
PLEKHA8P1 -4.947 < 0.001 0.025
DUSP1 2.903 < 0.001 0.027
LOC100008589 2.695 < 0.001 0.028
NRP2 6.969 < 0.001 0.028
EGR2 7.175 < 0.001 0.029
FCGR2B -6.697 < 0.001 0.033
NRG2 5.224 < 0.001 0.033
LOC221946 5.139 < 0.001 0.033
PLCXD1 3.230 < 0.001 0.033
LACC1 4.975 < 0.001 0.033
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Table 3.2 Top 50 genes that are differentially expressed in pDCs of IFNhigh SLE patients in 
comparison with pDCs from healthy controls (HC). 
IFNhigh SLE pDCs vs. HC pDCs
Gene Fold Change (log2) P value FDR
IFI44 5.403 < 0.001 < 0.001
CAMP 7.261 < 0.001 < 0.001
OASL 6.812 < 0.001 < 0.001
SLC8A2 5.644 < 0.001 < 0.001
ATF3 5.870 < 0.001 < 0.001
CMPK2 7.710 < 0.001 < 0.001
BCL2 5.485 < 0.001 < 0.001
LGALSL 6.240 < 0.001 < 0.001
ORM1 8.011 < 0.001 < 0.001
NCMAP 4.931 < 0.001 < 0.001
HCG11 -3.108 < 0.001 < 0.001
PARP14 3.402 < 0.001 < 0.001
MSL2 2.238 < 0.001 0.001
DDX60L 6.470 < 0.001 0.001
PPDPF 1.798 < 0.001 0.001
IER2 2.552 < 0.001 0.001
NR4A1 5.230 < 0.001 0.002
TFB1M -2.213 < 0.001 0.002
GFOD1 4.279 < 0.001 0.002
TP53INP2 5.236 < 0.001 0.002
TMEM177 -3.452 < 0.001 0.002
LIPT1 -2.499 < 0.001 0.002
JUND 2.486 < 0.001 0.002
THG1L -2.089 < 0.001 0.002
CCDC121 6.073 < 0.001 0.002
SNORD14C 4.151 < 0.001 0.002
C2orf74 -2.833 < 0.001 0.002
CISD1 -2.392 < 0.001 0.002
HIST1H4F -2.531 < 0.001 0.002
SEMA7A 3.150 < 0.001 0.002
ETV3L 3.865 < 0.001 0.002
CEACAM1 5.448 < 0.001 0.002
L3MBTL2 -1.887 < 0.001 0.002
ETV3 2.959 < 0.001 0.002
NPAS1 5.469 < 0.001 0.002
QRICH2 4.336 < 0.001 0.002
LTC4S 5.089 < 0.001 0.003
ARID5A 1.781 < 0.001 0.003
EIF2AK2 2.358 < 0.001 0.003
HES4 4.895 < 0.001 0.003
LINC00847 -2.487 < 0.001 0.003
NSUN7 5.334 < 0.001 0.003
DNAJB1 4.229 < 0.001 0.003
KLF8 -4.556 < 0.001 0.003
RSAD2 4.959 < 0.001 0.003
JUN 2.582 < 0.001 0.003
MON1A -2.248 < 0.001 0.003
IFI44L 3.195 < 0.001 0.004
WDR87 6.155 < 0.001 0.004
IRAIN 4.774 < 0.001 0.004
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Table 3.3 Genes that are differentially expressed in pDCs of both IFNlow and IFNhigh SLE 
patients in comparison with pDCs from healthy controls (HC). 
IFNlow SLE pDCs vs. HC pDCs IFNhigh SLE pDCs vs. HC pDCs
Gene Fold Change (log2) P value FDR Fold Change (log2) P value FDR
ETV3 3.037 < 0.001 0.017 2.959 < 0.001 0.002
ATF3 3.914 < 0.001 0.052 5.209 < 0.001 0.000
LIN9 -3.716 < 0.001 0.058 -2.423 < 0.001 0.031
LGALSL 6.161 < 0.001 0.007 6.240 < 0.001 < 0.001
ZNF2 -4.108 < 0.001 0.058 -2.907 < 0.001 0.020
LIPT1 -3.224 < 0.001 0.050 -2.499 < 0.001 0.002
SEC24D -2.559 < 0.001 0.051 -1.605 0.001 0.038
CXCL2 6.379 < 0.001 < 0.001 4.163 < 0.001 0.019
CBR4 -3.260 < 0.001 0.052 -1.546 < 0.001 0.011
DUSP1 2.903 < 0.001 0.027 2.386 < 0.001 0.021
LTC4S 5.509 < 0.001 0.033 5.089 < 0.001 0.003
SNORD95 4.390 < 0.001 0.007 3.106 < 0.001 0.016
PHF3 1.125 < 0.001 0.015 1.531 < 0.001 0.028
LOC441242 -2.798 0.001 0.068 -2.494 < 0.001 0.015
FUT10 -3.275 0.002 0.100 -2.388 < 0.001 0.016
LOC102724580 3.699 0.001 0.088 4.080 < 0.001 0.004
CCL19 4.468 < 0.001 0.057 3.828 < 0.001 0.020
CTSL 6.460 < 0.001 0.040 4.114 < 0.001 0.020
PUDP -2.632 < 0.001 0.058 -2.752 < 0.001 0.008
ATP7A -4.215 < 0.001 0.035 -2.853 < 0.001 0.020
SAT1 1.642 < 0.001 0.036 1.805 < 0.001 0.009
MIR6087 2.376 < 0.001 0.050 2.411 < 0.001 0.028
ZFP91 2.619 < 0.001 0.046 2.147 0.001 0.043
PAAF1 -3.453 0.001 0.066 -1.973 < 0.001 0.033
DUSP8 6.050 0.001 0.085 6.392 < 0.001 0.006
IRAK3 6.179 < 0.001 0.045 4.152 < 0.001 0.007
PLEKHA8P1 -4.947 < 0.001 0.025 -2.810 < 0.001 0.009
ACVR1B 5.196 0.001 0.059 4.169 < 0.001 0.017
RN7SL1 2.867 < 0.001 0.049 2.648 < 0.001 0.034
RN7SL2 3.107 < 0.001 0.033 2.806 < 0.001 0.021
ATG14 2.520 < 0.001 0.058 1.640 < 0.001 0.028
REREP3 3.757 < 0.001 0.046 3.672 < 0.001 0.019
IRAIN 5.493 < 0.001 0.015 4.774 < 0.001 0.004
CDH1 3.795 0.001 0.061 2.895 < 0.001 0.028
SCARNA21 2.549 0.001 0.074 2.980 0.001 0.041
C5AR1 6.724 0.002 0.098 5.210 < 0.001 0.031
SLC8A2 5.243 < 0.001 0.023 5.644 < 0.001 < 0.001
IER2 2.416 < 0.001 0.050 2.552 < 0.001 0.001
DNAJB1 2.108 < 0.001 0.015 4.097 < 0.001 0.005
NPAS1 5.880 < 0.001 0.020 5.469 < 0.001 0.002
LOC100008589 2.695 < 0.001 0.028 2.969 < 0.001 0.006
MIR3687-1 3.321 0.002 0.098 3.448 < 0.001 0.007
MIR3687-2 3.321 0.002 0.098 3.448 < 0.001 0.007
LOC100861532 2.839 < 0.001 0.007 2.930 < 0.001 0.005
WRB -2.306 0.001 0.068 -2.027 < 0.001 0.008
pDC-specific transcription factors
E2-2 (TCF4) 0.691 0.118 0.537 0.313 0.578 0.852
SPIB 0.657 0.279 0.719 0.235 0.744 0.922
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Figure 3.21 Differentially expressed genes in pDCs of healthy controls (HC), At-Risk 
individuals (At-Risk), IFNlow SLE and IFNhigh SLE patients. (A) Chemokines; (B) NF-κB 
inhibitors; (C) Phosphatases; (D) Transcriptional repressors. 
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3.2.8 pDCs from SLE patients present transcriptional and phenotypic features 
related to immune senescence 
In vitro functional assays presented in detail above demonstrated that the decreased 
secretory function upon TLR stimulation was universally observed in pDCs of SLE 
patients, independently of the IFN activity measured in the peripheral blood (Figure 
3.9). To investigate which biological pathways contribute to this defective 
phenotype, I studied the transcripts differentially expressed in both pDCs of IFNlow 
and IFNhigh SLE patients compared to those of healthy controls. Surprisingly, little 
overlap between differentially expressed genes in pDCs of IFNlow and IFNhigh SLE 
patients was detected (Figure 3.22A). Amongst the 80 shared transcripts, there were 
upregulated genes involved in cellular senescence and stress (ATG14, ATP7A, 
DNAJB1), protein degradation in lysosomes (CTSL), negative regulation of TLR 
signalling (IRAK3), negative regulation MAPK signalling (DUSP1, DUSP8) and negative 
regulation non-canonical NF-κB pathway (ZFP91), which are known to inhibit the 
production of type I IFNs and other pro-inflammatory cytokines (Figure 3.22B).  
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Figure 3.22 Commonly expressed transcripts in pDCs of IFNlow and IFNhigh SLE patients. (A) 
Venn diagram showing the number of differentially expressed transcripts (n = 80) common 
to both IFNlow and IFNhigh pDCs from SLE patients compared to pDCs from HC. (B) Expression 
level of representative genes differentially expressed in both IFNlow and IFNhigh pDCs from SLE 
patients in comparison with pDCs from HC. 
 
Moreover, the shared transcripts included upregulated genes for CXCL2 and CCL19 
(Table 3.3). Reactome Pathway Enrichment also showed that biological processes 
related to MAPK family signalling, Toll-like receptor signalling, IL-10 signalling and 
chemotaxis were significantly enriched (Figure 3.23). 
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Figure 3.23 Differentially expressed genes in IFNlow and IFNhigh pDCs from SLE patients. (A) 
Reactome Pathway Enrichment in DEGs in differentially expressed genes in IFNlow and IFNhigh 
pDCs from SLE patients. (B) Gene Ontology Biological Process Term Enrichment in 
differentially expressed genes in pDCs of IFNlow and IFNhigh SLE patients. 
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Increased telomere erosion is known to be related to cellular senescence, a feature 
which was found in other immune cells of patients with SLE but is still undescribed in 
pDCs. To address this question, I purified pDCs from healthy controls alongside SLE 
patients using negative and positive selection to achieve purity > 95%; pDCs were 
then hybridized with telomere PNA probe before they were analysed by flow 
cytometry. The determination of the relative telomere length was calculated as the 
ratio between the telomere signal of pDCs and the tetraploid control cells (1301 cell 
line) with correction for the DNA index of G0/1 cells (Figure 3.24A). The analysis 
confirmed that pDCs from SLE patients had shorter telomere length compared to 
pDCs from age- and sex-matched healthy controls (Figure 3.24B).  
RNA-sequencing data analysis also indicated that pathways related to cellular stress 
was differentially expressed in both IFNlow and IFNhigh pDCs of SLE patients. To further 
address how this is associated with the secretory function of pDCs, I investigated the 
effect of oxidative stress on type I IFN production in TLR-stimulated pDCs. Freshly 
isolated PBMCs from healthy donors were exposed to increasing concentrations of 
H2O2 (0 – 500 μM) for 15 minutes before they were stimulated with ODN 2216 for 6 
hours according to the protocol described in Materials and Methods. IFN-α 
production was measured by intracellular staining. I confirmed that oxidative stress 
–even at low concentrations of H2O2– negatively regulated TLR-mediated responses 
in viable pDCs leading to a gradual loss of their ability to produce IFN-α (Figure 
3.24C).  
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Figure 3.24 pDCs from SLE patients present increased telomere erosion. Purified pDCs from 
freshly isolated PBMCs were hybridized without (A; upper) or with (A; lower) telomere PNA 
probe. Gates were set in G0/1 phase for both sample cells (pDCs) and tetraploid control cells 
(1301 cell line). (B) Determination of the relative telomere length as the ratio between the 
telomere signal of pDCs purified from HC (n = 10) and SLE (n = 10) patients and the control 
cells (1301 cell line) with correction for the DNA index of G0/1 cells. (C) Freshly isolated PBMCs 
from healthy donors (n = 4) were exposed to H2O2 (0 – 500 μM) for 15 minutes. After H2O2 
exposure, cells were washed thoroughly and resuspended in culture medium before they 
were stimulated with 2μM ODN 2216 for 6 hours. The production of IFN-α was measured in 
viable pDCs by intracellular staining. ns = not significant; *P < 0.05; ****P < 0.001. 
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3.2.9 High IFN activity in skin characterises preclinical autoimmunity and systemic 
lupus erythematosus 
Since professional IFN-α-producing cells such as pDCs appeared dysfunctional in 
producing type I IFNs in SLE, the source of the aberrant type I IFN production seen in 
patients had yet to be identified. To find any potential correlation between type I IFN 
activity in blood and specific disease manifestations, I compared the level of 
expression of IFN Score A in blood with the disease activity in the most common 
affected organs, the skin and the joints. Active disease was defined as BILAG-2004 A 
or B and inactive disease as BILAG-2004 C-E. I found that IFN Score A was associated 
with mucocutaneous disease activity (Fold Difference 2.24 (95% CI 1.16 - 4.34); P = 
0.017), but not with musculoskeletal disease (Fold Difference 0.97 (95% CI 0.44 - 
2.09); P = 0.927) (Figure 3.25A-B). 
To investigate the above correlation further, I compared the fold increase in IFN 
Score A in blood and skin biopsies from At-Risk individuals and SLE patients compared 
to healthy controls. I analysed blood samples from 114 SLE patients, 105 At-Risk 
individuals, and 49 healthy controls; I also analysed lesional skin biopsies from 10 SLE 
patients and non-lesional skin biopsies from 10 At-Risk individuals as well as skin 
biopsies from 6 healthy controls. Total RNA was extracted from the acquired biopsies 
using RNeasy mini kit (Qiagen) and the RNA quantity was measured and assessed for 
quality using NanoDrop spectrophotometer, ND-1000. As described in detail in 
Materials and Methods, TaqMan assays (Applied Biosystems, Invitrogen) were used 
to perform the quantitative real-time reverse transcriptase-polymerase chain 
reaction (qPCR) for the same genes used in measuring type I IFN activity in peripheral 
blood. Data were normalised using Peptidylprolyl isomerase A (PPIA) as a reference 
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gene to calculate ΔCt. All analyses of IFN Scores were conducted using ∆Ct scaling; 
results were then converted to relative expression (2-ΔCt) or fold difference (2-ΔΔCt). 
In At-Risk individuals compared to healthy controls, mean (95% CI) fold increase in 
IFN Score A in blood was 2.21 (1.37, 3.53), while in non-lesional skin the fold increase 
was markedly higher at 28.74 (1.29, 639.48) (Figure 3.25C). The differential increase 
in ISG expression in blood and skin was even more extreme in SLE patients compared 
to healthy controls; in some SLE patients ISG expression in skin was more than 5,000 
times higher than healthy controls. Mean (95% CI) fold increase was 7.80 (4.75,12.80) 
in blood compared to 479.33 (39.32, 5842.78) in skin (Figure 3.25D). A detailed 
summary of the expression of each of the gene measured in skin biopsies of healthy 
controls, SLE patients, and At-Risk individuals can be seen in Figure 3.26. 
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Figure 3.25 Associations of IFN Score A with the two commonest disease manifestations 
(skin and joints) in patients with SLE. (A) Association of IFN Score A with active and 
inactive mucocutaneous disease in SLE patients. (B) Association of IFN Score A with active 
and inactive musculoskeletal disease in SLE patients. (C) Fold increase in IFN Score A of 
At-Risk individuals in blood (2.21; 1.37, 3.53) and skin (28.74; 1.29, 639.48) compared to 
healthy controls. (D) Fold increase in IFN Score A of SLE patients (D) in blood (7.80; 
4.75,12.80) and skin (479.33; 39.32, 5842.78) compared to healthy controls. 
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Figure 3.26 Expression of interferon-stimulated genes in skin biopsies. Skin biopsies from 
healthy controls (HC; n = 7), At-Risk individuals (At-Risk; n = 10), patients with SLE (SLE; n = 
10) were obtained and analysed for the expression of 30 ISGs using TaqMan assays. ISGs 
expressed in skin biopsies were clustered into two distinct groups different to the groups 
found in peripheral blood: (A) ISGs showed a stepwise increase of expression from healthy 
controls to At-Risk individuals and then to SLE patients. (B) ISGs showed no significant 
difference in expression between healthy controls and At-Risk individuals but they were 
significantly increased in skin biopsies of SLE patients. 
 
3.2.10 Patients with high IFN activity in blood present diffuse expression of type I 
IFNs in epidermis 
Although professional IFN-α-producing cells such as pDCs appear immune senescent 
in SLE, a prominent source of the aberrant type I IFN production seen in patients is 
yet to be identified. To study alternative sources of this dysregulation, skin biopsies 
from healthy controls (n = 4), SLE patients (n = 6) and At-Risk individuals (n = 4) were 
used as a representative example of tissue inflammation, since I previously showed 
Skin IFN Signature
We used skin biopsies obtained from Healthy control (n=7), At risk patients (n=10) and established SLE (n=10) to look for 
the skin IFN signature by analysing gene expression of 30 well-known ISGs from previous literature using TaqMan assays.
data show Our data demonstrated a unique IFN gene signature in the skin different than corresponding blood IFN signature.
data revealed two disticnt group of ISGs: 
A. Group of ISGs showed impressive step wise increase of gene expression from healthy control biopsies to At risk patients 
biopsies then to SLE biopsies.
B. Group of ISGs showed no detectable change from Healthy control biopsies compared to at Risk patients with 
remarkable increase in SLE skin biopsies only.
Interferon Scores
IFN-I status is usually measured using expression of 
IFN-stimulated genes. However, such “Interferon 
signatures” do not correlate with disease activity, 
which has previously been explained.  Our work has 
resolved this using more sophisticated scoring of gene 
expression as well as a cell specific flow cytometric 
assay (in next figure).
IFN stimulated gene expression is not a single 
phenomenon, but occurs in distinct modules 
(Chiche et al. 2014).  
We used in vitro stimulation and cell sorting to show that 
modular expression of IFN-stimulated genes is determined by different 
classes of IFN (alpha, beta, gamma etc.) as well as different responding cell types (monocytes, B cells etc).  
We derived IFN Scores that capture greater detail on IFN gene expression than a single “Interferon Signature” in a continuous 
fashion.  Score A represents predominantly Type I IFN response, while Score B represents mixed Type I/II IFN response.  
Data show IFN status at baseline of 118 therapy-naïve ANA positive patients with no CTD.  
At 12 months, 20 had progressed to a connective tissue disease.  Our data showed that IFN Scores were increased in this cohort 
at baseline and predicted outcome.  
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that mucocutaneous symptoms in SLE correlate well with IFN activity in peripheral 
blood (322). Skin biopsies were obtained from areas with an active lesion from SLE 
patients with a range of IFN Score A in peripheral blood, whilst skin biopsies from At-
Risk individuals had no signs of inflammation but they did present high IFN Score A 
in peripheral blood. Then I performed in situ hybridization to visualize the expression 
of type I IFNs transcripts (IFNK, IFNA2) in all skin biopsies obtained according to the 
detailed protocol described in Materials and Methods. 
 
Figure 3.27 SLE patients with high IFN activity in blood present diffuse expression of type I 
IFNs in epidermis. Skin biopsies were hybridized using RNAScope in situ hybridization 
technology with custom-designed target probes for IFNA2 and IFNK. Hybridization signals 
were amplified and detected using TSA Plus fluorescein (FITC) for IFNA2 and TSA Plus Cyanine 
3 (Cy3) for IFNK. Nuclei were highlighted using DAPI. Representative in situ hybridization 
images of: (A) healthy control, (B) IFNhigh SLE patient with active skin lesion. 
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As expected, skin biopsies from healthy controls with minimal IFN Score A in 
peripheral blood showed no expression of either IFNK or IFNA2 (Figure 3.27A). In 
contrast, lesional skin from SLE patients with high IFN Score A presented with diffuse 
expression of IFNK in epidermis among keratinocyte layers (Figure 3.27B). However, 
IFNK expression was less prominent in the epidermis of SLE patients with lower IFN 
Score A. Regarding IFNA2, I was able to detect its expression in cells in the dermis, 
possibly fibroblasts as they were located in areas with dense connective tissue, but 
not in leucocyte-infiltrating areas (Figure 3.28).  
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Figure 3.28 Area of lymphocyte infiltration and connective tissue of a patient with SLE with 
active skin lesion. Skin biopsies were hybridized using RNAscope in situ hybridization 
technology with custom-designed target probes for IFNA2 and IFNK. Hybridization signals 
were amplified and detected using TSA Plus fluorescein (FITC) for IFNA2 and TSA Plus Cyanine 
3 (Cy3) for IFNK. Nuclei were highlighted using DAPI. IFNA2 expression was detected in cells 
within the connective tissue but not in infiltrating leucocytes. 
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Interestingly, the epidermis of At-Risk individuals with high IFN Score A in peripheral 
blood was also characterised by diffuse expression of IFNK among keratinocyte 
layers, but unlike SLE patients there was no sign of cutaneous inflammation either 
clinically or histopathologically (Figure 3.29). 
 
 
Figure 3.29 At-Risk individuals with high IFN activity in blood present diffuse expression of 
type I IFNs in epidermis. Skin biopsies were hybridized using RNAscope in situ hybridization 
technology with custom-designed target probes for IFNA2 and IFNK. (A, B) Representative in 
situ hybridization images of epidermis from IFNhigh At-Risk individuals with no clinical or 
histopathological signs of inflammation. 
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3.2.11 UV provocation in vivo enhances IFNK expression in keratinocytes 
UV provocation was performed using a solar simulator, which replicated the protocol 
of UV-A and UV-B provocation in a single exposure. After the minimal erythema dose 
was determined, a 10 cm2 non-sun exposed area of skin was exposed to the dose x 
1.5 on three consecutive days. A biopsy of the pre-exposed and exposed area of skin 
was obtained when a reaction was seen clinically. The tissue biopsies were 
cryosectioned and stored at -80oC until RNAscope protocol for in situ hybridization 
was applied to measure the expression of IFNK transcripts in single cell level on the 
tissue section. A significant enhancement of IFNK expression in exposed area of skin 
of SLE patients was observed compared to the pre-exposed area that showed less 
IFNK expression (Figure 3.30). These results not only confirm an important role for 
UV light known to trigger lupus pathology but also show a new mechanism linking 
environmental stimuli and excessive type I IFN production by non-haematopoietic 
tissue cells such as keratinocytes. 
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Figure 3.30 UV provocation enhances type I IFN expression in epidermis of SLE patients. 
Skin biopsies were then hybridized using RNAscope in situ hybridization technology with 
custom-designed target probes for IFNA2 and IFNK. (A) IFNK expression in epidermis of 
patient with inactive SLE before UV provocation. (B) IFNK expression in epidermis of the 
same SLE patient after UV provocation. 
 
3.2.12 Keratinocytes from At-Risk and SLE patients present increased expression 
of IFNs in response to nucleic acids 
To validate the results from in situ hybridization, human keratinocytes and dermal 
fibroblasts were isolated from healthy controls (n = 3), At-Risk individuals (n = 5) and 
SLE patients (n = 5). Cells from patients with cutaneous discoid lupus erythematosus 
  
116 
(CDLE), who were ANA negative and had minimal IFN Score A expression in blood, 
were also used as an inflammatory control (n = 3). Cells were cultured in the presence 
or absence of TLR3 stimulation, Poly I:C (1 μg/mL), or RIG-I stimulation, Poly dA:dT 
(100 ng/ml), for 6 and 24 hours before the expression of IFNK was measured by qPCR. 
At baseline, without exogenous stimulation, keratinocytes from both At-Risk and SLE 
patients presented higher expression of IFNK. Interestingly, after both TLR3 and RIG-
I stimulation, the expression of IFNK was significantly increased in the keratinocytes 
of At-Risk and SLE patients. However, keratinocytes from CDLE did not show the 
same response (Figure 3.31A). For IFNB1, there was no expression at baseline in any 
sample. However, after stimulation with Poly(I:C) there was a trend to increased 
expression for At-Risk keratinocytes and a significant increase for keratinocytes from 
SLE and CDLE patients. IFNB1 expression was also increased in keratinocytes of SLE 
patients after Poly(dA:dT) stimulation but not in other conditions (Figure 3.31B).In 
contrast, IFNL1 expression was only observed in CDLE keratinocytes following 
Poly(I:C) stimulation but not in the other conditions or following Poly(dA:dT) 
stimulation (Figure 3.31C). Finally, IFNA2 expression by keratinocytes was not found 
in any sample or condition (data not shown). 
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Figure 3.31 In vitro culture and stimulation of human keratinocytes. Human keratinocytes 
were isolated from fresh skin biopsies and were then cultured in the absence or presence of 
Poly I:C (1 μg/mL) or Poly dA:dT (100 ng/mL). Expression level of IFNK (A), IFNB1 (B), IFNL1 
(C) in keratinocytes from healthy controls (HC), At-Risk individuals (At-Risk), SLE patients 
(SLE), and patients with cutaneous discoid lupus erythematosus (CDLE) after in vitro culture 
for 24 hours. Data are represented as mean ±SEM. *P < 0.05. 
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3.3 Discussion 
Type I IFNs are crucial mediators linking innate and adaptive immune responses and 
are recognized as key players in the pathogenesis of systemic autoimmune diseases. 
Although the main production of type I IFNs derives from pDCs during antiviral 
responses, the mechanism of IFN regulation in SLE seems more complicated than 
previously thought. Previous studies reported contradictory data about the numbers 
of pDCs in peripheral blood of SLE patients (329-331). The results presented in the 
current study confirmed that circulating pDCs were indeed decreased not only in SLE 
but also in pSS, while this feature was expanded to a stage of benign preclinical 
autoimmunity. Interestingly, the reduction in pDC numbers showed no association 
with the status of IFN activity, clinical disease activity, serology, treatment and it was 
independent of lymphopenia observed in SLE patients. The migration of pDCs to sites 
of inflammation, for instance skin lesions, was a valid hypothesis (332). Nevertheless, 
this hardly explains the fact that SLE patients in clinical remission or At-Risk 
individuals with no evidence of inflammation count low pDC numbers. These 
observations strongly suggest the lack of association between pDCs and type I IFN 
activity seen in autoimmunity. 
Regarding the secretory function of pDCs in SLE, I reported the lack of IFN-α and TNF-
α production upon TLR stimulation. Again, this feature was expanded to pDCs of 
patients with pSS as well as At-Risk individuals, although the latter could partially 
maintain a TLR7-mediated cytokine production. Previous data reported an impaired 
IFN-α-producing capacity of PBMCs in SLE patients in response to TLR9 stimulation, 
while a novel assay to measure human IFN-α demonstrated a striking presence of 
IFN-α in pDCs of STING patients, but it failed to confirm this finding in SLE (325, 331). 
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Trex1-deficient mice failed to regulate STING-mediated antiviral response leading to 
aberrant type I IFN production that initiated from non-haematopoietic cells (326). 
Experimental work on lupus-prone mice reported a gradual loss of pDC capacity to 
produce IFN-α at late stage of disease course (333, 334). Particularly, in the MRL/Mp-
Fas lpr (lpr) mouse model was found that pDCs expressed an increased level of MHC-
II suggesting a functional drift to antigen presentation. However, our pDC-T cell co-
culture revealed that pDCs from SLE were significantly defective in triggering T cell 
proliferation and activation, while they could potentially have a more regulatory role 
inducing T cell anergy.  
Recent findings on Systemic Sclerosis reported the abnormal expression of TLR8 in 
pDCs that leads to IFN-α production suggesting a key pathological role of RNA-
sensing TLR involvement in the establishment of fibrosis (335). However, in our RNA-
sequencing data in pDCs sorted from At-Risk individuals or SLE, we could not confirm 
positive expression of TLR8 in any of the samples. 
It is noticeable that impaired pDC-derived IFN-α production is not uncommon in 
cancer and chronic viral infections. In melanoma and ovarian cancer, tumour-
infiltrating pDCs do not produce IFN-α but actually their presence is associated with 
tumour growth (336-338). Additionally, hepatitis B virus can interfere with TLR9 
pathway by blocking MyD88-IRAK4 signalling and Sendai virus by targeting IRF7, 
while HIV impairs IFN-α production in pDCs via SYK phosphorylation (339, 340). 
Within pDC population, there are distinct subsets that can mediate different immune 
functions (341). Single-cell RNA-sequencing data revealed the diversification of 
human pDCs in response to influenza virus into three phenotypes (P1-, P2-, P3-pDCs) 
with distinct transcriptional profiles and functions (342). pDCs from SLE patients 
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were mostly similar to the P1-phenotype, which represented the conventional 
secretory function and morphology known about pDCs. This is consistent with the 
findings presented above that SLE pDCs demonstrated decreased ability to induce 
CD4+CD25highFoxP3+ T cells, the numbers and function of which are known to be 
impaired in patients with active SLE (343-345). Apart from that, the RNA-sequencing 
data reported that type I IFN activity was overall increased in pDCs of At-Risk and SLE 
patients compared to those of healthy controls, even though pDCs from IFNlow or 
IFNhigh SLE patients had distinct transcriptomic profiles related to different biological 
pathways. However, pDCs from both subgroups differentially expressed genes that 
are well known to be involved in cellular senescence and stress, negative regulation 
of TLR and MAPK pathways as well as IL-10 signalling downstream, which can inhibit 
cytokine production and survival of pDCs (346-348). Intriguingly, aging was shown to 
affect IFN-α-producing capacity of human pDCs by impairing IRF7 and PI3K pathways, 
while this defect was often associated with age-induced cellular stress (349-351). I 
confirmed that pDCs from SLE had increased telomere erosion, while oxidative stress 
had a deleterious effect on IFN-α production. Altogether, these findings suggest that 
pDCs in SLE could present increased biological aging as a regulatory mechanism to 
control systemic immune activation.  
IFN-κ is predominantly expressed by human keratinocytes with pleiotropic effects 
similar to IFN-α/β (352). Keratinocytes have been implicated in the pathogenesis of 
skin injury in SLE undergoing apoptosis or necrosis and eventually realising 
autoantigens (65). Previous studies demonstrated that keratinocytes from patients 
with cutaneous lupus erythematosus presented increased production of IL-6 
compared to healthy controls, with type I IFNs enhancing this process (353). In 
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addition, IFNK expression was reported to be significantly increased in lesional skin 
of patients with cutaneous lupus erythematosus related to photosensitivity (354).  
By using a novel assay for in situ hybridization, I was able to visualize the direct 
expression of type I IFN transcripts in human skin biopsies and not using a surrogate 
marker for IFN response (e.g. MxA). I demonstrated that keratinocytes of SLE patients 
exhibited enhanced IFN-κ-producing capacity at baseline or after stimulation with 
nucleic acids, a feature that was more prominent in cells of At-Risk individuals, 
possibly due to lack of any medication. Notably, diffuse IFNK expression was 
prominent in individuals with high IFN activity in blood but no skin inflammation, 
suggesting that keratinocytes can be predisposed to excessive type I IFN production 
in response to environmental triggers such as UV radiation. Increased recognition of 
danger signals from keratinocytes of predisposed individuals could potentially trigger 
enhanced IFNK production. Indeed, I demonstrated that UV provocation, a well-
known trigger for lupus pathology, induced higher expression of IFNK by 
keratinocytes in vivo. Interestingly, the failure to detect IFNK expression in 
keratinocytes from ANA negative CDLE patients, who exhibited minimal IFN activity 
in blood, may suggest an alternative pathophysiology with other inflammatory 
mediators demonstrating a more prominent role compared to type I IFNs. Further, 
the types of IFN produced in vitro after culture and stimulated with TLR3 and RIG-I 
agonists varied between systemic and discoid lupus as well as preclinical 
autoimmunity. These results therefore indicated production of IFN by non-
haematopoietic cells in the absence of production by pDCs or tissue leucocytes early 
in the initiation of autoimmunity and in a disease-specific manner. 
  
122 
In conclusion, while the importance of type I IFN in SLE is undeniable, the reasons for 
the failure of normal regulation of its production have never been clear. The current 
work provides an explanation for this dysregulation by demonstrating an abnormal 
source of IFN in non-haematopoietic tissue cells; whilst the professional IFN-α-
producing pDCs have lost their major immunogenic properties. The presence of this 
phenotype in the epidermis of At-Risk individuals indicates that these cells, rather 
than being a passive target of inflammatory processes, play an active role at a very 
early stage of disease development. In established autoimmunity, these insights 
indicate potential therapeutic targets outside the conventional immune system. 
Moreover, in the At-Risk stage, this is the first report on where IFN dysregulation 
occurs and how it might be targeted for disease prevention. 
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Key messages: 
• Type I IFN activity is increased in patients with SLE and pSS as well as At-Risk 
individuals compared to healthy controls. 
• The number of pDCs in peripheral blood is significantly decreased in patients 
with SLE and pSS as well as At-Risk individuals independently of disease 
activity, type I IFN activity, and treatment. 
• The capacity of pDCs to produce cytokines in response to TLR stimulation is 
significantly impaired in patients with SLE and pSS as well as At-Risk 
individuals compared to healthy controls. 
• The capacity of pDCs to induce T cell activation and proliferation is 
significantly impaired in patients with active SLE compared to healthy 
controls. 
• pDCs from SLE patients with low and high IFN activity present distinct 
transcriptional signatures. 
• pDCs from SLE patients present transcriptional and phenotypic features of 
immune senescence. 
• Type I IFN activity is significantly increased in lesional and non-lesional skin 
biopsies of SLE patients and At-Risk individuals. 
• The epidermis of lesional and non-lesional skin biopsies of SLE patients and 
At-Risk individuals, but not leucocyte-infiltrating areas, is characterised by 
diffuse expression of type I IFNs. 
• Keratinocytes from SLE patients and At-Risk individuals present increased 
expression of type I IFNs in response to UV light and nucleic acids. 
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CHAPTER 4.  
TNF-α REGULATES THE PHENOTYPE AND FUNCTION 
OF HUMAN PLASMACYTOID DENDRITIC CELLS 
4.1 Introduction 
Human plasmacytoid dendritic cells (pDCs) consist of a distinct dendritic cell 
population that play a vital role in modulating immune responses. A common DC 
progenitor in the bone marrow can generate both pDCs and conventional DCs (cDCs), 
but pDCs are unique in their ability to produce type I interferons (IFNs) in response 
to viral infection (119). Upon ligation of TLR7 and TLR9 with exogenous or 
endogenous nucleic acids, pDCs secrete massive amounts of type I IFNs, 
predominantly IFN-α, and other pro-inflammatory cytokines leading to activation of 
both innate and adaptive immune compartments such as enhancement of NK cell 
cytotoxicity, effector CD4+ and CD8+ T cell responses, B cell differentiation into 
plasma cells and antibody production (115, 155, 355-358).  
Although not as efficient as cDCs, pDCs express MHC class II molecules and they are 
able to capture, process and present antigens to CD4+ T cells inducing their activation 
(149, 150). TLR-activated pDCs have enhanced antigen-presenting function and can 
promote Th1 and Th17 differentiation (151-153). Despite their weaker antigen-
presenting properties, pDCs can also cross-present exogenous antigens to CD8+ T 
cells and therefore induce antiviral and antitumor responses (155-157). However, 
unstimulated or HIV-stimulated pDCs are predominantly known to be involved in the 
induction of tolerogenic immune responses by expressing indoleamine-2,3-
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dioxygenase (IDO) and promoting CD4+ T cell anergy and Treg differentiation (158-
162). In addition, pDCs can secrete granzyme B, which impairs their capacity to 
induce T cell proliferation (359). 
As the main drivers of type I IFN responses, pDCs have been implicated in many 
diseases, especially chronic viral infections, cancer and autoimmunity (321, 360, 
361). Multiple regulatory surface receptors (e.g., BDCA-2, ILT7, BST2, NKp44) control 
the aberrant production of type I IFNs by TLR-activated pDCs (362-364). Cross-
regulation of TNF-α and IFN-α appears to be important in many immune-mediated 
diseases (365, 366). TNF-α downregulates the influenza-induced IFNα production 
and strongly inhibits the in vitro generation of pDCs by CD34+ hematopoietic 
progenitors (367).  
In this study, I investigated the regulatory role of TNF-α on the phenotype and 
function of blood-purified human pDCs. I found that TNF-α is a major cytokine 
produced alongside IFN-α by TLR9- or TLR7-stimulated pDCs and that exogenous 
TNF-α strongly inhibited both IFN-α and TNF-α production, an effect which is 
predominantly TLR9- and less TLR7-mediated. Additionally, TNF-α induced a distinct 
transcriptomic profile to pDCs by promoting pathways related to antigen processing 
and presentation as well as T cell activation and differentiation. Even though TNF-
treated pDCs failed to produce type I IFNs, they indeed induced higher T cell 
proliferation, activation and differentiation towards Th1 and Th17. Our findings 
demonstrate that TNF-α is a major regulator of human pDCs and can enhance their 
function by switching their main role as IFN-α-producing cells to a more conventional 
DC phenotype. 
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4.2 Results 
4.2.1 Human pDCs produce both IFN-α and TNF-α in response to TLR9 and TLR7 
agonists 
Although pDCs are mostly recognised for their IFN-α-producing capacity, they are 
also capable of producing other pro-inflammatory cytokines. To evaluate the level of 
this, peripheral blood pDCs were analysed by flow cytometry for the production of 
both IFN-α and TNF-α upon stimulation with TLR9 (ODN 2216) or TLR7 (ORN R-2336) 
agonists. Freshly isolated PBMCs were cultured with 2μM ODN 2216 or 2μM ORN R-
2336 agonists for 6 hours and then pDCs were gated as lineage-HLA-
DR+CD123hiCD303+ cells (Figure 4.1A).  
Cytokine production was measured using intracellular staining. As previously 
described, circulating pDCs produced no IFN-α and/or TNF-α without external 
stimulation (Figure 4.1B). After external stimulation with TLR9 agonist, three major 
populations of pDCs could be observed: (1) non-producers, (2) TNF-α-producers, (3) 
IFN-α- and TNF-α-producers (Figure 4.1C). Similar results could be seen when the 
cells were stimulated with TLR7 agonist (Figure 4.1D). Thus, TNF-α is a major cytokine 
produced by TLR9 or TLR7 stimulated pDCs, while the co-expression with IFN-α may 
suggest a cross-regulation between the two. 
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Figure 4.1 Human pDCs produce both IFN-α and TNF-α in response to TLR9 and TLR7 
agonists. (A) Gating strategy for human pDCs; pDCs are characterised by the lack of lineage 
markers (CD3, CD19, CD14, CD56, CD11c), intermediate to high expression of MHC class II 
(HLA-DR), high expression of CD123 and CD303 (BDCA-2). Freshly isolated PBMCs were 
cultured and stimulated with TLR9 (ODN 2216) or TLR7 (ORN R-2336) agonists for 6 hours, 
then IFN-α and TNF-α production was detected using intracellular staining. (B) Unstimulated 
pDCs produced no IFN-α and/or TNF-α. (C and D) Upon stimulation with TLR9 or TLR7 
agonists, there were 3 major pDC populations: (1) non-producers, (2) TNF-α-producers, (3) 
IFN-α- and TNF-α-producers. Results shown are representative of three independent 
experiments.  
 
4.2.2 TNF-α regulates IFN-α and TNF-α production in TLR-stimulated pDCs 
To unravel the role of TNF-α on pDC function, I first investigated the effect of TNF-α 
on cytokine production in the presence or absence of TLR stimulation. Freshly 
isolated PBMCs were cultured in the absence or presence of different concentrations 
of recombinant human TNF-α (1 – 50 ng/mL) for 24 hours. No induction of IFN-α 
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and/or TNF-α production was observed in TNF-treated pDCs without exogenous 
stimulation. However, treatment with TNF-α significantly altered the function of 
pDCs to produce pro-inflammatory cytokines in response to stimulation with TLR9 or 
TLR7 agonists, as detected by intracellular staining (Figures 4.2 & 4.3).  
 
 
Figure 4.2 TNF-α regulates IFN-α production in TLR-stimulated pDCs. (A-B) Freshly isolated 
PBMCs were cultured in the absence or presence of recombinant human TNF-α. After 24 
hours, PMBCs were washed twice and stimulated with TLR9 (ODN 2216) or TLR7 (ORN R-
2336) agonists for 6 hours, then IFN-α production by pDCs was measured using intracellular 
staining. Results shown are representative of three independent experiments. 
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Figure 4.3 TNF-α regulates TNF-α production in TLR-stimulated pDCs. (A-B) Freshly isolated 
PBMCs were cultured in the absence or presence of recombinant human TNF-α. After 24 
hours, PMBCs were washed twice and stimulated with TLR9 (ODN 2216) or TLR7 (ORN R-
2336) agonists for 6 hours, then TNF-α production by pDCs was measured using intracellular 
staining. Results shown are representative of three independent experiments. 
 
In particular for TLR9 activation, exogenous TNF-α (1 ng/mL) strongly inhibited both 
IFN-α (Figure 4.4A) and TNF-α (Figure 4.4B) production by pDCs, while no significant 
further reduction was observed at higher concentrations (10 ng/mL – 50 ng/mL). For 
TLR7 activation, exogenous TNF-α (1 ng/mL) had a similar effect on inhibiting IFN-α 
production with a further reduction at higher concentrations (20 – 50 ng/mL); a 
significant reduction in TNF-α production by TLR7-stimulated pDCs was only seen at 
higher concentrations (20 – 50 ng/mL) of exogenous TNF-α.  
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Figure 4.4 TNF-α regulates IFN-α and TNF-α production in TLR-stimulated pDCs. (A-B) 
Freshly isolated PBMCs were cultured in the absence or presence of recombinant human 
TNF-α (1 ng/ml, 10 ng/ml, 20 ng/ml, 50 ng/ml). After 24 hours, PMBCs were washed twice 
and stimulated with TLR9 (ODN 2216) or TLR7 (ORN R-2336) agonists for 6 hours, then IFN-
α and TNF-α production by pDCs was measured using intracellular staining). Bars represent 
median value with 95% CI. *P < 0.05, **P < 0.01 
 
Considering the above findings of the effect exogenous TNF-α on pDCs, I examined 
whether neutralization of endogenous TNF-α had an impact on IFN-α production. I 
isolated a pDC-enriched population from PBMCs by negative selection using 
magnetic beads (purity >92%) and the cells were stimulated with ODN 2216 or ORN 
R-2336 in the absence or presence of anti-TNF antibody or isotype control. After 24 
  
131 
hours, the supernatants were collected and IFN-α production was measured by ELISA 
(Figure 4.5A). The cells were then washed twice, re-stimulated with ODN 2216 or 
ORN R-2336 and the supernatants were collected after additional 24 hours. IFN-α 
production was measured by ELISA (Figure 4.5B). In the first culture (0 – 24 h), neither 
anti-TNF neutralizing antibody nor isotype control altered the levels of IFN-α 
secreted. However, in the secondary culture (24 – 48 h), anti-TNF-treated pDCs re-
stimulated with ODN 2216 (TLR9 agonist) could partially maintain IFN-α secretion in 
comparison with the control-treated pDCs. This effect could not be seen in pDCs re-
stimulated with ORN R-2336 (TLR7 agonist), as the levels of IFN-α secreted were 
similar in both anti-TNF- and control-treated pDCs. Taken all together, TNF-α 
regulates IFN-α production in a manner that is predominantly TLR9-mediated. 
 
 
Figure 4.5 Purified pDCs were stimulated with TLR9 or TLR7 agonists in the absence or 
presence of anti-TNF antibody or isotype control. (A) After 24 hours, the supernatants were 
collected and IFN-α production was measured by ELISA (0 – 24 h). (B) pDCs were washed 
twice, re-stimulated with TLR9 and TLR7 agonists and the supernatants were collected after 
additional 24 hours. IFN-α production was measured by ELISA (24 -48 h). Bars represent 
median value with 95% CI. 
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4.2.3 RNA-sequencing: data generation 
The next step was to investigate how TNF-α regulates TLR-mediated cytokine 
production and induces further transcriptional changes in human pDCs. pDCs from 
healthy subjects (n = 3) were purified by negative selection using magnetic beads 
(Miltenyi Biotec). The pre-enriched pDCs (purity > 85%) from each donor were 
counted using an automated cell counter (Beckmann Coulter) and then divided into 
two aliquots before they were cultured in RPMI medium 1640 with GlutaMAX 
supplement (ThermoFisher Scientific) containing 10% (vol/vol) FBS and 100 U/ml 
penicillin/streptomycin in the presence or absence of human recombinant TNF-α (10 
μL/mL) for 18 hours. After incubation, untreated and TNF-treated pre-enriched pDCs 
from all three donors (n = 6) were washed thoroughly before they were finally sorted 
using BD Influx 6 Way Cell Sorter (BD Biosciences) based on CD304 (BDCA-4) 
expression to achieve purity > 99%. Unlike CD303 (BDCA-2) that is known to inhibit 
IFN-α production, CD304 (BDCA-4) does not interfere with the type I IFN pathway. 
After sorting, RNA was purified by sorted pDCs using PicoPure RNA Isolation kit 
(ThermoFisher Scientific) and quantified using Qubit RNA HS Assay Kit (Thermo Fisher 
Scientific). RNA libraries were made by using SMART-Seq V4 ultra low Input RNA Kit 
(Takara Bio USA) and Nextera XT DNA Library Preparation Kit (Illumina) for Next 
Generation Sequencing. Indexed sequencing libraries were pooled and sequenced on 
a single lane on HiSeq 3000 instrument as 151bp paired-end reads. Pooled sequence 
data was demultiplexed using Illumina bcl2fastq software allowing no mismatches in 
the read index sequences.  
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Figure 4.6 All 1,800 differentially expressed genes (DEGs) at < 5% false discovery rate (FDR) 
between untreated and TNF-treated pDCs. Principal component analysis (PCA) shows that 
the main source of variation in the data derives from the treatment with TNF-α. 
 
Principal component analysis (PCA) demonstrated that the main source of variation 
in each sample derived from the treatment with TNF-α (Figure 4.6). In total, the 
analysis indicated 1,800 differentially expressed genes (DEGs) at < 5% false discovery 
rate (FDR) between untreated and TNF-treated pDCs. The top 100 upregulated and 
downregulated genes by TNF-α in pDCs can be found in Table 4.1 and Table 4.2 
respectively. 
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 pDCs vs. TNF-treated pDCs 
Gene Fold Change (log2) P value FDR 
CRIP2 6.846 < 0.001 < 0.001 
FXYD2 3.599 < 0.001 < 0.001 
FXYD6-FXYD2 3.575 < 0.001 < 0.001 
ANO9 4.520 < 0.001 < 0.001 
CRIP1 2.803 < 0.001 < 0.001 
TYW3 2.740 < 0.001 < 0.001 
TNFRSF4 3.115 < 0.001 < 0.001 
HDGFRP3 4.350 < 0.001 < 0.001 
HLA-DQA1 2.169 < 0.001 < 0.001 
CCDC28B 2.696 < 0.001 < 0.001 
BCL2A1 2.589 < 0.001 < 0.001 
TMEM138 2.036 < 0.001 < 0.001 
TFEC 2.382 < 0.001 < 0.001 
UNQ6494 5.108 < 0.001 < 0.001 
CTSH 2.375 < 0.001 < 0.001 
KDM2B 2.617 < 0.001 < 0.001 
PDGFA 4.535 < 0.001 < 0.001 
CDKN1A 2.015 < 0.001 < 0.001 
HLA-DQB1 1.814 < 0.001 < 0.001 
NEK6 2.364 < 0.001 < 0.001 
CD83 1.929 < 0.001 < 0.001 
EDNRB 4.598 < 0.001 < 0.001 
FAS 3.784 < 0.001 < 0.001 
LAGE3 2.247 < 0.001 < 0.001 
RELB 2.367 < 0.001 < 0.001 
CRYZ 1.981 < 0.001 < 0.001 
IL6ST 2.175 < 0.001 < 0.001 
GPX4 1.646 < 0.001 < 0.001 
LSR 2.904 < 0.001 < 0.001 
GGT1 3.310 < 0.001 < 0.001 
KREMEN2 3.689 < 0.001 < 0.001 
BID 1.578 < 0.001 < 0.001 
MAD2L2 1.817 < 0.001 < 0.001 
UQCC2 2.382 < 0.001 < 0.001 
DPCD 3.829 < 0.001 < 0.001 
SEMA4A 1.986 < 0.001 < 0.001 
DNASE1L3 1.411 < 0.001 < 0.001 
HSD17B10 1.858 < 0.001 < 0.001 
BTN2A2 2.168 < 0.001 < 0.001 
TFRC 1.855 < 0.001 < 0.001 
SSH1 2.579 < 0.001 < 0.001 
CX3CR1 2.330 < 0.001 < 0.001 
WNT10A 2.311 < 0.001 < 0.001 
ANK3 3.667 < 0.001 < 0.001 
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 pDCs vs. TNF-treated pDCs 
Gene Fold Change (log2) P value FDR 
MARCKS 2.336 < 0.001 < 0.001 
CD59 2.135 < 0.001 < 0.001 
TIMM10 1.838 < 0.001 < 0.001 
TNFAIP2 2.723 < 0.001 < 0.001 
HLA-DQB2 1.817 < 0.001 < 0.001 
HLA-DQA2 1.857 < 0.001 < 0.001 
HIVEP3 3.310 < 0.001 < 0.001 
SWAP70 2.380 < 0.001 < 0.001 
HLA-DRB1 1.180 < 0.001 < 0.001 
MGLL 1.619 < 0.001 < 0.001 
SYNGR2 1.270 < 0.001 < 0.001 
FSCN1 2.109 < 0.001 < 0.001 
NME1 2.258 < 0.001 < 0.001 
TVP23A 2.441 < 0.001 < 0.001 
BLVRB 2.908 < 0.001 < 0.001 
SEC61B 1.157 < 0.001 < 0.001 
TMEM120B 1.773 < 0.001 < 0.001 
GPATCH4 2.068 < 0.001 < 0.001 
NCCRP1 3.587 < 0.001 < 0.001 
RHOF 1.689 < 0.001 < 0.001 
DGAT2 3.027 < 0.001 < 0.001 
TXN 1.243 < 0.001 < 0.001 
DDB2 3.466 < 0.001 < 0.001 
NFKBIA 1.352 < 0.001 < 0.001 
DCANP1 2.159 < 0.001 < 0.001 
DNPH1 1.714 < 0.001 < 0.001 
TIGIT 3.193 < 0.001 < 0.001 
ICAM1 1.579 < 0.001 < 0.001 
GRHPR 1.572 < 0.001 < 0.001 
HLA-F 1.592 < 0.001 < 0.001 
TLCD1 2.062 < 0.001 < 0.001 
FDPS 1.324 < 0.001 < 0.001 
CYB5A 1.984 < 0.001 < 0.001 
CFLAR 1.430 < 0.001 < 0.001 
PPIL1 3.010 < 0.001 < 0.001 
TTC39A 2.011 < 0.001 < 0.001 
PPA1 2.043 < 0.001 < 0.001 
RPSA 1.146 < 0.001 < 0.001 
LRRC75A-AS1 1.299 < 0.001 < 0.001 
BIRC3 1.575 < 0.001 < 0.001 
TCEB3 1.299 < 0.001 < 0.001 
HLA-DPB1 1.245 < 0.001 < 0.001 
RSL1D1 1.270 < 0.001 < 0.001 
ADAT2 2.994 < 0.001 < 0.001 
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 pDCs vs. TNF-treated pDCs 
Gene Fold Change (log2) P value FDR 
SMS 2.337 < 0.001 < 0.001 
FEZ1 3.242 < 0.001 < 0.001 
ATOX1 1.333 < 0.001 < 0.001 
LINC01268 3.205 < 0.001 < 0.001 
MRPL14 1.615 < 0.001 < 0.001 
HLA-DRA 1.116 < 0.001 < 0.001 
IL10RA 1.289 < 0.001 < 0.001 
HLA-DRB5 1.042 < 0.001 < 0.001 
CLIC2 1.878 < 0.001 < 0.001 
SPRED2 2.875 < 0.001 < 0.001 
GRPEL1 1.667 < 0.001 < 0.001 
NKG7 2.605 < 0.001 < 0.001 
Table 4.1 Top 100 genes upregulated by TNF-α in pDCs. 
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 pDCs vs. TNF-treated pDCs 
Gene Fold Change (log2) P value FDR 
CST3 -2.557 < 0.001 < 0.001 
HS3ST1 -4.792 < 0.001 < 0.001 
S100A4 -2.993 < 0.001 < 0.001 
RASD1 -3.091 < 0.001 < 0.001 
S100A6 -2.513 < 0.001 < 0.001 
LOC100507600 -3.040 < 0.001 < 0.001 
BTLA -4.467 < 0.001 < 0.001 
SCN9A -2.466 < 0.001 < 0.001 
PLXNA4 -3.152 < 0.001 < 0.001 
IFITM2 -2.324 < 0.001 < 0.001 
ACY3 -2.246 < 0.001 < 0.001 
PLD4 -1.910 < 0.001 < 0.001 
SPNS3 -2.950 < 0.001 < 0.001 
PLP2 -1.707 < 0.001 < 0.001 
LIME1 -2.156 < 0.001 < 0.001 
MS4A6A -1.850 < 0.001 < 0.001 
TXNIP -1.819 < 0.001 < 0.001 
METTL7A -2.991 < 0.001 < 0.001 
RNA5S1 -1.692 < 0.001 < 0.001 
RNA5S10 -1.692 < 0.001 < 0.001 
RNA5S11 -1.692 < 0.001 < 0.001 
RNA5S12 -1.692 < 0.001 < 0.001 
RNA5S13 -1.692 < 0.001 < 0.001 
RNA5S14 -1.692 < 0.001 < 0.001 
RNA5S15 -1.692 < 0.001 < 0.001 
RNA5S16 -1.692 < 0.001 < 0.001 
RNA5S17 -1.692 < 0.001 < 0.001 
RNA5S2 -1.692 < 0.001 < 0.001 
RNA5S3 -1.692 < 0.001 < 0.001 
RNA5S4 -1.692 < 0.001 < 0.001 
RNA5S5 -1.692 < 0.001 < 0.001 
RNA5S6 -1.692 < 0.001 < 0.001 
RNA5S7 -1.692 < 0.001 < 0.001 
RNA5S8 -1.692 < 0.001 < 0.001 
CD300A -2.557 < 0.001 < 0.001 
TGFBR3 -3.922 < 0.001 < 0.001 
CD99 -1.737 < 0.001 < 0.001 
OAS1 -3.590 < 0.001 < 0.001 
MIR7641-2 -1.636 < 0.001 < 0.001 
PLAC8 -1.626 < 0.001 < 0.001 
KIAA0125 -2.059 < 0.001 < 0.001 
MMP23A -3.094 < 0.001 < 0.001 
GLIPR1 -1.619 < 0.001 < 0.001 
THBS1 -2.809 < 0.001 < 0.001 
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FCER1A -2.407 < 0.001 < 0.001 
CMTM3 -2.069 < 0.001 < 0.001 
ATP13A2 -2.403 < 0.001 < 0.001 
DERL3 -1.505 < 0.001 < 0.001 
PECAM1 -2.112 < 0.001 < 0.001 
C12orf75 -1.411 < 0.001 < 0.001 
IGFBP3 -2.742 < 0.001 < 0.001 
NCF1B -1.548 < 0.001 < 0.001 
RUNX2 -1.786 < 0.001 < 0.001 
SYNGR1 -2.075 < 0.001 < 0.001 
RN7SL1 -1.195 < 0.001 < 0.001 
GAPT -1.333 < 0.001 < 0.001 
CXCL16 -2.246 < 0.001 < 0.001 
LOC101928034 -2.745 < 0.001 < 0.001 
LILRB2 -3.286 < 0.001 < 0.001 
RNF166 -2.115 < 0.001 < 0.001 
RAB11FIP4 -3.369 < 0.001 < 0.001 
GAS6 -1.888 < 0.001 < 0.001 
CMTM7 -2.490 < 0.001 < 0.001 
MAPKAPK2 -2.060 < 0.001 < 0.001 
LILRA4 -1.351 < 0.001 < 0.001 
EPS8L2 -2.669 < 0.001 < 0.001 
FCER1G -1.302 < 0.001 < 0.001 
C1orf162 -1.706 < 0.001 < 0.001 
TNFRSF17 -2.301 < 0.001 < 0.001 
HHEX -1.698 < 0.001 < 0.001 
LINGO3 -3.276 < 0.001 < 0.001 
HPCAL1 -2.144 < 0.001 < 0.001 
CD164 -1.315 < 0.001 < 0.001 
RN7SL2 -1.166 < 0.001 < 0.001 
UCP2 -1.378 < 0.001 < 0.001 
RGS14 -2.451 < 0.001 < 0.001 
NCF1C -1.264 < 0.001 < 0.001 
LRRC25 -3.003 < 0.001 < 0.001 
LOC102724297 -2.073 < 0.001 < 0.001 
SPON2 -3.220 < 0.001 < 0.001 
CD300LB -3.146 < 0.001 < 0.001 
CCR2 -2.201 < 0.001 < 0.001 
ABHD15 -1.832 < 0.001 < 0.001 
ZFP36L2 -1.464 < 0.001 < 0.001 
PRICKLE3 -1.474 < 0.001 < 0.001 
IFI44L -3.043 < 0.001 < 0.001 
CCR5 -3.003 < 0.001 < 0.001 
ID3 -1.874 < 0.001 < 0.001 
TXNDC5 -1.269 < 0.001 < 0.001 
RAC2 -1.244 < 0.001 < 0.001 
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CYTH4 -1.356 < 0.001 < 0.001 
TRAF3IP3 -1.442 < 0.001 < 0.001 
PLCG2 -1.413 < 0.001 < 0.001 
PROC -1.653 < 0.001 < 0.001 
MMP23B -2.807 < 0.001 < 0.001 
BLOC1S5-
TXNDC5 -1.240 < 0.001 < 0.001 
DUSP1 -1.689 < 0.001 < 0.001 
CD52 -1.388 < 0.001 < 0.001 
APBB1IP -1.265 < 0.001 < 0.001 
ANXA1 -1.885 < 0.001 < 0.001 
Table 4.2 Top 100 genes downregulated by TNF-α in pDCs. 
4.2.4 TNF-α promotes transcriptional changes associated with antigen processing 
and presentation 
TNF-α induced the upregulation of genes in pDCs, which were particularly enriched 
for pathways associated with MHC class II antigen processing and presentation, Th17 
differentiation, Th1 and Th2 differentiation, MHC class I antigen processing and 
cross-presentation, induction of TCR signalling and co-stimulation of CD28, 
phosphorylation of CD3 and TCR zeta chains, translocation of ZAP70 to 
immunological synapse amongst other pathways. A detailed presentation of 
enriched KEGG pathways and Reactome pathways in differentially expressed genes 
can be seen in Figure 4.7 and Figure 4.8 respectively. Among the most enriched 
biological processes induced by TNF-α were found to be lymphocyte aggregation, T 
cell activation, immune response-activating cell surface receptor signalling, antigen 
processing and presentation of exogenous antigen, T cell co-stimulation. Regarding 
the enriched cellular components in differentially expressed genes, these included 
units and functions mainly related to antigen processing and presentation (Figure 
4.9); for instance, endocytic vesicle membrane, MHC class II protein complex, 
clathrin-coated vesicle membrane and other. 
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Figure 4.7 Enriched KEGG pathways in differentially expressed genes (DEGs) upregulated 
by TNF-α in pDCs. 
 
Figure 4.8 Enriched Reactome pathways in differentially expressed genes (DEGs) 
upregulated by TNF-α in pDCs. 
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Figure 4.9 Heatmap showing that TNF-α promotes differentially expressed genes 
associated with antigen processing and presentation pathways in pDCs. 
 
Among the upregulated genes in TNF-treated pDCs compared to the untreated ones 
were HLAs corresponding to MHC class I (HLA-A, HLA-B, HLA-F) as well as MHC class 
II (HLA-DPA1, HLA-DPB1, HLAD-DRA, HLA-DRB1, HLA-DRB5, HLA-DQA1, HLA-DQA2, 
HLA-DQB1, HLA-DMB). 
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4.2.5 TNF-α promotes transcriptional changes associated with T activation and 
differentiation  
Analysing further the RNA-sequencing data for biological effects of TNF-α on the 
function of pDCs, differentially expressed genes associated with positive regulation 
of T cell proliferation and activation were particularly enriched (Figure 4.10). Apart 
from the upregulated MHC class II molecules, upregulated genes included co-
stimulatory molecules (CD80, CD86, CD83), molecules promoting endocytosis (CD59) 
and cell adhesion (ADAM8), ICOS ligand (ICOSLG) as well as IL-27 subunit beta (EBI3). 
In contrast, downregulated genes included CCR2, PTPRC, SYK, IL1B, LILRB2, SOCS1 
amongst others. 
 
Figure 4.10 Heatmap of differentially expressed genes in TNF-treated vs. untreated pDCs 
showed significant enrichment in positive regulation of T cell proliferation and activation. 
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TNF-α also upregulated genes associated with T cell differentiation, for instance 
RPL22, ADAM8, IRF4, CD83, RELB, FAS, SEMA4A, whilst it downregulated others such 
as SOX4, BATF, RUNX2, FCER1G (Figure 4.11). In detail, RNA-sequencing data analysis 
suggested induction of T cell differentiation towards Th17, Th1 and Th2 (Figure 4.12). 
 
Figure 4.11 Heatmap of differentially expressed genes in TNF-treated vs. untreated pDCs 
showed significant enrichment in positive regulation of T cell differentiation. 
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Figure 4.12 Heatmap of differentially expressed genes in TNF-treated vs. untreated pDCs 
showed significant enrichment in induction of Th17, Th1 and Th2 cell differentiation. 
 
4.2.6 TNF-α inhibits TLR cascade signalling pathways 
Despite the transcriptional changes towards antigen processing and presentation as 
well as T cell activation and differentiation, TNF-α seems to negative regulate other 
functions of pDCs. Among the downregulated genes in TNF-treated pDCs compared 
to untreated pDCs there were enriched pathways associated with negative 
regulation of G protein–coupled receptor (GPCR) cascade signalling, negative 
regulation of TLR cascade signalling and IFN-α/β secretion (MyD88 and MAPK 
signalling pathways), phagosomal maturation (early endosomal stage) as well as 
negative regulation of trafficking and processing of endosomal TLRs (Figure 4.13). 
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Figure 4.13 Enriched Reactome pathways in differentially expressed genes (DEGs) 
downregulated by TNF-α in pDCs. 
 
As type I IFN and pro-inflammatory cytokine production by pDCs is primarily 
mediated by TLR7 and TLR9 ligation with nucleic acids in early endosomes, the effect 
of TNF-α in TLR-cascade signalling was investigated in the RNA-sequencing data 
analysis. Not surprisingly, as the in vitro experiments confirmed that TNF-α inhibits 
the secretory function of pDCs, there was a significant downregulation of genes 
encoding intracellular proteins and kinases mediating the phosphorylation of IRF7, 
NF-κB and AP-1 with eventual outcome the production of type I IFNs and pro-
inflammatory cytokines (Figure 4.14). In more detail, there was a statistically 
significant reduction in expression levels of TLR7 and TLR9, MyD88-IRAK1/2/4 
complex as well as IRF7. On the other hand, there was upregulation of NF-κB inhibitor 
(NFKBIA) known to block the translocation of NF-κB to the nucleus (Figure 4.15). 
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Figure 4.14 Heatmap of differentially expressed genes in TNF-treated vs. untreated pDCs 
showed negative regulation of TLR cascade signalling and MAPK signalling pathway. 
 
Figure 4.15 Differentially expressed genes in TNF-treated vs. untreated pDCs associated 
with negative regulation of TLR-mediated type I IFN production. 
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In addition, TNF-treated pDCs presented a significant downregulation of common 
interferon-stimulated genes (ISGs) including SOCS, IFI30, IRF7, IFITM2, IFITM3, 
OAS1, whilst there was upregulation of other ISGs such as BST2, IRF4, NUP62 and 
IFNGR2 (Figure 4.16). 
 
 
Figure 4.16 Heatmap of differentially expressed genes in TNF-treated vs. untreated pDCs 
showed negative regulation of TLR cascade signalling and MAPK signalling pathway. 
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4.2.7 TNF-α promotes the upregulation of co-stimulatory and maturation 
markers on pDCs 
RNA-sequencing data analysis indicated that TNF-α upregulated transcripts of 
maturation markers and costimulatory molecules in pDCs. To validate the data at 
protein level, pDCs were enriched from PBMCs by negative selection using magnetic 
beads (purity >92%) and were cultured in the presence or absence of exogenous TNF-
α for 24 hours. The expression of surface molecules was then measured by flow 
cytometry (Figure 4.17). The flow cytometric analysis confirmed that TNF-α strongly 
upregulated maturation markers such as HLA-DR (MHC-II) and CCR7 (CD197) as well 
as the costimulatory molecules CD80 and CD86 on pDCs. In addition, TNF-α induced 
the upregulation of molecules related to IFN-α negative regulation such as ILT7 
(CD85j) and CD317 (BST2, tetherin). On the other hand, TNF-α induced the 
downregulation of the pDC-specific marker BDCA-2 (CD303), while the expression of 
BDCA-4 (CD304) remained unchanged (data not shown). 
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Figure 4.17 TNF-α promotes the maturation of pDCs. pDCs were purified from freshly 
isolated PBMCs and cultured in the absence or presence of recombinant human TNF-α. After 
24 hours, pDCs were analysed by flow cytometry. Fluorescence intensity is shown on the x 
axis. Results shown are representative of three independent experiments. (A) TNF-α 
upregulates HLA-DR (MHC-II), costimulatory molecules such as CD80 and CD86, CCR7, but 
downregulates pDC-specific markers such as BDCA-2 (CD303). TNF-α also upregulates 
receptors related to type I IFN regulation such as ILT7 (CD85g) and CD317 (BST2, tetherin). 
 
4.2.8 TNF-α-treated pDCs enhance T cell proliferation and activation 
Human pDCs express HLA-DR and are able to induce CD4+ T cell activation. Following 
the RNA-sequencing data analysis, I performed a series of in vitro allogeneic pDC – 
naïve CD4+ T cell co-cultures to evaluate whether TNF-α could enhance the T cell 
activation properties of pDCs. First, pDCs were cultured in the presence or absence 
of exogenous TNF-α (10 ng/mL) for 24 hours. After washing thoroughly, pDCs were 
co-cultured with allogeneic naïve CD4+ T cells for 5 days. T cell proliferation was 
assessed based on CellTrace Violet dilution upon cell division using flow cytometry. 
As expected, naïve CD4+ T cells alone did not proliferate in the absence of pDCs. On 
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the other hand, both pDC groups could induce T cell proliferation without exogenous 
stimulation (Figure 4.18A). However, TNF-treated pDCs were more efficient, as they 
induced a significantly higher percentage of proliferating T cells (Figure 4.18B).  
 
 
Figure 4.18 TNF-α-treated pDCs enhance T cell proliferation. (A) Allogeneic naïve CD4+ T 
cells were labeled with CellTrace Violet and cultured alone or with pDCs or TNF-α-treated 
pDCs for 5 days. T cell proliferation was analysed by flow cytometry based on CellTrace Violet 
dilution. One representative experiment is shown out of three independent experiments. (B) 
Average percentage of proliferated CD4+ T cells co-cultured with pDCs or TNF-α-treated pDCs 
(n = 3). *P < 0.05. 
  
  
151 
Similarly, although pDCs promoted T cell activation, TNF-treated pDCs showed better 
capacity of promoting T cell activation as measured by surface expression of CD69 
(Figure 4.19).  
 
 
Figure 4.19 TNF-α-treated pDCs enhance T cell activation. (A) Expression of CD69 on CD4+ T 
cells from the cultures shown in A. One representative experiment is shown out of three 
independent experiments. (B) Average expression of CD69 on CD4+ T cells co-cultured with 
pDCs or TNF-α-treated pDCs (n = 3). *P < 0.05. 
 
Furthermore, I investigated whether TNF-treated pDCs favoured or enhanced 
specific T cell differentiation. I co-cultured allogeneic naïve CD4+ T cells with pDCs or 
TNF-treated pDCs for 5 days and I then measured multiple cytokine production in T 
cells by intracellular staining. Although both pDC groups induced T cell activation, 
TNF-treated pDCs induced notably higher production of TNF-α (Figure 4.20A, 2.39% 
vs. 4.74%) and IFN-γ (Figure 4.20B, 9.54% vs. 13.05%) as well as IL-17A (Figure 4.20C, 
1.05% vs. 2.08%). Collectively, these results confirmed that TNF-α enhanced the 
properties of pDCs to induce T cell proliferation and activation and to favour T cell 
differentiation towards Th1 and Th17 phenotype.  
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Figure 4.20 TNF-α-treated pDCs enhance the production of Th1 and Th17 cytokines. 
Allogeneic naïve CD4+ T cells were cultured alone or with pDCs or TNF-α-treated pDCs for 5 
days. Percentage of TNF-α, IFN-γ and IL-17A production by CD4+ T cells was measured by 
intracellular staining. One representative experiment is shown out of three independent 
experiments.  
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4.3 Discussion 
Apart from the major role of pDCs as type I IFN-producing cells, pDCs are able to 
capture, process and present antigens to CD4+ T cells. However, the regulation of 
each of these functions still remains elusive. Previous studies reported the cross-
regulation of TNF-α and IFN-α during in vitro stimulation of pDCs with influenza virus, 
however the precise mechanism for this effect was entirely addressed (367). Here I 
demonstrated that TNF-α not only inhibited IFN-α production even at minimal 
concentrations, predominantly in a TLR9-mediated manner, but also had a similar 
regulatory effect on autologous TNF-α production.  
Novel single cell RNA-sequencing data revealed new subsets of DCs with distinct 
transcriptomic profiles and immune functions (368). Apart from the traditional pDC 
population which is characterised by expression of genes associated with pathogen 
sensing and induction of type I IFNs as well as the master regulator transcription 
factor TCF4, a novel DC subset was described with a unique gene signature (AXL, 
SIGLEC1, SIGLEC6, CD22/SIGLEC2) sharing features of both cDCs and pDCs. Moreover, 
a novel CD2hiCD5+CD81+ pDC subset was shown to induce strong T and B cell 
activation but not to be able to secrete type I IFNs (341).  
The RNA-sequencing data of TNF-treated pDCs revealed a downregulation of this 
pDC-specific gene signature associated with pathogen sensing (IRF7, TLR7, SLC15A4, 
PACSIN1) and secretion (DERL3, LAMP5, SCAMP5) as well as TCF4 alongside its 
binding targets (SLA2, PTCRA, PTPRCAP). Hence, it can be concluded that TNF-α 
strongly influences the transcriptional profile of pDCs by downregulating their 
classical pathways and upregulating genes (e.g., LY86) mostly related to the 
conventional DC phenotype. 
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Other cytokines such as IL-21 had a regulatory impact on the function of pDCs 
promoting their tolerogenic properties (359). In contrast, TNF-α enhanced the 
immunogenic properties of pDCs towards antigen presentation and T cell activation. 
Regarding TNF receptor superfamily, TNF-α downregulated TNFRSF1A (TNF receptor 
1A; CD120a) but not TNFRSF1B (TNF receptor 1B; CD120b), TNFRSF6B (Decoy 
receptor 3; TR6; M68), whilst it upregulated TNFRSF4 (OX40; CD134), FAS (Fas 
receptor; Apo-1; CD95), and CD40 (Bp50; CD40). Interestingly, TNF-α promoted the 
downregulation of IFNAR1 and IFNAR2 but the upregulation of IFNGR1 and IFNGR2 
indicating a potential synergistic effect with other major pro-inflammatory cytokines 
such as IFN-γ.  
Linking these data to human disease, anti-TNF treatment has been associated with 
lupus-like symptoms as well as an induction of IFN signature in peripheral blood (366, 
369, 370). Synovium of rheumatoid arthritis patients was reported to contain pDCs 
able to activate T cells more efficiently (371). Notably, pDCs were found to localise in 
RA synovium expressing Il-18 in close proximity to clusters of CD3+CD8+ T cells. TNF-
α as one of the main pathogenic cytokines driving synovial inflammation can alter 
pDC function enhancing antigen presentation and promoting Th1 and Th17 cell 
differentiation. 
Although pDCs possess weak antigen-presenting properties, TNF-α can enhance their 
maturation by switching their main role as IFN-α-producing cells to a more 
conventional DC phenotype. The functional status of pDCs might be strongly 
influenced by the overall inflammatory environment, whilst TNF-α might regulate 
IFN-α-mediated aspects of a range of autoimmune and inflammatory diseases. 
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Key messages: 
• TNF-α is a major cytokine produced by human pDCs upon TLR stimulation. 
• TNF-α inhibits IFN-α and TNF-α production by TLR-stimulated pDCs by 
negatively regulating IRF7 and NF-κB pathways.  
• TNF-α upregulates pathways in pDCs related to antigen processing and 
presentation as well as T cell activation and differentiation. 
•  TNF-α upregulates costimulatory molecules and maturation markers on 
human pDCs. 
• TNF-α-treated pDCs induce higher CD4+ T cell proliferation and activation 
enhancing the production of Th1 and Th17 cytokines.  
  
  
156 
CHAPTER 5.  
GENERAL DISCUSSION 
The data presented in the current thesis highlight novel findings in the regulation of 
type I IFNs in patients with SLE. As described in full detail in Chapter 1, type I IFNs are 
a large group of molecules with pleiotropic functions on the immune system linking 
innate and adaptive immune responses. As the predominant antiviral and antitumor 
cytokines, they also appear to be key players in systemic autoimmune diseases 
triggering autoreactive phenomena and possibly leading to certain pathologies and 
organ involvement in SLE. In addition, they might have an important role in initiating 
autoimmunity, since individuals with ANA positivity but no clinically overt disease 
present with a high IFN signature in peripheral blood. 
It has long been speculated that pDCs, the professional type I IFN-producing cells of 
the immune system, are primed to produce large amounts of these molecules and 
hence responsible for the increased IFN activity observed in patients with SLE. 
However, previous studies suggesting the above statement had major limitations; 
they isolated pDCs from healthy donors and they mimicked SLE conditions in vitro.  
In addition, the numeration of circulating pDCs, even in blood samples of patients 
with SLE, was often problematic; an appropriate flow cytometry gating to identify 
the pure pDC population within the PBMCs was not followed, neglecting potential 
contamination with cells belonging to another lineage, such as cDCs or monocytes. 
For the purpose of this thesis, to resolve this problem an extensive 
immunophenotyping was used carefully to exclude lineage negative cells (B cells, T 
cells, NK cells, monocytes conventional DCs) and choose double positive cells for 
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both CD123 and CD303 within the HLA-DR positive population. As a result, a clear 
reduction in the circulating pDCs was observed analysing a large number of fresh 
samples obtained from patients with established autoimmune rheumatic diseases 
(SLE and pSS) as well as individuals with preclinical autoimmunity (At-Risk). 
Importantly, the data from the current PhD thesis clearly demonstrated that pDCs 
were significantly defective in promoting TLR-mediated cytokine production, both 
IFN-α and TNF-α, while their phenotype did not associate with any clinical or 
immunological features of SLE patients, such as disease activity, treatment with 
immunosuppressive drugs, autoantibody profile, and IFN activity in peripheral blood.  
This is the first known study to provide a comprehensive analysis of pDCs in human 
autoimmune conditions, not only studying TLR-mediated responses, but also 
providing valuable associations with the clinical background as well as other 
immunological and treatment-related factors that could affect the results. 
Interestingly, I showed for the first time a new function of human pDCs; IL-3 is not 
only an important cytokine enhancing pDC survival and IFN-a production as 
previously thought, but also a robust stimulus for the induction of IL-6 production. 
This novel feature was independent of TLR stimulation of pDCs and it did not appear 
to be defective in pDCs from SLE patient and At-Risk individuals.  
Furthermore, pDCs from SLE patients presented other immunological deficiencies 
including their inability to induce sufficient T cell activation and proliferation in 
comparison with pDCs from healthy individuals. On the other hand, a novel 
regulatory role for a conventional pro-inflammatory cytokine such as TNF-α was also 
described. TNF-α can change the transcriptional profile of human pDCs from their 
IFN-producing role towards a functional drift antigen presentation inducing stronger 
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T cell activation. However, one of the major limitations of this PhD thesis was the 
design of pDC-T cell co-cultures. Human pDCs are hard to be cultured in vitro because 
they cannot survive for more 48 hours after isolation. Apart from that, pDCs are 
dramatically reduced in the circulation of SLE patients resulting in unexpected 
difficulties in isolating adequate numbers of the cells to perform the co-culture. As a 
consequence, T cells were practically exposed to pDCs only for the first 48 hours 
regarding the co-culture in Chapter 3, whilst that period of time was practically 
reduced to 24 hours for the experiment in Chapter 4 (pDCs were first treated with 
TNF for 24 hours before they were co-cultured with T cells). This is the main reason 
for the discrepancies observed in the co-cultures. To further optimise the results in 
Chapter 3, I decided to add anti-CD3/CD28 soluble beads at low concentration, so I 
can boost the survival of T cells but not affecting the primary effect of pDCs on T cells 
at the same time. Indeed, with the optimisation described above, the T cells 
proliferated stronger and produced more cytokines upon secondary stimulation with 
PMA/Ionomycin.  
Another novelty of the current PhD thesis was the transcriptomic analysis of pDCs 
from patients with SLE as well as individuals at preclinical stage. However, data 
analysis of the RNA-sequencing data was challenging. Human samples from all 
donors were highly heterogeneous and the further clustering into groups simply by 
a disease diagnosis was ineffective. As a consequence, a new approach based on the 
expression of an IFN Score (describing the IFN activity in the pDCs of each donor) was 
adopted to resolve the classification issue and acquire more information about 
transcriptional differences between autoimmune and healthy pDCs. The highly 
sensitive full-length RNA-sequencing demonstrated transcriptional changes 
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associated with immune senescence and immune tolerance. These insights were in 
accordance with the in vitro work that clearly demonstrated that pDCs presented 
dysfunctional TLR responses in patients with SLE and At-Risk individuals. All data 
together pointed that pDCs in human preclinical and established autoimmunity 
exhibit an exhausted phenotype. A better investigation would require a single-cell 
based RNA-sequencing analysis that would enable a diversification of possibly 
distinct pDC populations in patients with SLE. That would be a challenging approach 
requiring an in-depth analysis of single cells from many patients, as SLE is a very 
heterogenous condition. Although IFN activity seems to be able to classify the 
patients into to major groups (low and high), other immunological or clinical 
parameters could be investigated in relation to pDC phenotype.  
One of the first findings observed was the strong correlation between type I IFN 
activity in peripheral blood -measured as IFN Score A- and mucocutaneous disease 
activity. This correlation could possibly indicate a link between skin tissue and type I 
IFN dysregulation SLE. Acquiring skin biopsies from non-lesional skin of both SLE and 
At-Risk patients, I observed a significant upregulation of ISGs in samples of both 
groups compared to those of healthy donors. The overall expression level of IFN 
Score A in skin biopsies of At-Risk individuals was notoriously higher [29.5 fold 
increase (1.3 - 635.0)] in comparison with the IFN signature in peripheral blood [2.2 
fold increase (2.0 – 2.3). Nonetheless, measuring ISGs and creating an IFN score does 
not provide an answer to the fundamental question what the primary source of type 
I IFN overproduction is. 
To address this complicated question, I utilised a novel in situ hybridization assay 
(RNAscope) enabling to detect transcripts of the actual type I IFN in the skin biopsies. 
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Surprisingly, when I hybridized the lesional skin biopsies obtained from SLE patients, 
I found out a diffuse expression of IFNK across the epidermis but not in leucocyte-
infiltrating areas. These data were in accordance of the in vitro work carried out from 
pDCs isolated from peripheral blood showing lack of TLR stimulation and a phenotype 
associated with immune senescence. However, the most interesting data were 
generated by the hybridization of non-lesional skin biopsies of the At-Risk individuals. 
Gene expression analysis had previously demonstrated a massive upregulation of 
ISGs in those skin biopsies. In addition, the RNAscope assay provided vital 
information regarding the localization of the type I IFN transcripts -not the outcome 
of their effect (ISGs)- indicating that the source of type I IFN production is not the 
infiltrating leucocytes but the non-haematopoietic tissue cells. These results are 
strongly supported by the fact that keratinocytes were primed to express high levels 
of IFNK even in skin biopsies of At-Risk individuals who had no signs of clinical and/or 
histopathological abnormalities.  
Alongside the in situ hybridization data, the in vitro culture of isolated human 
keratinocytes from four different conditions (healthy, SLE, CDLE, At-Risk) confirmed 
and complemented the imaging results. Keratinocytes from non-lesional skin 
biopsies of both SLE patients and At-Risk individuals showed a significantly higher 
expression of IFNK in response to nucleic acids, whilst SLE patients demonstrated an 
upregulation of IFNB as well. In contract, keratinocytes from CDLE showed an 
immune response towards type III IFNs. From these data, it can be concluded that 
keratinocytes in preclinical autoimmunity and SLE can respond to environmental 
triggers (e.g. UV light) or self-nucleic acids through endoplasmic TLRs or cytoplasmic 
receptors and produce excessive amounts of type I IFNs, particularly IFN-κ.  
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Considering all the data discussed above, the role of non-haematopoietic cells in 
initiation of autoimmunity seems to be prominent and hence this requires further 
investigation. Keratinocytes do not consist of homogenous population of cells but 
they present different transcriptomic profiles and functional features. To decipher 
that, single-cell RNA-sequencing of keratinocytes from both patients with SLE and 
more importantly treatment-naïve At-Risk individuals would be an excellent tool 
elucidate many pathways and pathogenic phenotypes contributing to the excessive 
type I IFN production. In addition, single-cell RNA-sequencing can provide novel 
information about unique cellular population among the conventional keratinocytes 
and also elucidate novel functions that play a key role in the pathogenesis of human 
autoimmunity and cutaneous inflammation. On the other hand, it would be crucial 
to investigate how these non-haematopoietic tissue resident cells shape immune 
responses and affect the microenvironment of skin inflammation. T and B 
lymphocyte clonal expansion can be seen early in SLE, while their role in escalating 
inflammation and tissue damage is undeniable. Therefore, the cellular interactions 
between keratinocytes and cells of the adaptive immune system can be studied in 
vitro concluding important results about the escalation of immune response and 
factors determining persistent inflammation. 
Last but not least, the role of epithelial tissues other than the skin should be 
investigated further to shed more light on specific organ involvement and the role of 
its tissue in driving the inflammatory process. SLE is such a heterogeneous disease 
and even though mucocutaneous manifestations are among the commonest, other 
pathologies including lupus nephritis appear to be more severe and often life 
threatening. As a consequence, similarly to the novel role of keratinocytes in the 
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regulation of type I IFNs in systemic autoimmunity, other cell types such as 
glomerular epithelial cells can potentially contribute to type I IFN dysregulation. 
The data analysed in this PhD thesis fundamentally change our understanding of IFN-
mediated autoimmunity in humans. In the established disease, these insights might 
indicate potential therapeutic targets outside the conventional immune system. 
Moreover, at the preclinical stage, this is the first report on where IFN dysregulation 
occurs and how it might be targeted for disease prevention. These results have 
greater translational implications as I used exclusively human samples -not an animal 
lupus model- from different autoimmune rheumatic diseases, such as SLE and 
primary Sjögren’s Syndrome, but most importantly samples from ANA positive 
individuals at preclinical stages, the majority of whom will remain at this benign 
autoimmune phase. This could indicate that even though type I IFN dysregulation 
may be an essential feature for development of autoimmunity at early stages, it may 
not be sufficient for progression to a clinical syndrome. 
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